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An example of a "signature of selection" in a population is a region of the genome that
exhibits a reduction in genetic variability with a particular linkage disequilibrium pattern.
This reduction in variation can arise when the phenotype of a neutral beneficial allele
experiences a favourable change in environmental conditions. This results in an increased
frequency of both the allele, and linked sites, within a population. Polynesian populations
share a common genetic ancestry with East Asia, but little characterisation of genetic
selection has been undertaken in Polynesian populations.
Serum urate has been associated with metabolic disorders such as obesity, type 2 diabetes,
renal disease and metabolic syndrome. It is hypothesised that serum urate may have
undergone positive selection in Polynesians due to some of the beneficial properties, such as
its role as an anti-oxidant, or as an adjuvant for the innate immune system. New Zealand
Polynesians have inherently elevated serum urate levels and increased rates of gout. This
thesis presents the results of a genome-wide study of selection in Polynesian (and other)
populations, focusing on testing the hypothesis that genomic loci containing genes involved
in urate processing have undergone selection.
There was no evidence of wide-spread selection at genes associated with urate and gout,
or related metabolic disorders, but there was evidence at some individual loci. Pathway
analysis showed that of the significant pathways, there was a dominance of metabolic
pathways that were enriched for genes with signatures of selection. Calcium related
transport and signalling was a theme amongst loci that displayed signs of possible selection.
Regions of the genome that were possibly selected in modern-day Polynesian populations
also had similarities to those of modern-day East Asian populations.
This thesis has provided identification and characterisation of regions in the genome with
possible evidence of genetic selection in Polynesian populations, that previously was not
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This thesis investigates the role that positive genetic selection has played in causing the health
disparities of metabolic disease in Polynesian populations.
This chapter provides the background and rationale for the research presented in this thesis. It covers
the settlement of the Pacific, and highlights the health disparities facing Polynesian populations and
the relevance of genetics. It then introduces natural selection and the methodologies for detecting
‘signals of selection’, followed by how genetic selection may have played a role in creating the health
disparities caused by metabolic disease in Polynesian populations.
1.1 Settlement of Polynesia
The Polynesian triangle is defined as the geographic region in the Pacific Ocean bounded by New
Zealand (NZ) in the southwest, Hawaii in the north, and Easter Island in the east (Barcham et al.,
2009). The settlement history of this region begins with the Out of Africa migration approximately
50-100 thousand years ago (ya) (Nielsen et al., 2017). This migration flowed up the Levant and Arabian
peninsula (45-55 kya) and then split into a migration to South Asia, Indonesia, and Australia (50 kya,
Kivisild et al. (1999); Quintana-Murci et al. (1999)), with a migration into Europe under way 45 kya.
From South Asia, the migration continued into East Asia (20 kya, Groucutt et al. (2015)).
Near Oceania is the geographic region from New Guinea and the Bismark Archipelago, through to
the Solomon Islands in the east, with the remainder of the Pacific Islands east from the Reef/Santa
Cruz group, southeast of the Solomon Island being Remote Oceania (Matisoo-Smith and Gosling,
2018). The settlement of Near Oceania occurred first (40 kya), and was followed by the settlement of
Remote Oceania, which reached as far as Samoan and Tonga (Western Polynesia) as part of the Lapita
expansion (3 kya, (Matisoo-Smith, 2015; Skoglund et al., 2016)). After this settlement, came the
peopling of the Eastern Polynesia (including the Cook Islands) (1-1.2 kya; Wilmshurst et al. (2011))
and then finally, the settlement of New Zealand by NZ Māori 800 ya (Duggan and Stoneking, 2014;
Matisoo-Smith, 2015).
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In the 1950’s and 60’s there was a rural to urban migration of the Polynesian populations, for mostly
economic reasons. As part of this, many individuals and families relocated from Samoa, Tonga, and
the Cook Islands to New Zealand in search of work, and now the populations in New Zealand largely
out-number the populations of their islands of origin (Matisoo-Smith, 2012). Within New Zealand, the
largest number of Polynesian people is found within the Auckland region (Barcham et al., 2009).
1.2 Metabolic syndrome
The World Health Organisation has previously defined Metabolic Syndrome to be glucose intolerance,
or diabetes mellitus, and or insulin resistance combined with at least two of the following: impaired
glucose regulation or diabetes, insulin resistance, raised arterial pressure, raised plasma triglycerides
or low high-density lipoproteins to cholesterol levels, central obesity, and microalbuminuria (Alberti
and Zimmet, 1998). Hyperuricaemia can also be considered a component but is not required for the
condition to be recognised. hyperuricaemia is defined as a serum urate ≥ 0.42 mmol/L in males and
≥ 0.36 mmol/L in females (Choi and Ford, 2007). There has been a slight revision and refinement
in the criteria for a diagnosis of metabolic syndrome (Alberti et al., 2009). The requirement for
diabetes mellitus and or insulin resistance is no longer used, instead a requirement of having 3 of the 5
co-morbidities is used.
Obesity is defined as a body mass index (BMI) of >30 kg/m2 and is a contributing risk factor for many
other diseases such as type 2 diabetes and cardio vascular disease (CVD) (Haslam and James, 2005).
Obesity has been a key focus for research as the prevalence continues to increase and is posing a major
threat to health systems in many countries (Wang et al., 2011c). With respect to Pacific people obesity
is a major problem, with an obesity rate of 68%. New Zealand Māori have an obesity prevalence of
48% (New Zealand Ministry of Health, 2013). From 2012 to 2013 the prevalence of obesity increased
by 6% in Pacific populations.
Type 2 diabetes is diagnosed by a fasting blood glucose of >7.0 mmol/L or 2-hr post blood glucose
load of >11.1 mmol/L (Alberti and Zimmet, 1998). The risk of developing type 2 diabetes is strongly
correlated with excess weight (Rana et al., 2007). The prevalence of diabetes is 13% in Pacific people
and 7% in NZ Māori (New Zealand Ministry of Health, 2013) compared to 5.5% in Europeans (Winnard
et al., 2013). In New Zealand, the rate of diabetes is twice that in Māori compared to non-Māori, and
the rate is 3.6 fold higher in Pacific compared to non-Pacific ethnicities.
1.2.1 Hyperuricaemia and gout
Hyperuricaemia can be caused by diet, genetic predisposition or under-excretion of urate. The elevated
uric acid levels in the blood contributes to the forming of urate crystals in the joints, triggering an
inflammatory response by stimulating the synthesis and release of humoral and cellular inflammatory
mediators (Choi et al., 2005). There is a clear relationship between hyperuricaemia and the causal
role in gout (Snaith, 2004). There is also an increased prevalence in gout in different ethnicities.
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New Zealand Māori and Pacific ethnicities have a prevalence of 12% and 14%, respectively, in males,
compared to 4% in both European and Asian males (Winnard et al., 2012, 2013). While New Zealand
Māori and Pacific people have an increased prevalence of hyperuricaemia, they also have a genetic
predisposition to elevated urate and risk of gout (Hollis-Moffatt et al., 2009; Phipps-Green et al., 2010;
Hollis-Moffatt et al., 2011). The prevalence of metabolic syndrome in US gout patients is ~60%, or
nearly 3 fold higher than US adults without gout (Choi and Ford, 2007).
1.3 Genetic variation
As with many complex diseases, such as gout, type 2 diabetes, obesity, kidney disease, and metabolic
syndrome, there is an environmental component and a genetic component. Genetic variation at a
single locus, or at many, influences the genetic risk of an individual for developing disease. Genetic
variation refers to the differences in DNA sequence that occur between individuals of a species. Types
of genetic variation include, single nucleotide polymorphism (SNP) which are single base changes (or
polymorphisms), and insertion or deletions (INDELs). INDELs are either additional DNA, or DNA
that had been lost, and can be short (a single base, up to approximately 100 base pairs) or long
(kilobases to megabases) at which point that can also become structural variants. Other types of
genetic variation includes copy number variation (alterations in the number of copies of a gene from
what would be expected from the ploidy of the organism), and re-arrangements such as translocations
- segments of DNA moving to different chromosomes, or inversions - segments of DNA that are excised,
inverted, and reinserted at the same location on the chromosome. Within population based genetic
studies, such as case-control association studies, the prominent type of genetic variation that is studied
are SNPs.
Common methodologies of genotyping, to determine the genetic variation of an individual, are SNP
arrays or sequencing. SNP arrays, such as the Illumina Human CoreExome bead-chip contain probes
designed for specific genetic variants that bind DNA samples, and after a single base extension step
with a labelled nucleotide, enable a genotype to be determined from a fluorescence sensitive scanner
(Wang et al., 1998; Gunderson et al., 2005; Shen et al., 2005). Sequencing technologies, such as the
short read sequencing performed by the next-generation sequencers, take DNA and randomly fragment
it, then determine the bases sequentially in the fragment to approximately 150 bp from the start to
create a ‘read’ (Metzker, 2010). The reads are then aligned to a reference genome and at each base of
the genome a genotype is called by using the distribution of bases from reads overlapping that position
(Li et al., 2008a; McKenna et al., 2010). One of the key differences between SNP arrays and sequencing




Charles Darwin (1909) in The Origin of Species declared: “[The] preservation of favourable individual
differences and variations, and the destruction of those which are injurious, I have called Natural
Selection or Survival of the Fittest. Variations neither useful or injurious would not be affected by
natural selection, and would be left either a fluctuating element, as perhaps we see in certain polymorphic
species, or would ultimately become fixed, owing to the nature of the organism and the nature of the
conditions.” This theory set the scene for research in population biology. Selection acts upon the
phenotype and this pressure transfers through to act upon the genetic contribution of that phenotype.
Most important to Darwin’s Theory was it created models for what natural selection should look like
and the methods for being able to detect selective events on the genetics of organisms. A focus on
selection in humans has added insight into past events since migration out of Africa (Soares et al.,
2012) and yielded possibilities of the influences on human disease.
1.4.1 Neutrality and genetic drift
The random sampling of alleles can cause an increase or decrease in allele frequency of a population
leading to genetic drift. Wright (1931) proposed genetic drift as an evolutionary model. He put forward
that by chance, in a finite population without selection acting, an allele could increase in frequency
over generations and time, changing significantly from the original frequency values. Fisher believed
that “Natural Selection depends on the succession of favourable chances”, and thought that genetic
drift was insignificant compared to selection (Fisher, 1930). In Fisher’s model, genetic variation would
disappear at an extremely slow rate in a population without selection, and a moderate rate of new
mutations would be enough to maintain the population variability (Fisher, 1922). Feller (1951) unified
the population models from both Wright and Fisher into what is now known as the Wright-Fisher
model. The Wright-Fisher model in its simplest form treats a diploid population of size N as a haploid
population of 2N . In unifying the population models Feller noted that the assumption of constant
population size contributes more than was previously thought, and this had been crucial in Wright’s
model for gene frequency to satisfy a diffusion equation.
Adding further to the genetic drift side of the discussion was the neutral theory of molecular evolution.
The neutral theory of molecular evolution put forward by Kimura (1979a) states that most evolutionary
change is not due to selection but is due to random genetic drift. The term “drift” was used because
the variants under neutrality are expected to convey no advantage, and rise and fall (or drift) randomly
in prevalence over time. Random genetic drift plays a role in population structure by keeping the
number of co-existing alleles down (Kimura, 1955). One of the problems with the neutral theory was
how the diversity of species could be accounted for. The solution to this can be explained through a
positive correlation between increased genetic diversity and an increase in recombination, hinting at a
rise in mutation rate as frequency of genetic exchange increases (Hellmann et al., 2003). This link
provided an explanation of a neutral process leading to increased genetic diversity.
Crucial to both the neutral theory and the theory of natural selection is the estimation of the population
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mutation rate, commonly referred to as θ. The Watterson estimator, θ = 2 × ploidy × Ne × µ,
represents the expected number of new mutations for a population per generation (Watterson, 1975),
where µ is the mutation rate and Ne is the effective population size. Effective population size is the
size of an idealised population with the same amount of inbreeding or random gene frequency drift
as the population under consideration (Kimura and Crow, 1963). Other estimators of θ include: θ̂ =
FST (Weir and Cockerham, 1984), and θ̂ = E(π), in the infinite sites model, where π is the average
pair-wise nucleotide differences per site (Tajima, 1996). The infinite sites model assumes only one
mutation occurs per site.
The neutral model allows for natural selection, but proposes that the majority of the genome is
selectively neutral (Kimura, 1979b). The methodology for detecting selection utilises the neutral
hypothesis for many of the methods mentioned later (section 1.5). These methods use a model for
neutrality, and if the statistic reaches a level that is considered to be beyond that of the neutral model,
the model is rejected. Typically, the neutral hypothesis is a composite hypothesis using assumptions
for which it would be difficult to find a human population that fulfils them, such as: “the population is
in equilibrium at constant size with no population subdivision or gene flow from other populations”
(Nielsen et al., 2005).
1.4.2 Selection
Possible types of selection that can act upon a population include balancing, background, or directional
selection. Balancing selection maintains both alleles in a population and is often the case when the
heterozygote has an advantage over the homozygote and can be referred to as “over-dominant selection”.
Two examples of this are MHC class 1 (Hughes and Nei, 1988) and sickle-cell anaemia (Allison, 1956).
With sickle-cell anaemia, individuals homozygous for normal haemoglobin alpha are susceptible to
malaria, individuals that are homozygote for the ‘sickling’ mutation develop sickle-cell disease, and
the heterozygote has a protective effect against malarial infection (Aidoo et al., 2002). “Background
selection” is a reduction of genetic diversity at a locus because of deleterious selection acting on a
separate but linked locus (Charlesworth et al., 1993). Background selection can be thought of as the
opposite effect to genetic hitch-hiking. Genetic hitch-hiking occurs when a locus is under selection,
linked sites on the same chromosome will increase in frequency, causing a change in frequency of the
alleles that are not on the same chromosome (Maynard Smith and Haigh, 1974). Linkage disequilibrium
(LD) can arise at sites that are under directional selection, even when the loci are unlinked (Felsenstein,
1965) but, recombination will act to reduce this LD.
Directional selection operates in two fashions, positive or negative. Positive selection is where an allele
conveys an advantage in fitness that enhances reproductive success, resulting in the beneficial allele
increasing in frequency within the population. An example of positive selection is the lactase gene
in European populations which enables the absorption of lactose (Bersaglieri et al., 2004). Negative
selection occurs when the allele conveys a fitness disadvantage and ends with reduced reproductive
success, decreasing the frequency of the allele in the population. The cystic fibrosis gene CFTR, is an
example of negative selection, where in males splicing mutations can lead to sterility (Pagani et al.,
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2005).
The way selection can affect allele frequencies can be thought of as a sweep: as an allele is selected,
it increases in frequency, “sweeping” through the population. The intensity of this sweep can be
classified as, hard, soft, and partial or incomplete. A hard sweep, also known as a classical sweep,
is when a beneficial allele rapidly rises in frequency and through hitch-hiking the neutral variation
is simultaneously reduced at linked sites, as shown in Figure 1.1 (Maynard Smith and Haigh, 1974;
Hermisson and Pennings, 2005; Nielsen, 2005; Hermisson and Pennings, 2017).
Figure 1.1: Representation of alleles before and after a hard sweep. Each rectangle
represents a haplotype within a population. A new mutation is shown in red and
neutral alleles are shown in black. After a hard sweep the new mutation becomes
fixed in the population, along with the neutral allele that is linked to it.
A soft sweep occurs when an initially fitness-neutral allele evolving under drift experiences a beneficial
environmental change and increases in frequency until fixation. The initial neutral nature of the allele
prior to becoming beneficial means there is a range of surrounding haplotypes and there is not as much
reduction in genetic diversity as happens with a hard sweep (Hermisson and Pennings, 2005; Schrider
et al., 2015; Hermisson and Pennings, 2017). The result of a soft sweep is multiple haplotypes of
intermediate frequency around the selected site. If the selective environment for a population changes
frequently enough, soft sweeps could be the main method of adaptation (Schrider et al., 2015).
A partial or incomplete sweep occurs when part way through a sweep the selective pressure is
changed/removed resulting in an increase in frequency for the allele that then returns to random
genetic drift.
In order to determine if a selective event has occurred, one can attempt to find what are termed
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“signatures of selection”. Population differentiation can sometimes be indicative of a selective event. If
extreme levels of differentiation are observed at a locus between populations, this can be interpreted as
evidence of positive selection. Regions of the genome that have a reduction in variability in a population
can be the effect of a selective sweep. A third example of a signature of selection is deviation in the
frequency spectrum for alleles beyond what would be considered possible under neutrality (Przeworski,
2002). A key signature of positive selection is the increase in proportion of high frequency variants
(Fay and Wu, 2000).
Assuming a background of neutrality means that there needs to be a way to identify variants under
selection as opposed to population demographic events, such as bottlenecks or expansions. In the
case of Polynesian settlement, there is evidence for a founder effect which needs to be considered
when interpreting selection results (Kayser et al., 2006). It is for this reason that the unique features
of a selective event need to be able to be identified from other possible features such as population
demography or admixture. Population events and demography affect the entire genome, whereas
selection acts on a localised region (Stajich and Hahn, 2005). To be able to recreate demography, the
choice in the SNPs used in the calculation of neutrality and selection statistics is important as there is
chance for a large ascertainment bias if SNPs are only selected from a small number of populations
(Wall et al., 2008). The SNPs used also need to be sampled away from genic areas.
1.5 Methods for detecting selection
Since 2005 there have been multiple reviews published (see Nielsen (2005), Sabeti et al. (2006),
Utsunomiya et al. (2015), Vitti et al. (2013) and Haasl and Payseur (2016)) on methods of identifying
selection, as there has been a renewed interest to examine selection at a genome wide scale due
to increased availability of whole genome genotype data. Methods that have been developed to
detect signatures of selection can be placed into two main categories, those that only work on a
single population and those that compare between populations. There are also specific underlying
genetic features that these methods can use, such as allele frequency (frequency spectrum methods) or
differences in haplotype (linkage methods). Also, there are methods that combine different approaches
(composite methods). A summary of selection methods is provided in Table 1.1.
The different methods for detecting selection work best over different time periods. Recent soft sweeps
are able to be detected well with LD-based methods, but frequency spectrum tests struggle (Hermisson
and Pennings, 2005). The opposite applies in the case of hard sweeps (Hermisson and Pennings, 2005).
In humans, the method that is able to detect the most ancient selection, ranging to millions of years
ago is the Ka/Ks ratio, however if a strong background of neutrality is present this can undermine
the effectiveness of the test. Tajima’s D is able to detect selection events as old as 250,000 years
ago in regions of low diversity containing an excess of rare alleles. Fay and Wu’s H is able to detect
events less than 80,000 years ago based on derived alleles having arisen through mutation and then
risen to a high frequency via hitch-hiking. FST, in the range of less than 50,000 to 70,000 years ago,
picks up geographic separation of populations that have been subject to different physical and cultural
environments based on the changes in allele frequency in one population versus another. Methods
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Ka/Ks Within and Between Ancient selection Hughes and Nei (1988)
HKA Within and Between Hudson et al. (1987)
Haplotypic
iHS Within < 30,000 years Voight et al. (2006)
XPEHH Between Tang et al. (2007)
nSL Within Ferrer-Admetlla et al. (2014)
Frequency spectrum
Tajima’s D Within < 250,000 years Tajima (1989)
Fay and Wu’s H Within < 80,000 years Fay and Wu (2000)
Fu and Li’s F Within Fu and Li (1993)
Zeng’s E Within Zeng et al. (2006)
FST Between < 50-70,000 years Weir and Cockerham (1984)
∆DAF Between Grossman et al. (2010)
SCCT Within Wang et al. (2014)
Composite
CLR Within Kim and Stephan (2002)
XP-CLR Between Chen et al. (2010)
CMS Within and Between Grossman et al. (2010)
Meta-SS Within and Between Utsunomiya et al. (2015)
CSS Within and Between Randhawa et al. (2014)
relying on long haplotypes such as integrated haplotype homozygosity score (iHS) have the shortest
range at less than 30,000 years ago for a long haplotype that has not had time to break down through
recombination and contains a high frequency variant. Partial sweeps can also be detected down to a
minor allele frequency (MAF) of approximately 10% (Sabeti et al., 2006).
1.5.1 Macroevolutionary methods
1.5.1.1 Ka/Ks
The ratio of non-synonymous to synonymous mutations is called the Ka/Ks ratio (or dN/dS ratio as it
is often referred to), and is used to infer functional impact from selection, since synonymous mutations
are thought of as silent mutations with a neutral effect on the protein (Hughes and Nei, 1988). Ka
is the number of non-synonymous differences between sequences normalised by the total number of
non-synonymous sites in the sequence. Ks is likewise, but for synonymous differences normalised
by the total number of synonymous sites in the sequence. Comparing the baseline rate of mutation
(synonymous) to the non-synonymous rate gives an understanding of the tolerance of amino acid
alternatives in the protein, with an excess of non-synonymous mutations indicating the novel protein
structures are being favoured and the protein is being positively selected for. A Ka/Ks ratio greater
than 1 is indicative of positive selection, while a value less than 1 is indicative of negative selection
against deleterious mutations and for keeping the protein conserved.
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1.5.1.2 HKA
The HKA test (Hudson et al., 1987) compares between and within populations the polymorphism
and divergence of two or more loci, and uses this to establish if a locus has been under selection,
since variation within, and diversity between, species under neutrality should be based only on the
mutation rate. The assumption that mutation rates at neutral loci are constant over time is important,
because if the rate changes, it will affect the difference between the polymorphism and divergence. In
practice the HKA test is powered for recent selection events, however, in practice it is difficult to find
a putatively neutral locus (Zhai et al., 2009).
1.5.2 Haplotypic methods
There are a few methods that are different derivations and applications of looking at haplotype
decay around a core SNP. Sabeti et al. (2006) put forward the concept of using extended haplotype
homozygosity (EHH). The haplotypes that had unusually long haplotype homozygosity and a high
frequency in the population indicated that the polymorphism had risen in prominence faster than it
would be expected under the neutral model and therefore under selection. The main concept is that a
beneficial mutation would not solely be selected for, with the surrounding region initially “hitch-hiking”
and therefore it would have a conserving effect. As time and generations progressed, this haplotype
would decay due to recombination, and this haplotype decay can be used to assist in the ageing of the
selection event. In order to use haplotypic methods, there is a requirement to establish the alleles that
were inherited from the maternal side and those that were inherited from the paternal side constituting
the two haplotypes (phasing).
1.5.2.1 Integrated haplotype homozygosity score
The iHS (Voight et al., 2006; Szpiech and Hernandez, 2014) calculation starts with EHH, which is the
probability that 2 chromosomes carrying a core haplotype are homogenous to the distance x. A value
of 0 represents no homozygosity, meaning all haplotypes are different, while a value of 1 is complete
homozygosity meaning all haplotypes are the same. The EHH value versus distance is integrated
to find the area under EHH curve until EHH decays to 0.05. This integrated extended haplotype
homozygosity (iHH) is calculated based on the ancestral or derived allele and annotated as iHHA or
iHHD. The unstandardised iHS is calculated in equation (1.1), which is the selscan version (Szpiech
and Hernandez, 2014). Standardisation of iHS is shown in equation (1.2), where the expectations and
standard deviation of equation (1.1) are estimated from the empirical distribution of SNPs where
the derived allele frequency (DAF) (see section 1.5.3.7) p matches the frequency at the core SNP
(Voight et al., 2006). Large positive values indicate long haplotypes carrying the derived allele, whereas
negative values indicate haplotypes carrying the ancestral allele. The calculation in Voight et al. (2006)
has iHHA and iHHD switched. The Szpiech and Hernandez (2014) iHS calculation is used in this thesis













1.5.2.2 Cross population extended haplotype homozygosity
Cross-population extended haplotype homozygosity (XP-EHH), created by Tang et al. (2007), is
also known as Rsb. XP-EHH was designed for use with SNP data rather than sequence. XP-EHH
lacks power to detect intermediate frequency variants but is designed to detect variants that are
near fixation or completely fixed. The EHH of SNP site (EHHS), integrates to sum the area under
the decay by distance in EHH (iHH) which is then used as a log ratio between populations at a
single site (equation (1.3)) and in a standardised form (equation (1.4)), with 1 and 2 indicating the
population. Recombination rate is mostly conserved within populations, so provides an internal control
in XP-EHH for effects of heterogeneous recombination rates. Extreme values of XP-EHH indicate a
slower decay of EHH in one population compared to the other. XP-EHH relies on the breakdown of
LD over time and has weak power to detect selective sweeps that were historical and ended thousands
of generations ago (Chen et al., 2010). FST is better than XP-EHH for differential selection between
closely related populations because haplotype-based signals are mostly shared between geographically












1.5.2.3 Number of segragating sites by length
Number of segregating sites by length is another single population haplotypic method that is extremely
similar to iHS, however number of segregating sites by length (nSL) also measures the length of a
segment of haplotype homozygosity between a pair of haplotypes in terms of number of mutations in the
remaining haplotypes in the data set in the same region (Ferrer-Admetlla et al., 2014). Demographic
events affect nSL less than iHS. Under simulations for different demographic events, nSL had a smaller
total difference in variation between the standard distribution of the test statistic and the distribution
of the modelled demographic event (Ferrer-Admetlla et al., 2014).
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1.5.3 Frequency spectrum methods
The frequency spectrum methods are based on finding deviations in the frequency spectra of alleles
that are outside of what would be expected under neutrality. These can involve an increase in
particular types of frequencies such as low, intermediate, high variant frequencies, or a difference in
allele frequencies between populations.
1.5.3.1 Tajima’s D
Tajima’s D (Tajima, 1989) counts the number of segregating sites of individuals in a population and
finds the ratio between polymorphisms and pair-wise individual comparisons. Tajima’s D is a test of
the neutral hypothesis. The hypothesis is rejected when there is an excess of low frequency variants.
A negative Tajima’s D is indicative of positive selection or weak negative selection but a negative
value can also be attributed to population events such as population expansion. Positive values of
Tajima’s D indicate an excess of intermediate frequency variants. An excess of intermediate frequency
variants could also be attributed to balancing selection, population structure, or population bottlenecks
(Kreitman, 2000; Nielsen, 2005; Nielsen et al., 2007). The comparison of other polymorphisms, such as
changes in SNPs versus changes in INDEL numbers can provide further evidence for either selection or
a population event, since population events should affect both SNPs and INDELs in an equal fashion.
The direction (positive, zero, or negative) of Tajima’s D values after a population bottleneck depends
on the strength and duration of the bottleneck and can generate similar Tajima’s D values, and can be
positive, negative or zero (Fay and Wu, 1999). After a population reduction or selective event, it is
expected the population will have excess rare alleles (recent, low frequency) as the population recovers,
therefore Tajima’s D will be negative (Barton, 1998). Tajima’s D is sensitive to sequencing errors that
are called as SNPs because they appear equivalent to low frequency variants (Achaz, 2008).
1.5.3.2 Fu and Li’s F
Fu and Li’s F is the comparison of the number of derived singleton mutations and the mean pair-wise
difference between sequences (Fu and Li, 1993). It can be calculated both with or without an out-group
(F*), with Fu and Li’s F* having the greatest power of the Fu and Li statistics (Fu and Li, 1993;
Ramírez-Soriano et al., 2008).
1.5.3.3 Fay and Wu’s H
Fay and Wu’s H is sensitive to SNPs rising to moderate to high frequency and uses an out-group (such
as the ancestral reference sequence) to determine the derived/ancestral state of the allele. A positive
value indicates a deficit in derived moderate to high frequency SNPs. A negative value indicates an
excess of derived moderate to high frequency SNPs. Fay and Wu’s H rejects neutrality when there is an
excess of high but not low frequency variants. An increase in the proportion of high frequency variants
compared to intermediate frequency variants is a unique signature of positive selection (Fay and Wu,
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2000). Fay and Wu’s H can be used in regions of low recombination to distinguish hitch-hiking from
neutral or background selection where it is expected there will be the same level of intermediate to
high frequency variants.
1.5.3.4 Zeng’s E
In contrast to Fay and Wu’s H and Tajima’s D, which compare either high or low frequency variants
with intermediate frequency variants, Zeng’s E compares the low and high frequency variants (Zeng
et al., 2006). After a selective sweep, the lower frequency variants are expected to ‘bounce back’ faster
than the higher frequency variants. The E test is not sensitive to population subdivision. A negative
value for Zeng’s E is indicative of a selective sweep, but a rapid population expansion can also produce
a negative value.
1.5.3.5 FST
FST is a population differentiation metric that measures the differences in heterogeneity of a sub-
population compared to a global population. Initially created by Wright (1951), as an inbreeding
coefficient for inbreeding as a whole in a population (equation (1.5)), FIT is the inbreeding coefficient for
the individual in the total population and FIS is the inbreeding coefficient for inbreeding of the individual
in the subpopulation. Both FIT and FIS compare the observed heterozygosity of the individual with
the expected heterozygosity in either the total population (FIT), or the subpopulation (FIS). These
fixation indices provide ways of summarising population structure. Selection will act to drive an allele
to fixation, whereas immigration usually reduces the frequency. When the selective advantage is strong,
selection will be the dominant force on the locus, however, when the selective advantage approaches
zero, the allele will begin to act neutrally and disappear with a probability of one minus its frequency
(Kimura, 1968). Cockerham (1969; 1973) equated θ (population genetic differentiation) with FST,
extending FST from calculating population structure to population differentiation too. The fixation
indices were further developed by Weir and Cockerham (1984) to add population size weightings to
the calculation. FST values fall between 0 and 1, each representing the fixation of an allele. Large
differences in FST values are indicative of population differentiation, suggesting directional selection
at that locus, whereas small differences in FST indicate that the populations are similar. FST can
have high variation in neighbouring loci under neutrality (Weir et al., 2005). Unless populations are
closely related, such as northwest and southeast Europeans (Price et al., 2008), the noise will drown
out the signal, and identification of genome-wide significance in FST will be difficult. Weir et al. (2005)





FST has been used in multiple studies as evidence for natural selection (Myles et al., 2007; Pickrell et al.,
2009; Akey, 2012). Akey (2012) used FST at individual loci and compared this to the distributions for
the genome, chromosome and gene levels. The use of the empirical distribution to compare to FST
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for each SNP controlled for the effects of demography. FST as a method for detecting selection was
developed further into di , which is a function of pair-wise FST between population i and the remaining
populations (Akey et al., 2010). Outside of the human context FST has been a very popular method of
reporting both population structure and evidence of selection (Akey et al., 2010; Hancock et al., 2011;
Qanbari et al., 2011; Wei et al., 2015). The population branching statistic is a FST based statistic that
involves the use of an out-group to compare estimates in divergence time between populations (Yi
et al., 2010).
1.5.3.6 Selection by conditional coalescent tree
Selection by conditional coalescent tree (Wang et al. (2014)) detects recent positive selection by
searching for an imbalance of genetic variants and conditions these on the allele frequencies of the
candidate loci. Selection by conditional coalescent tree pinpoints the causal variant more accurately by
using a method that is based on the conditional coalescent tree method from Wiuf and Donnelly (1999),
where haplotypes are partitioned into two subgroups according to the allelic state at a particular locus.
It is assumed one subgroup carries the derived allele at the locus and the other subgroup carries the
ancestral allele. The coalescence of a sample of haplotypes, conditioning on the particular mutation,
means each group should coalesce together individually before the two subgroups coalesce. This is a
similar idea to that of EHH used by iHS, and the results of iHS and selection by conditional coalescent
tree tend to be similar. The selection statistic (S) is based on comparing the lineage lengths of the two
groups. Under neutrality S approaches θ, with significant departures from θ being considered evidence
of positive selection. When natural selection has a strong hitch-hiking effect on a selectively favoured
allele, selection by conditional coalescent tree (and iHS) is more powerful than Tajima’s D, Fay and
Wu’s H, and measuring change in derived allele frequency (see 1.5.3.7). In most cases the power of
selection by conditional coalescent tree is equivalent to iHS except when selection is very strong, in
which case iHS has more power (Wang et al., 2014). The power of selection by conditional coalescent
tree can be improved by increasing the sample size. Selection by conditional coalescent tree performs
moderately with population demographic events (such as bottlenecks) and out performs Tajima’s D
and iHS in false discovery rate, although it does not perform as well as Fay and Wu’s H (Wang et al.,
2014).
1.5.3.7 Change in derived allele frequency
Similar to FST, change in derived allele frequency (∆DAF) looks at population differentiation. The
derived allele is determined through the use of an ancestral out-group such as chimpanzees when
used in human populations. DAF itself is calculated by determining the ancestral and derived state
for an allele and calculating the allele frequency with regard to the derived state. ∆DAF measures
the absolute difference in the derived allele frequency between two populations (Grossman et al.,
2010) and has greater power to detect sweeps, both partial and complete, and outperforms XP-EHH
for partial sweeps (Colonna et al., 2014). ∆DAF is part of the composite of multiple sites statistic
(Grossman et al., 2010) but has also been used as a standalone metric in humans (Colonna et al., 2014;
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Gudbjartsson et al., 2015) and in other species such as cattle (Randhawa et al., 2014) to measure
differentiation.
1.5.4 Composite methods
Composite methods combine multiple methods with the goal of increasing overall power and/or spatial
resolution for detecting selection. The combination of methods also gives greater resilience against
demographic events.
1.5.4.1 Composite likelihood ratio
The composite likelihood ratio (CLR), created by Kim and Stephan (2002), is a test for local hitch-
hiking selection along a recombining chromosome. It calculates a null distribution of variation from
neutral coalescent simulations involving recombination, and uses this to calculate the probability of
observing a threshold ratio of segregating variants. The Nielsen et al. (2005) version of composite
likelihood ratio is similar to Kim and Stephan’s test but creates the null distribution from the data
itself, instead of using the neutral population model. A key consideration for the use of composite
likelihood ratio is that it is very sensitive to SNP ascertainment bias (Chen et al., 2010).
1.5.4.2 Cross population composite likelihoods ratio
The cross-population composite likelihoods ratio (XP-CLR) is an extension of the composite likelihood
ratio test developed by Nielsen et al. (2009) that scans for multi-locus allele frequency differentiation
between two populations and then tests if these frequency differences are too recent to be consistent
with neutrality based on the LD in the region (Chen et al., 2010). A down-weighting of SNPs that
are in perfect or high LD is performed because they essentially provide the same information. By
doing this it is hoped that false positives are reduced, since the correlation of marginal likelihood
terms in the composite likelihood function is often overlooked and leads to false positives. Normalised
cross-population composite likelihoods ratio scores should be resistant to variation in demographic
events, however a conservative approach of using rank-order of scores across the genome is usually
taken. Unlike single population composite likelihood ratio and similar to XP-EHH, cross-population
composite likelihoods ratio is resistant to SNP ascertainment bias because population differentiation is
not affected by ascertainment bias. There is also a strong correlation between genes identified with
cross-population composite likelihoods ratio and XP-EHH. cross-population composite likelihoods ratio
is also considered an extension of FST and is beginning to be used as a replacement for investigating
selection in animal studies (e.g., Cattle – Lee et al. (2014); Goats - Benjelloun et al. (2015))
1.5.4.3 Composite of multiple signals
Composite of multiple signals (CMS) is a combination metric composed of iHS, XP-EHH, FST, ∆DAF,
and ∆iHH. ∆iHH is used to compare the actual length of the haplotype. Composite of multiple signals
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was created to take advantage of the combined power gained from using all metrics together to be able
to detect the source of the selective signal better than any test individually could (Grossman et al.,
2010). In composite of multiple signals, it was found that XP-EHH and FST contributed mostly to
spatially locating the causal variant whereas iHS, ∆DAF, and ∆iHH did poorly in spatially locating
the selective signal but performed well at identifying the precise causal variant.
1.5.4.4 Meta-analysis of multiple tests
Meta-analysis of multiple tests (meta-SS) (Utsunomiya et al., 2013, 2015) is only able to combine
selection statistics that generate P-values. It uses an adapted version of a weighted Stouffer method
(Stouffer et al., 1949; Zaykin, 2011) to combine Z-transformed P-values. For each marker from each
test i the respective P-value is transformed into a Z score by Zi = - φ -1(1 - π), where φ is the normal
cumulative density function. Each test is weighted (wi) to 1/n where n is the number of comparisons.









1.5.4.5 Composite of selection signals
Composite of selection signals (CSS) is similar to meta-analysis of multiple tests, in that it is a method
for combining the results from multiple selection tests but is not limited to tests that produce P-values
(Randhawa et al., 2014). Composite of selection signals currently uses FST, XP-EHH, and ∆DAF or
change in selected allele frequency, and combines them by taking the test statistic for each method
across each SNP(1,. . . ,n) then obtaining the rank of each statistic across each SNP(1 . . . n) and
converting these into fractional ranks so they lie between 0 and 1, that is, 1/(n+1) to n/(n+1). By
doing this the magnitudes of the original statistics are not used, thus increasing the robustness. The
fractional ranks are converted to Z-statistics and the average z-values are calculated at each SNP
position. P-values are obtained from the distribution of the means with the -log10(p) being the
composite of selection signals value. The composite of selection signals is plotted against genomic
position with an excess in the number of values at a position showing a common signal between the
multiple test statistics.
1.5.5 Power
Power to detect selected sites can be very limited if the site is not an outlier from empirical methods,
such as simulations or using permutations of the data, as they would not ‘stand out’ (Teshima et al.,
2006). A key consideration when selecting a particular method for detecting selection is the limitations
the method has on power to detect a selective event, such as starting and final allele frequency of the
15
variant after a sweep. Tajima’s D is powered for low and intermediate frequency variants (Simonsen
et al., 1995) whereas Fay and Wu’s H is powered for intermediate and high frequency variants. Some
methods such as iHS, are good for detection of middle frequency variants. XP-EHH, on the other
hand is powered at the fixation ends of the spectrum. XP-EHH, because it is correlated with LD,
lacks power to detect ancient selective events (Chen et al., 2010). Sample size is another factor to
consider. IHS has modest reduction of power when reducing samples until approximately 40 samples of
single chromosomes. XP-EHH can maintain power down to about 20 samples of single chromosomes,
so long as the reference population is a fixed size. The grouping of similar genetic populations may be
an option to increase power with low sample sizes (Pickrell et al., 2009)). For FST, power to detect
selection should be sufficient if sample size is > 1/FST (Bhatia et al., 2011, 2013)
Power of a statistic also needs to be considered for the type of selective sweep that may have occurred,
such is the case with nSL, which has similar power to detect selection to iHS, but performs better for
larger starting allele frequencies. It also outperforms iHS in power in both hard and soft sweep scenarios
(Ferrer-Admetlla et al., 2014). When it comes to picking up demographic events, haplotype tests
are useful at detecting recent and more moderate bottlenecks, frequency spectrum tests (such as Fay
and Wu’s H/ Tajima’s D) have the best power for detecting moderately ancestral severe bottlenecks
(Depaulis et al., 2003), whereas Zeng’s E and Fu and Li’s F have the most power during population
expansion (Zeng et al., 2006; Ramírez-Soriano et al., 2008). Assessment of power to detect selection
has previously been done through simulation or the use of well established loci as positive controls
(Voight et al., 2006; Zhai et al., 2009; Cadzow et al., 2016). When simulating, it important to generate
scenarios that include different demographic events as well as selection events. Simulated models are
generally done in one of three ways, as a coalescent model, or a forward-in-time model, or by resampling
(Yuan et al., 2012). The coalescent model (and most commonly used) works backwards-in-time to find
the most recent common ancestor, and then permutes through models to arrive at the current state
(Kingman, 1982; Yuan et al., 2012). The forward-in-time simulations will take a starting ancestral
population and then apply a population model, iterating through subsequent generations (Peng and
Amos, 2010; Yuan et al., 2012). Another approach can be to take the observed data and shuffle and
resample it to generate empirical distributions. From each of these methods false positive and false
negative rates can be calculated.
1.5.6 Challenges
When scanning genome-wide in a population (such as in a genome-wide association study (GWAS), or
genome-wide selection scan), the variability in the genome also has population demographic events that
have acted upon it, such as population bottlenecks, migration, or growth. Mutation and recombination
are also acting on the genome. Methods based on comparing non-synonymous to synonymous variants
are relatively unaffected, but methods based on allele frequency are susceptible to detecting population
demographic events, along with mutation and recombination rate changes (Nielsen et al., 2009). A
meta population is a population which can be subdivided into many different sub-populations among
which there is some pattern of migration, extinction, and recolonization (Wakeley and Aliacar, 2001).
Bottlenecks with a meta-population model can lead to a high frequency of derived alleles, greater than
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would be expected to arise through a neutral model (Jensen et al., 2005) and as previously mentioned
by Fay and Wu (2000) about high frequency derived alleles being a unique signature of selection, it
not actually unique (Przeworski, 2002).
SNP ascertainment bias is caused by the non-random sampling of SNPs on array chips. This is a
problem that affects the selection detection methods to different extents, with frequency spectrum
methods being the most susceptible. Tajima’s D is biased upwards due to the SNP discovery process
having ascertainment biases, which leads to an excess of intermediate frequency alleles in the sample
(Kelley et al., 2006). Tests that rely on long haplotypes are less susceptible to ascertainment bias
(Sabeti et al., 2006) but because long haplotypes can be quickly broken down through recombination,
they are only useful for short time periods. SNP ascertainment bias can be overcome with the use of
whole genome sequencing (Albrechtsen et al., 2010).
Many of these statistics were developed to investigate selection at a particular locus, at a time when
applying the statistics across a genome was not possible. Up until recently, genome scans have been
performed using SNP genotypes identified through a SNP discovery process, which means they are
not random samples – which would include non SNP genotypes (such as INDELs) and create an
ascertainment bias (Nielsen et al., 2005)
Identification of exactly what is deemed as being “significantly selected”" has issues. The current
practice is to take outlier loci, usually from an empirical distribution of the selection statistic and
report these as significant. This is not necessarily indicative of selection, as cut off levels are created
subjectively rather than derived from the model (Qanbari et al., 2012). Using an empirical approach
will result in many false positives, however this is considered an acceptable approach for selecting
candidate genes so long as it is realised that the false positive rate is high (Kelley et al., 2006).
In order to use haplotypic methods, (re)construction of haplotypes is required. Currently this involves
the need for the phasing of haplotypes from genomic data. Phasing is the process of determining which
alleles are found together on the same physical chromosomes. There are a number of ways that this
can be done, such as through a pedigree, through the use of large population data, or using the reads
from next generation sequencing. Phasing through pedigree information is utilised in most agricultural
species, whereas for human populations the population genotypes are largely from unrelated individuals.
Phasing of unrelated individuals currently relies on probabilistic methods (Browning and Browning,
2009; Delaneau et al., 2012, 2013) in order to make the best guess at each individual haplotype. Newer
methods have been developed to use the reads from next generation sequencing and are able to trace a
haplotype across multiple overlapping reads and be used to complement other probabilistic phasing
methods, however these read-backed methods are dependent on the depth of coverage and read quality
(Delaneau et al., 2014).
1.6 Improving GWAS
GWAS is a method to scan genomes, usually SNP genotype data, for association with a phenotype.
Association is usually tested between a trait and a single SNP using either linear regression (continuous
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variable) or logistic regression (binomial variable), with confounders included where possible as
covariates to the models. These association tests are repeated for each SNP across the genome (for a
comprehensive explanation of GWAS methods see Bush and Moore (2012)). Commonly an additive
model is used for the SNP. The strength of GWAS is that prior knowledge of loci is not required and
can be used as a tool for hypothesis generation. GWAS, because of the large number of association
tests, require large cohorts of samples to achieve sufficient power for statistical significance. As the
effect size for a variant decreases, larger sample sizes are also needed, as power is proportional to
the square of the effect size (Hemani et al., 2013; Korte and Farlow, 2013). Limitations in recruiting
sufficient numbers of participants for GWAS therefore requires new ways of increasing power to detect
smaller effects without needing to increase sample size, as outlined in this section. The goal of being
able to prioritise GWAS results by using additional information, such as incorporating LD or selection
statistics by using a weighting system to increase the power of a GWAS, has been suggested (Roeder
et al., 2006; Ayodo et al., 2007). When LD between observed SNPs and causal variants is high, such
as in the case of selection, greater power in GWAS can be achieved by focusing on searching for
non-additive variance (Hemani et al., 2013).
The basis of GWAS studies is to identify SNPs that are associated with differences in the mean of
a trait. These studies do not necessarily identify the causal SNP but instead identify a marker for
the causal variant, usually in LD. Fisher (1919) showed that total genetic variance could be split into
components of additive, dominance and epistatic effects. The additive component has been shown to
contribute the most to the overall genetic variance, with epistatic variance contributing little in an
outbred population (Hill et al., 2008). Complex traits gain their complexity from being the sum of
interactions from many small effect loci, or the product of non-additive interactions between loci and
the environment, making it challenging to find the exact contribution of a locus to a trait (Fu et al.,
2013). These small, true effect loci can end up non-significant due to the noise in the data but might
be retrieved using methods that find non-additive effects.
Explained heritability is defined as the proportion of heritability (or phenotypic variance) explained
by a collection of genetic variants, with the “missing” portion referring to the unaccounted genetic
variance that has been estimated through family studies. When the ratio of explained heritability to
total heritability is < 1, the unexplained component is defined as missing heritability (Zuk et al., 2012).
The use of methods that capture additional loci with non-additive effects should be able to explain
more of missing heritability.
1.6.1 Selection and GWAS
The significance of GWAS results is greatly increased when selection statistics and association studies
are combined, this has been applied in a GWAS for malarial resistance variants (Ayodo et al., 2007).
A smaller sample size can be used if there is evidence of positive selection because the beneficial allele
will rise in prevalence and be in high LD with other variants (due to genetic hitch-hiking) which can
act as proxy markers (Karlsson et al., 2014). The converse would apply for negative selection. Complex
disease traits compared to Mendelian disease associated traits have a bias towards larger mouse-human
18
Ka/Ks ratios, by comparing the Ka/Ks ratios for ortholog genes between mouse and human, which
suggests that evidence of positive selection could be utilised in identifying variation associated with
complex disease (Thomas and Kejariwal, 2004).
1.6.2 Pathway analysis
A biological pathway is a dependency graph detailing the genes or proteins involved in a series of
biochemical reactions, such as a metabolic pathway like the Krebs cycle. There are curated databases
of many of the biological pathways used by living organisms, such as Kyoto Encyclopedia of Genes and
Genomes (KEGG) (Kanehisa et al., 2017) or Reactome (Fabregat et al., 2018). Pathways have been
hypothesised to be involved in the genic adaptation of populations since altering a gene in a biochemical
pathway is likely to alter different genes in the same pathway (Bigham et al., 2010). The use of pathway
analysis rather than focusing on individual SNPs is another way to increase the power of a GWAS (Jia
et al., 2011). This increase in power is largely obtained through a reduction in dimensionality in ways
that attempt to remove noise from the underlying biological signal. There are however limitations to
the effectiveness of using such an approach, such as the selection of pathway database, density of SNPs
per gene, or gene length and boundaries. The pathway database is important because pathways can
differ based on curator, age of the database - with older databases not incorporating current knowledge,
or differing focuses. SNPs per gene, and gene length or boundaries all affect the pathway analysis as
smaller genes or SNP density reduces the observations for the gene compared to large genes or genes
with high SNP density. Pathways that involve many large genes also have a higher chance of a SNP
having an extreme statistic value under a null model, because overall, they are more likely to have
more SNPs than pathways containing small length genes.
1.7 Applications
1.7.1 Genome-wide selection
Genome-wide selection in humans has been investigated by Sabeti et al. (2006), Voight et al. (2006),
Hancock et al. (2008), Pickrell et al. (2009), the 1000 Genomes Project Consortium (1000 Genomes
Project Consortium, 2010, 2012, 2015), Grossman et al. (2010), Colonna et al. (2014), and Mallick
et al. (2016). The population datasets used involved the HapMap Project (The International Hapmap
Consortium, 2005), the Human Genome Diversity Project (Cann et al., 2002; Rosenberg et al., 2002) and
the 1000 Genomes Project (populations are defined in section 2.2; 1000 Genomes Project Consortium
(2010)). The 1000 Genomes Project Consortium (1000 Genomes Project Consortium, 2010, 2012,
2015) reported genome wide diversification between main population groups based on FST and ∆DAF.
Genome wide mean FST was found to only be a maximum of 8%, indicating overall little genetic
differentiation between populations, however several thousand SNPs had large FST indicating local
population adaptation (1000 Genomes Project Consortium, 2010). The analysis also found 139 non-
synonymous SNPs with large frequency differences between populations. Investigation of the 1000
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Genomes Project (1KGP) data set was also performed by Colonna et al. (2014). Using ∆DAF, it
was found that sites of high population differentiation (∆DAF > 0.7 between and > 0.25 within
continents) clustered together, the same was found for sites of low differentiation. Genes containing
highly differentiated sites were likely to also have additional evidence of positive selection in a third.
There was also a strong association of highly differentiated sites with genes and gene regulatory
elements.
Metabolic syndrome and gout have associations and interactions with genes in metabolic pathways and
the immune system (Osborn and Olefsky, 2012). The categories of genes that have displayed evidence
of selection from the previously mentioned genome-wide selection scans include: metabolism of sugars
(Voight et al., 2006; Tang et al., 2007), drug metabolism (Tang et al., 2007), immune system (Tang
et al., 2007; Grossman et al., 2010), and climate adaptation (Hancock et al., 2008). Genes that play a
role in adaptation to climate extremes are likely to play a role in metabolic disorders that make up
metabolic syndrome (Hancock et al., 2008). In contrast, variation in metabolic related genes can lead
to elite phenotypes in athletes, showing that metabolic genes also impact on fitness (Ahmetov et al.,
2009).
1.7.1.1 Selection in Polynesia
The inclusion of Oceanic populations in multi-population studies has had a focus on genetic structure,
measured via FST for differentiation to investigate population ancestry, rather than selection (Fried-
laender et al., 2008; Tennessen and Akey, 2011). The migratory history of Polynesian populations
suggests that the points of differentiation are likely the events possibly occurring since the out of
Africa dispersal ~60,000 years ago (Soares et al., 2012) with settlement of Near Oceania ~40,000 years
ago, and Remote Oceania ~3,100 years ago (Matisoo-Smith and Robins, 2004) and the Polynesian
Triangle (bounded by New Zealand, Easter Island, and Hawaii) ~1,000-1,200 years ago (Wilmshurst
et al., 2011). The time frame for these events means that nearly all the previously mentioned methods
would still be within their powered time frames to detect selective events. The haplotypic methods
would possibly not be able to detect selective events as old as the Africa dispersal and may be at the
fringe of the time period for the Near Oceania settlement.
Large population comparison studies have used Oceanic populations, but analyses were limited to
Melanesian and Papuan populations because the cohort used was the Human Genome Diversity
Project (Cann et al., 2002) which did not include Polynesian populations. The Melanesian and Papuan
populations are often used to infer the genetics of Polynesian populations. This extrapolation does not
take into account the current ancestry predictions of Polynesians populations being more closely related
to Asian/Taiwanese Aboriginal populations than Melanesian groups, or the presence of European
admixture (Friedlaender et al., 2008). Genomic DNA and mitochondrial DNA suggest Polynesians
have East Asian ancestry, with substantial male Melanesian admixture (Kayser et al., 2008). There
has been limited analysis of selection in Polynesian populations beyond Kimura et al. (2008), where 24
Tongan samples in conjunction with other populations were analysed using both FST and a modified
EHH test. Genomic regions with evidence of having been selected in the Tongan samples were potential
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candidates for increased fat, muscle and bone masses (Kimura et al., 2008).
A few candidate-genes for selection which also have been associated with obesity and type 2 diabetes
in Polynesian populations have been investigated, such as the PPARGC1A (Myles et al., 2011) and
CREBRF (Minster et al., 2016) genes. The “Thrifty-gene hypothesis” (Neel, 1962) has been the
reasoning behind why these loci may have undergone selection. The hypothesis was originally conceived
to attempt to explain the difference in prevalence of type 2 diabetes, that is, given that there should
be a strong selective pressure against it, there must be some genetic advantage. This hypothesis has
been challenged in the Polynesian context as fitting a particular narrative (Gosling et al., 2014, 2015;
Cadzow et al., 2016) with an alternative hypothesis being a link between the metabolic diseases and
the innate immune system that is under selective pressure via an infectious agent, such as malaria,
leading to disease susceptibility in these populations (Gosling et al., 2015).
1.7.2 Selection of metabolic syndrome and urate
The genetic influence of urate and gout is found in the under-excretion of serum urate. There are 28
loci that have been identified as having a role in hyperuricaemia and gout, of which, two (ABCG2 and
SLC2A9 ) are responsible 3.4% of the variability of urate (Köttgen et al., 2013). SLC2A9 encodes a
urate transporter expressed on both the apical and baso-lateral membranes in the proximal tubule
of the kidney and reabsorbs urate (Mandal and Mount, 2015). ABCG2 encodes an ATP powered
urate transporter and is responsible for urate excretion mostly in the gut (Maliepaard et al., 2001;
Mandal and Mount, 2015). Twenty-six other loci associated with serum urate explain a further 3.6%
of the variance (Köttgen et al., 2013). The heritability of serum uric acid ranges from 40 - 70% (Yang
et al., 2005; Nath et al., 2007). This difference in explained variability and total heritability leaves a
large component yet to be explained. This missing heritability could be reduced through identifying
additional variance attributed to non-additive effects.
There have been multiple genetic loci associated with type 2 diabetes (Billings and Florez, 2010) and
BMI (Locke et al., 2015a), however, Chen et al. (2010) found no evidence for enrichment in selection
for BMI, but found significant enrichment for type 2 diabetes. The genes associated with type 2
diabetes have been found to be differentiated by population, however the individual SNPs are often
not (Pickrell et al., 2009). Koh et al. (2014) identified six SNPs in or near nine genes that had been
reported as type 2 diabetes associated and overlapped with evidence of positive selection in East
Asian populations. Common variants that have been found in European populations associating with
obesity do not replicate in the Samoan population, although this is likely due to power (Karns et al.,
2012). The non-replication of European variants in Polynesians and the high prevalence of obesity in
Polynesian populations suggest there is likely to be some population specific variants that are yet to be
identified, similar to the Polynesian specific variant in CREBRF (rs373863828), associated with obesity
and protection for type 2 diabetes, identified in the Samoan population (Minster et al., 2016). Rare
variants tend to be recent and therefore geographically restricted (1000 Genomes Project Consortium,
2012).
The benefits of urate are in line with the categories found to be enriched by selection in genome wide
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scans. Urate is an anti-oxidant in the blood, acting to protect not just erythrocytes but also T and B
lymphocytes and macrophages (Ames et al., 1981). Urate has also been hypothesised to have had a
survival advantage during the Miocene period, when a series of mutations in urate oxidase occurred,
leading to elevated urate. Hyperuricaemia enables blood pressure to be maintained under low salt
dietary conditions (Watanabe et al., 2002). Serum urate is also a potent anti-oxidant which accounts
for >50% of the anti-oxidant activity of the blood (Glantzounis et al., 2005; Parmar, 2009). Later in
life elevated serum urate is associated with increased cognitive function (Euser et al., 2009). Urate
crystals activate the NLRP3 inflammasome which plays an important role in systemic infection and
sepsis (Opitz et al., 2009). The role of urate in these situations shows that while hyperuricaemia is now
considered as contributing to disease (such as gout), in the past it may have influenced longevity and
survival, therefore increasing reproductive success and being a phenotype that has undergone selection.
An elevated prevalence of metabolic syndrome co-morbidities and hyperuricaemia against a unique
genetic background of Polynesian populations provides an important opportunity to study the role
and effects that selection might have played on these metabolic conditions.
1.8 Research purpose and aims
This thesis seeks to understand selection in the context of Polynesian populations, and the effect it
may have played in the metabolic disease burden that is present in these populations. There are
three research chapters, each with their own aims. In Chapter 3: “Positive Selection in Polynesian
Populations”, the aims were to discover and characterise regions that have undergone selection in
Polynesian populations. In Chapter 4: “Clustering of Selection Statistics”, the aims were to investigate
potential shared ancestry regions that are relevant to urate and metabolic disease. And in Chapter 5:
“Selection and Association Studies”, the aims were to investigate the use of gout definition in genetic
association studies, and the use of selection statistics in conjunction with GWAS results.
It is hoped that the investigation of genetic selection in Polynesian populations will further under-




This chapter describes the methods and datasets used in this thesis. Section 3.2 covers the methods
used for the preparation of the datasets, such as haplotype phasing, principal component analysis
(PCA), and file format conversions, as well as the methods used for the analysis of the datasets, such as
the calculation of selection statistics. Section 2.2 contains a description of the two main data sources
that were used and how they were transformed for the analysis.
2.1 Methods
All genomic resources and co-ordinates reported in this project use the human genome reference build
GRCh37, unless otherwise specified.
2.1.1 Phasing
Haplotype phasing is a method of establishing the parental origin of haplotypes. It looks for the
co-location of alleles to form haplotypes. In diploids such as humans, there is a maternal and a paternal
haplotype at any given position in the genome. Selection statistics such as iHS require phased data in
order to calculate the degradation of haplotypes by recombination. Phasing can be performed through
the use of trios (parents and offspring), or it can be done through probabilistic phasing using large
population haplotype reference panels (such as created from the 1KGP, see section 2.2.1 and Table 2.4)
and probabilistically determining the most likely haplotype(s) for an individual given a set of markers.
Phasing was performed using SHAPEIT2 v2.r837 (Delaneau et al., 2013) using the 1KGP reference
haplotype panel (Table 2.4). There were two steps involved for phasing of genotypes. The first was to
check the markers in each data set were matched with the markers in the reference haplotypes. Markers
were marked for exclusion by this step for reasons such as the marker not being in the reference panel,
or if the marker had different allele types to that in the reference panel. An example of this step is
provided in the following code.
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# Check alignment of markers against reference haplotypes










The second step was the phasing of genotypes into their haplotypes by using the 1KGP phased
haplotype reference and a genetic map that was provided as part of the reference files. Markers that
were marked for exclusion from the previous step were excluded. The most likely pair of haplotypes
were outputted. The haplotypes were then converted from the haps format1 into a phased variant call
format (VCF)2. These two steps are shown in the following code.
# Run phasing against reference haplotypes
# Exclude misaligned markers
# Use 8 threads




















The PopGenome package (v2.2.3, Pfeifer et al. (2014)) for R was used for the calculation of Tajima’s
D, Fay and Wu’s H , Fu and Li’s F , and Zeng’s E . Popgenome calculates the D* and F* version from
Fu and Li (1993) which do not require an outgroup that should be a closely related population or
species. The selection and neutrality statistics were calculated using a sliding window approach with
a window size of 100 kb and a slide of 10 kb. Windows that had fewer than four segregating sites
were filtered out, and window co-ordinates were altered to be +/- 5 kb from the centre of the window.
The empirical distribution for each statistic, for each population, was used to create a significance
threshold. The lower threshold was min(1st percentile, 0). The upper significance threshold was
max(99th percentile, 0). The greater or less than zero condition was to enable the interpretation of
the selection and neutrality statistic results, as zero is the point at which these statistics indicate an
excess or deficit of a particular allele frequency category. FST was also calculated in the same sliding
window setup, and pair-wise between the Polynesian populations and the other populations. Negative
FST values were set to 0 because FST is biologically bounded to [0,1]. Negative values occur when the
variation within a population is larger than between populations.
The ancestral allele was used as annotated in the 1000 Genomes Phase 3 VCF file where possible, for
use as the out-group population. A new sample identified as ‘Ancestor’ was included in the phased VCF,
and for each marker the genotype for this sample was set as the homozygote for either the reference or
alternate allele, dependent on the ancestral allele matching, otherwise the Ancestor genotype was set
to missing. When the phased VCF files were loaded into PopGenome, populations were identified using
panel files which were white-space delimited files with sample id, population, and super population as
the columns. The out-group population for Fay and Wu’s H was set to be that of the Ancestor sample
so that the ancestral allele would be used in the calculation.
2.1.2.2 SelectionTools
SelectionTools v1.1 (Cadzow et al., 2014) was used to generate the haplotypic selection statistics of iHS,
nSL, and XP-EHH. The combined population phased VCF file was split into individual populations.
Within each population, markers were filtered for a MAF of > 0.01 and a Hardy-Weinberg Equilibrium
(HWE) exact test of P > 10-6 (Wigginton et al., 2005). Markers were converted into “ancestral” or
“derived” by comparing alleles to the homo sapiens ancestral fasta (see Table 2.4) with alleles that
matched the ancestor set to 0, and non-missing, non-matching alleles set to 1.
iHS, nSL, and XP-EHH normalisation with frequency bins of 0.05 was done using norm as part of
selscan v1.1.0b (Szpiech and Hernandez, 2014). Markers with an |iHS|, |nSL| or |XP-EHH| value > 2.6
met the threshold for significance, which was equivalent to approximately 1% of the most extreme
values.
Significant markers were also clustered into genomic regions using the DBSCAN package v1.1.1 (Hahsler
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and Piekenbrock, 2017) in R, where nearby SNPs were assigned the same group identifier. The search
radius used was 200 kb and the minimum number of points for a cluster was one. Cluster regions were
created by taking both the minimum and maximum position for each group identifier, population, and
chromosome.
2.1.3 Disease associated gene lists
In order to create lists of genes that were associated with urate, gout, obesity, type 2 diabetes,
metabolic syndrome, and kidney disease, disease trait entries were downloaded from the GWAS
catalog3 (MacArthur et al., 2017). The file was a rectangular format, with rows for each study result,
and columns such as reference paper, disease trait, association statistics, and mapped genes. Entries
were then filtered for P < 5x10-8. From the filtered results, the kidney disease gene list was created by
filtering the “disease trait” column to select rows with the keywords “kidney” or “renal”. Entries were
then removed that had the keywords “transplant”, “carcinoma”, “Type”, “stones”, “gout”, “related”,
or “Diabetic kidney disease”. For the gout, urate, obesity, type 2 diabetes, and metabolic syndrome
gene lists the following keywords were used on the “disease trait” column to select rows of the P-value
filtered data: “metabolic syndrome”, “obesity”, “diabetes”, “urate”, “gout”, “body mass”, and “lipid
traits”. This subset was then filtered to remove rows containing these keywords in the “disease trait”
column: “child”, “erectile”, “lean”, “autoantibodies”, “gestational”, “cancer”, “psychopharmacol”,
“metaformin”, “metformin”, “obstructive”, “interaction”, “asthmatics”, “omega”, “pain”, “cataracts”,
“time”, “bilirubin”, “chain”, “thyroid”, “zhi”, “Type 1”, or “cystic”. From this filtered data, keywords
were used to select rows relating to each trait of interest from the “disease trait” column. The keywords
“urate” and “gout” were used for gout and urate, “obesity” and “body mass” used for obesity, “diabetes”
used for type 2 diabetes, and “syndrome” used for metabolic syndrome. The keywords “kidney”
and “renal” were used for kidney disease, with entries removed that had keywords of “transplant”,
“carcinoma”,“type”, “stones”,“gout”, “related”, and “Diabetic kidney disease”.
Additional gene lists were created for malaria, auto-immune and auto-inflammatory diseases, and
neurological diseases. The keyword “malaria” was used to filter the disease trait column to create
the malaria gene list. The auto-immune and auto-inflammatory gene list was based on diseases
that were listed in Table 2 of Zhang et al. (2013). The following keywords were filtered for in the
disease trait column: “Crohn’s disease”, ‘Celiac disease’, “Ulcerative colitis”, “Inflammatory bowel
disease”, “Type 1 diabetes”, “Rheumatoid arthritis”, “Multiple sclerosis”, “Psoriasis”, “Systemic lupus
erythematosus”, “Primary biliary cirrhosis”, and “Vitiligo”. Finally, a list of genes associated with
neurological diseases was created by filtering the disease trait column for the keywords “Parkinson’s
disease” and “Alzheimer’s disease”. All keyword matching was case-insensitive. The code used for the
creation of the gene lists is found in Appendix B1. A list of the traits for each category can be found
in Table S7 and a list of the genes and what category they are from is in Table S8.
3gwas_catalog_v1.0.1-associations_e89_r2017-06-19.tsv https://www.ebi.ac.uk/gwas/ accessed 19 June 2017
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2.1.4 Principal component analysis
Principal component analysis is a statistical dimension reduction technique that transforms potentially
correlated variables into a linear and non-correlated set of variables. In a genetic context PCA is
used to reduce variation at many thousands of markers into a handful of components that represent
the majority of the variation of the data (Patterson et al., 2006). The components are ordered such
that the first principal component (PC) captures the most variation, with each subsequent component
capturing less. These components often, but not necessarily, represent population differences and
population substructure.
PCA was used to identify the genetic ancestry of the samples from the Genetics of Gout in Aotearoa
study to be used in the selection analysis (section 2.2.3). It was also used in the clustering analysis
to identify the genetic groupings for the populations (section 4.3.1.1). To calculate the principal
components of the genetic data, all populations and chromosomes were combined into a single VCF
file with BCFtools v1.3.1, and then the independent markers were identified via Plink v1.9b4.9, using
a sliding window to remove markers that had an inter-marker LD R2 > 0.2, with windows of 50 kb
and a slide of 5 markers. The first 10 principle components were calculated using smartPCA v13050




-o -o NZ_1KGP_allchr.vcf.gz \
--threads 10 $(ls NZ_1KGP.chr*gz | sort -n -t'r' -k2)
#find the independent markers
plink1.9b4.9 --vcf NZ_1KGP_allchr.vcf.gz \
--maf 0.1 \
--indep-pairwise 50 5 0.2 \
--out NZ_1KGP_allchr
# create an empty affection file that is required for Plink to use the --make-pheno
# which in turn is required for the creation of the ped file just the way
# SmartPCA wants it
touch cases.txt





# create the eigenstrat file









# calculate the principle components











Admixture arises when two populations that were previously separate, begin to interbreed, changing
the allele frequencies in the new population (Pritchard et al., 2000). Genetic admixture analysis
estimates the proportions and the variant frequencies of the ancestral populations that contributed to
the admixture. This is often done to account for population structure in GWAS studies. Admixture
analysis was performed to estimate the number of ancestral populations that that contributed to the
populations used in the selection analysis. It was also used because the Polynesian populations have
varying degrees of admixture (Wollstein et al., 2010).
Admixture analysis was performed using ADMIXTURE v1.3.0 (Alexander and Novembre, 2009). VCF
files for all autosomes were concatenated and the independent markers were selected by a moving
window of 50 kbp sliding by 10 markers and removing markers with a marker LD R2 > 0.1. This was
done using Plink v1.9b4.9. Following this, cross validation was performed to find the best value of K
(number of ancestral populations), for values of K from 1 to 15. The default of 5-fold cross-validation
was used, whereby the data were partitioned into five groups, with four used to train the model, and
the fifth to test the model. This was repeated five times, using a different combination of the partitions
each iteration. The following code was used to calculate the cross-validation errors.





--threads 10 $(ls NZ_1KGP.chr*gz | sort -n -t'r' -k2)
# find the independent snps
plink1.9b4.9 \
--vcf NZ_1KGP_allchr.vcf.gz \
--indep-pairwise 50 10 0.1 \
--out NZ_1KGP_allchr_admix
# extract the independent snps
plink1.9b4.9 \
--vcf NZ_1KGP_allchr.vcf.gz \
--make-bed --extract NZ_1KGP_allchr_admix.prune.in \
--out NZ_1KGP_allchr_admix
# do the cross-validation for the admixture components for K 1-15
for K in $(seq 1 15)
do
admixture -s 123456 --cv NZ_1KGP_allchr_admix.bed $K -j20 | tee log${K}.out
done
grep CV log* | cut -d':' -f1,3 |tr -d ':' | sed 's/log\|\.out//g' > CV_error.txt
2.1.6 Heritability analysis
Heritability analysis is a method for determining what proportion of phenotypic variation can be
attributed to environmental effects (non-heritable) and genetic effects (heritable) (Visscher et al., 2008).
There are two measures of heritability, the first is known as broad-sense heritability (H2) and is the
ratio of the total genetic variance to the total phenotypic variance. The second measure is narrow-sense
heritability (h2) and is the ratio of the genetic variance attributed to an additive genetic model to the
total genetic variance.
The Genome-wide Complex Trait Analysis (GCTA) v1.26.0 software (Yang et al., 2011a) was used to
calculate the proportion of genetic heritability explained for gout. First the UK Biobank genetic data
(section 2.2.4) were subsetted to only contain gout cases and controls and the genome partitioned into
chromosomes. A genetic relationship matrix (GRM) was created for each chromosome. The genetic
variance explained was calculated for each chromosome using restricted maximum likelihood analysis
and a general population prevalence for gout of 2%. The following code was used to calculate the
GRM and partition the genetic heritability by chromosome.
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# load fam into R
# sample(10000, fam[AFF == controls]) -> controls.txt
# cat condition.fam |
# awk '{if($6 == 2){print $1"\t"$2}}' | cat - controls.txt > ids_keep.txt
# Subset samples
for i in $(seq 1 22)
do









# Calculate the genetic relationship matrix by chromosome







--thread-num 16 > grm_${i}.log \
done
# Calculate the genetic variance explained using a
# general population gout prevalence of 2%













Gene set analysis was performed by inputting gene lists into Enrichr4 (Chen et al., 2013; Kuleshov et al.,
2016). The pathway enrichment results were based on the KEGG 2016 table, which is a long-standing
database, curated by a small group of experts (Kanehisa et al., 2017). A significance threshold for a
pathway was set at P < 0.05 after Benjamini-Hochberg adjustment (Benjamini and Hochberg, 1995)
for multiple hypothesis testing, as provided by Enrichr.
2.2 Datasets
The following sections describe the genomic datasets used in this thesis.
2.2.1 1000 Genomes Project Phase 3
The 1000 Genomes Project was an international consortium that was established in 2007 to provide a
comprehensive record of human genetic variation (Siva, 2008). The project consisted of three main
data phases. A pilot phase that whole-genome sequenced 179 individuals from four populations at low
coverage (2-4x), along with high coverage sequencing for two trios (mother, father, and child), and exon
targeted sequencing for 697 individuals from seven populations (1000 Genomes Project Consortium,
2010). The second main data phase provided sequencing data for 1092 individuals from 14 populations.
This sequencing data set was a combination of low coverage whole-genome and exon sequencing (1000
Genomes Project Consortium, 2012). The third main phase (Phase 3) was a dataset consisting of low
coverage whole-genome sequencing, deep exome sequencing, and dense SNP array genotyping for 2504
individuals from 26 populations (1000 Genomes Project Consortium, 2015). The 1000 Genomes data
set used in this thesis was the Phase 3 release5.
2.2.2 Genetics of Gout in Aotearoa study
The genetics of Gout in Aotearoa study is a case-control cohort for gout, with recruitment mainly
from the Auckland, Wellington, Christchurch and Dunedin regions of New Zealand. Participants
were asked to fill in a questionnaire regarding demographic information, clinical information, and
gout-relevant food consumption at the time of recruitment. Gout cases fulfilled the American College
of Rheumatology (ACR) criteria (Wallace et al., 1977). Controls self-reported no history of gout at the
time of recruitment. All individuals gave written informed consent, and ethical approval was obtained
4http://amp.pharm.mssm.edu/Enrichr/
5ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/ accessed 20 March 2017
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Table 2.1: Description of Populations used in the selection analysis (n = 3004).
Population Description n Genotype Platform
African Super Population (AFR) n = 661
ACB African Caribbeans in Barbados 96 Illumina HiSeq
ASW Americans of African Ancestry in SW USA 61 Illumina HiSeq
ESN Esan in Nigeria 99 Illumina HiSeq
GWD Gambian in Western Divisions in the Gambia 113 Illumina HiSeq
LWK Luhya in Webuye Kenya 99 Illumina HiSeq
MSL Mende in Sierra Leone 85 Illumina HiSeq
YRI Yoruba in Ibadan Nigeria 108 Illumina HiSeq
Admixed American Super Population (AMR) n = 347
CLM Colombians from Medellin Colombia 94 Illumina HiSeq
MXL Mexican Ancestry from Los Angeles USA 64 Illumina HiSeq
PEL Peruvians from Lima Peru 85 Illumina HiSeq
PUR Puerto Ricans from Puerto Rico 104 Illumina HiSeq
East Asian Super Population (EAS) n = 504
CDX Chinese Dai in Xishuangbanna China 93 Illumina HiSeq
CHB Han Chinese in Bejing China 103 Illumina HiSeq
CHS Southern Han Chinese 105 Illumina HiSeq
JPT Japanese in Tokyo Japan 104 Illumina HiSeq
KHV Kinh in Ho Chi Minh City Vietnam 99 Illumina HiSeq
European Super Population (EUR) n = 603
CEU Utah Residents (CEPH) with Northern and Western Ancestry 99 Illumina HiSeq
FIN Finnish in Finland 99 Illumina HiSeq
GBR British in England and Scotland 91 Illumina HiSeq
IBS Iberian Population in Spain 107 Illumina HiSeq
TSI Toscani in Italia 107 Illumina HiSeq
NZC* Europeans in New Zealand 100 CoreExome_v24
Polynesian Super Population (POL)* n = 400
CIM* Cook Island Maori in New Zealand 100 CoreExome_v24
NZM* Maori in New Zealand 100 CoreExome_v24
SAM* Samoans in New Zealand 100 CoreExome_v24
TON* Tongans in New Zealand 100 CoreExome_v24
South Asian Super Population (SAS) n = 489
BEB Bengali from Bangladesh 86 Illumina HiSeq
GIH Gujarati Indian from Houston Texas 103 Illumina HiSeq
ITU Indian Telugu from the UK 102 Illumina HiSeq
PJL Punjabi from Lahore Pakistan 96 Illumina HiSeq
STU Sri Lankan Tamil from the UK 102 Illumina HiSeq
* NZC, NZM, TON, SAM, and CIM are from the ’Genetics of Aotearoa’ study. All others are from the 1000
Genomes Project.
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from the New Zealand multi-region ethics committee (MEC/105/10/130). Individuals from this study
were genotyped on Illumina CoreExome v24 SNP arrays using DNA extracted from blood samples
provided at the time of recruitment. Table 2.2 provides the overall clinical characteristics for this
cohort.
A subset of the individuals from this study were used to form four populations of Polynesian ancestry,
two for East Polynesia (Cook Island Māori in New Zealand (CIM) and Māori in New Zealand (NZM)),
and two for West Polynesia (Samoans in New Zealand (SAM) and Tongans in New Zealand (TON)),
and one population of European ancestry (Europeans in New Zealand (NZC)). These sub-populations
formed part of the selection analysis dataset described in section 2.2.3).
2.2.2.1 CoreExome
The Infinium CoreExome-24 bead-chip is a genotyping platform available from Illumina and is comprised
of a core set of 551,839 markers. A subset of the individuals in the Genetics of Gout in Aotearoa
study were genotyped on this platform at the University of Queensland (Centre for Clinical Genomics).
Genotype quality control was performed by Dr Tanya Major (Merriman Lab) following the protocol from
Guo et al. (2014) and the Illumina GenomeStudio best practice guidelines6. Illumina’s GenomeStudio
v2011.1 genotyping module v1.9.4 was used for the initial calling of genotypes. Samples were exported
from GenomeStudio that had a call rate > 98%, markers were removed if the call-rate was < 95%.
Individuals who had not reported their sex were assigned their genetic sex where possible. Individuals
were removed where genetic and reported sex did not match. The cohort was checked for genotype
consistency between duplicated markers, with duplicates subsequently removed.
Markers were subsetted to only include biallelic SNPs, with a final marker number of 305214 and
density of 9142 bp/marker. Relatedness between individuals was assessed through inheritance by
state using Plink v1.9b3.32 and a pedigree of families created by Dr Tanya Major (Merriman lab) to
identify family groups. Duplicates and first-degree relations were excluded and single individuals were
randomly selected from family groups identified through identity by state analysis, which determined
the proportions of individual genomes that were identical in a pair-wise manner. In order to account
for population specific genetic differences, self-report of grandparent ethnicity was used to infer the
genetic ancestral populations from clusters of individuals after plotting different PCs from the PCA on
the genetic markers (section 2.1.4). Individuals were removed from further analysis where there was
disagreement between self-reported grandparent ethnicity and the inferred genetic ancestry. Hardy-
Weinberg equilibrium of markers was checked for European, East Polynesian, and West Polynesian
populations using a HWE exact test (Wigginton et al., 2005) in Plink v1.9b3.32, and variants were
removed if they had a Bonferroni multiple testing corrected P < 0.05.
6https://www.illumina.com/Documents/products/technotes/technote_infinium_genotyping_data_analysis.pdf ac-
cessed 18 January 2016
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Table 2.2: Clinical information for samples that were genotyped on the CoreEx-
ome platform by genetic ancestry.
European Eastern Polynesian Western Polynesian
Control Gout Control Gout Control Gout
Fatty liver, n (%) 10 (0.88) 27 (2.45) 2 (0.23) 4 (0.66) 1 (0.26) 6 (1.34)
Kidney disease, n (%) 32 (2.82) 240 (21.82) 26 (3.01) 133 (21.8) 11 (2.85) 83 (18.53)
Mean Diastolic BP (SD) 130.3 (17.4) 139.4 (45.7) 130.6 (19.3) 135.9 (20.4) 130 (18.4) 132.6 (17.6)
Diabetes, n (%) 54 (4.77) 159 (14.45) 100 (11.59) 159 (26.07) 53 (13.73) 99 (22.1)
n 1133 1100 863 610 386 448
Heart disease, n (%) 114 (10.06) 387 (35.18) 96 (11.12) 225 (36.89) 22 (5.7) 90 (20.09)
Mean age, years (SD) 48.79 (18.36) 63.54 (13.05) 44.17 (15.46) 56.12 (12.65) 38.54 (14.45) 48.82 (12.58)
Mean BMI (SD) 27.16 (5.47) 30.33 (5.4) 31.9 (7.84) 35.42 (8.17) 34 (6.7) 36.64 (7.32)
Mean Systolic BP (SD) 76.9 (10.9) 79.3 (11.5) 81.1 (13.8) 83.9 (13.6) 79.8 (15.2) 82.3 (11.7)
Sex, n male (% male) 606 (53.49) 927 (84.27) 333 (38.59) 466 (76.39) 207 (53.63) 406 (90.62)
BP = blood pressure (mmHg). BMI = body mass index (kg/m2).
2.2.3 Selection dataset
2.2.3.1 Sample selection
A subset of the individuals were chosen to create representative sample Polynesian populations of
similar size to the other populations in the 1KGP to be used in a comparison for the selection analyses.
Principal components were calculated for all individuals genotyped on the CoreExome SNP array using
SmartPCA (EIGENSOFT v6.0.1, see section 2.1.4) using 2858 ancestry informative markers (Guo et al.
(2014) supplementary material). The first 10 eigenvectors were outputted, with no outlier removal or
population size limit. Individuals were removed who did not match between self-reported ethnicity
of grandparents and their genetic ancestry, or if they had self-reported all grandparent ethnicities as
unknown.
Principal component 2 was identified as providing the best separation of European ancestry from
Polynesian ancestry, and PC 4 had the best separation of East Polynesian from West Polynesian
ancestry. Individuals were then filtered for European or Polynesian ancestry. Individuals reporting
four grandparents of European, New Zealand Māori, Cook Island Māori, Samoan, and Tongan ancestry
were used to define the threshold values, as they were most likely to represent the ancestral populations.
The mean and SD for PC 2 and PC 4 were calculated for the individuals who had self-reported
four grandparents of the same ethnicity. Thresholds were then applied using the four grandparent
population mean ± 2 SD for PC 2 and PC 4 for each corresponding self-report population group.
Samples were filtered so that only those that lay within the thresholds remained. Population samples
of 100 individuals were created by using genetic ancestry for the following populations: Māori in New
Zealand, Cook Island Māori in New Zealand, Samoans in New Zealand, Tongans in New Zealand, and
Europeans in New Zealand, by randomly sampling from within each ancestry group (Figure 2.1). To
create a population sample that resembled the general population for gout prevalence, individuals were
prioritised based on gout affection to reach population specific prevalences based on Winnard et al.
(2013) of 2.3% for NZC, 7.7% for NZM, and 8.6% for CIM, SAM, and TON. Final sample population
prevalence of 2.0% (NZC), 7.0% (NZM), 45.0% (CIM), 12.0% (SAM), and 54.0% (TON) were obtained
for gout (Table 2.3).
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Figure 2.1: Principal components 2 and 4 for individuals used in the selection
analysis.
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2.2.3.2 Filter individuals and markers
To create a data set from which to calculate selection statistics, the subset of the Genetics of Aotearoa
individuals genotyped on the Illumina CoreExome chip were combined with all of the individuals in
the 1KGP phase 3 release. This was done in order to have a common set of markers between all
populations, making the populations comparable. Before the data sets could be combined there were a
series of steps that were performed. The first step (code following) was to keep only the individuals who
had been selected through PCA and had a genotyping rate (percentage of all markers with genotypes)













' ::: $(seq 1 22)
The second step was to ensure that all the CoreExome markers were normalised against the hs37d5
human reference. This was to make sure the reference (REF) and alternative (ALT) alleles would
match with the 1KGP phase 3 for a successful merge after phasing and subject selection. SHAPEIT2
was then used to find SNP alleles that disagreed with the 1KGP haplotype reference and phase the















' ::: $(seq 1 22)
After normalisation, the VCF files were phased using the 1000 Genomes Project phase 3 reference
haplotypes as described in section 2.1.1.
2.2.3.3 Merge genotypes
In order to efficiently merge the data sets, the intersection of the markers from the 1KGP dataset and
the CoreExome dataset was found. This was done by extracting the marker positions and alleles from
the CoreExome data and then matching these to the marker positions extracted from the 1KGP phase
3. The 1KGP phase 3 markers were also filtered to remove non-biallelic SNPs. The following code
demonstrates these steps.
# extract markers from core exome
parallel '
zgrep \
-v "^#" QC1_7-plus_correctAff_norm.chr{}.phased.vcf.gz |\
cut -f1,2,4,5 > coreExome_chr{}_biallelic_markers.txt
' ::: $(seq 1 22)









grep -v "^#" |\
cut -f 1,2,4,5 > 1kgp_chr{}_biallelic_markers.txt
' ::: $(seq 1 22)
An R script (below) was created in order to merge the two marker lists based on chromosome position
and the reference and alternate alleles.









ce_markers <- do.call(rbind, tmp_list)




tmp_list2[[i]] <- read.table(file= paste0(
'1kgp_chr',i,'_biallelic_markers.txt'),
header=FALSE)
# find the markers in common between CoreExome and 1KGP
tmp_list2[[i]] <- tmp_list2[[i]][ tmp_list2[[i]][,2] %in% tmp_list[[i]][,2],]
}
kg_markers <- do.call(rbind, tmp_list2)
ce_kg <- merge(ce_markers, kg_markers, by = c("V1","V2","V3","V4"))
# write out the common markers
write.table(file = 'ce_1kg_matched_markers.txt', ce_kg[,c(1,2)],
row.names = FALSE, col.names=FALSE, quote=FALSE)
Once the combined marker list was created, both the CoreExome and 1KGP data sets had markers
filtered to match this consensus set. The code for marker filtering of the VCF files and subsequent
merge is shown below.
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' ::: $(seq 1 22)
Sample identifiers were then updated to match the panel file that described the population and super
population an individual belonged to. The following code applies this step to each merged VCF file.
# Combine FID and IID of CoreExome samples so they match the panel file






tr '\t' '\n' |\







The UK Biobank is a collection of 500,000 individuals, mostly of European ancestry from around the
United Kingdom, and aged between 40 and 69. It consists of genetic, health, and lifestyle information.
The interim release dataset (approval number 12611) was downloaded in November 2015 and contained
genotypes for 152,249 individuals. Gout affection was determined by self-report, or self-reported use of
urate lowering therapy, or an International Classification of Diseases, Tenth Revision (ICD-10) code
for gout (M10, including sub-codes). The dataset was also filtered to individuals with a self-reported
ethnic background of British, Irish, or ‘any other white background’. Individuals were removed who
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had a mismatch between self-reported sex and genetic sex, or whose samples failed genotype quality
control. The remaining individuals were eligible for inclusion in the GWAS performed in section 5.2.1.
2.2.5 Reference datasets
Table 2.4 provides the name of the dataset, the date it was accessed, and the URL from which the
dataset was downloaded. These datasets were incorporated into many of the analysis steps.
Table 2.4: Reference Datasets
Name Date URL
1000 Genomes Project
Phase 3 release 5
20 Mar 2017 http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/
release/20130502/
1000 Genomes Phase 3
phased haplotypes














Positive Selection in Polynesian
Populations
In this chapter I investigate regions of the genome that exhibit signatures of selection in Polynesian
populations, with a particular focus on loci associated with serum urate levels and metabolic conditions.
3.1 Introduction
At the turn of the millennium the draft reference human genome was released (Lander et al., 2001).
Following from this, there were a number of large projects to characterise human variation and diversity.
The first project was the HapMap project (The International Hapmap Consortium, 2005) and was
based on single nucleotide polymorphism (SNP) array data. This was followed by the 1000 Genomes
Project (1000 Genomes Project Consortium, 2010, 2012, 2015) which was the first large project to be
based on whole-genome (re)sequence data. Alongside these variation projects were a few projects that
aimed to focus on the genomic diversity of humans, such as the Human Genome Diversity Project
(Cann et al., 2002; Rosenberg et al., 2002), and later the Simons Genome Diversity Project (Mallick
et al., 2016).
Over the last decade there has been a steady flow of studies on genome-wide selection (Sabeti et al.,
2006; Voight et al., 2006; Tang et al., 2007; Coop et al., 2009; Pickrell et al., 2009; Grossman et al.,
2010). The main population samples for this have been part of the 1000 Genomes Project, which
sampled over 2500 individuals for full genome (re)sequencing from five ‘super’ population groups (1000
Genomes Project Consortium, 2015). The five super populations cover each of the geographical regions
of Africa, Europe, East Asia, South Asia, and the Americas. This dataset, while capturing a large




3.1.2 Selection in Polynesian populations
Projects to capture the genetic diversity of humans have sampled populations worldwide, but outside
the populations sampled by the 1000 Genomes Project, the population sample sizes have been small
(Cann et al., 2002; Rosenberg et al., 2002; Mallick et al., 2016). Past studies that have included Oceanic
populations have had minimal representation of Polynesian populations, for example, Kimura et al.
(2008) only had 24 Tongan individuals. The latest project for human diversity, the Simons Human
Diversity Project, did include New Zealand Māori but they were only represented by a single individual
and did not feature in many of the analyses (Mallick et al., 2016).
More recently there have been studies that have looked at selection in Polynesian populations but with
a focus on a few candidate loci, not at a genome-wide scale (Myles et al., 2011; Cadzow et al., 2016;
Minster et al., 2016). The main feature of these studies has been the investigation of “thrifty genes”.
3.1.2.1 Thrifty gene hypothesis
The “Thrifty genotype hypothesis” was originally hypothesised by Neel (1962), whereby it was posed
there must be a genetic advantage to a disease, given what should be a strong selection pressure against
it, for it to continue to have a high prevalence - referring to diabetes. In the Polynesian context, this
hypothesis has been invoked in an attempt to explain the higher prevalence of metabolic related diseases
such as type 2 diabetes and obesity (Myles et al., 2011; Minster et al., 2016). However, there are
several refutations of the thrifty genotype for Polynesian populations as fitting a particular narrative
(Gosling et al., 2014, 2015; Cadzow et al., 2016). An alternative to the ‘thrifty-gene’ hypothesis is that
the link between metabolic diseases and the innate immune system, susceptibility of populations to
metabolic disease might be due to selective pressure from infectious disease, such as malaria (Gosling
et al., 2015). Uricase, the enzyme for metabolising urate, was lost through multiple mutations - a
reduction in promoter activity followed by two further loss of function mutations and occurred before
the divergence of humans from the great apes (Kratzer et al., 2014). The evolutionary history of
uricase however has also been described as “the original thrifty-gene” (Kratzer et al., 2014).
3.1.3 Selection in urate and gout
The benefits of urate include the its ability to increase blood pressure and it is thought to have
helped early hominins to stand upright (Watanabe et al., 2002) and increase blood flow to the brain.
Serum urate is also a potent anti-oxidant which accounts for >50% of the anti-oxidant activity of the
blood (Glantzounis et al., 2005; Parmar, 2009). Mono-sodium urate crystals that form in conditions
of elevated urate are a potent adjuvant for the immune system and enhances the immune response
(Ames et al., 1981; Opitz et al., 2009). Uric acid has also been identified as being an important part
of the malarial response, contributing to cytokine secretion and response of dendritic and T-cells
(Gallego-Delgado et al., 2014).
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An increased level of urate in the blood is called hyperuricaemia and is causal of gout (Choi et al., 2005).
The prevalence of hyperuricaemia in Polynesian populations is higher than many other populations
(Gosling et al., 2014), and co-morbid with it are higher prevalences of the co-morbidities of gout,
diabetes, obesity, dyslipidaemia, kidney disease, and cardio vascular disease (CVD) (Winnard et al.,
2013). In New Zealand, gout prevalence is ~3.1%, however, prevalence in Māori and Pacific peoples is
6-8% with 40% of individuals with gout also having diabetes or CVD (Winnard et al., 2013). Gout
is an immune response to the monosodium urate crystals that are formed from the precipitation of
urate from the blood, with hyperuricaemia being a prerequisite for the formation of these crystals
(Merriman and Dalbeth, 2011).
Hyperuricaemia has two main components: overproduction of urate, and under-excretion. Overpro-
duction is influenced by diet, such as high purine or fructose content, or increased cell turnover as
observed in cancer, or under genetic control. Under-excretion is the main cause of hyperuricaemia,
caused by either increased reabsorption or decreased secretion. The kidneys are the organ where the
majority of secretion and excretion of urate is performed, with about 90% of urate being reabsorbed
(Kutzing and Firestein, 2008). In the proximal tubule, on the apical membrane, the urate transporters
of URAT1 (SLC22A12 ), OAT4 (SLC22A11 ), and GLUT9 (SLC2A9 ) reabsorb urate, whereas ABCC4,
NPT4 (SLC17A3 ), and NPT1 (SLC17A1 ) are responsible for secretion (Figure 3.1) (Mandal and
Mount, 2015). On the basolateral membrane, OAT1-3 (SLC22A6-8 ), increase intracellular uric acid,
but GLUT9 moves uric acid from intracellular to extracellular (Mandal and Mount, 2015). The ATP
powered transporter ABCG2 is responsible for excretion of urate in the gut and there are SNPs that
lead to a reduction of function in ABCG2 in all populations (Figure 3.1) (Phipps-Green et al., 2010;
Cleophas et al., 2017). Together the genes SLC2A9 and ABCG2 account for 3.4% of the genetic
variability of urate (Köttgen et al., 2013).
Figure 3.1: Diagram representing the urate transporters in the gut (entrocyte)
and kidney (renal proximal tubule cell). Direction of urate movement is indicated
by arrows. Adapted from Major et al. (2018).
From previous studies there is prior evidence of selection at urate associated loci (Grossman et al., 2013;
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Zhang et al., 2013; Ramos, 2017). In the review from Ramos (2017) on natural selection in rheumatic
disease, one of the main loci for gout, SLC2A9, in the Yoruba in Ibadan Nigeria (YRI) population was
reported as having been selected. The region of BCAS3 and NACA2 also had evidence, originally
found by Grossman et al. (2013) in the Asian population from the HapMap project data. Zhang et al.
(2013) had evidence for the urate-associated loci of ATXN2 (rs653178) and RREB1 (rs675209) having
undergone selection when using a FST-based method. The co-morbidities of hyperuricaemia also show
signs of selection, with loci associated with type 2 diabetes having been reported as having undergone
selection (Voight et al., 2006; Pickrell et al., 2009; Grossman et al., 2010, 2013). Most recently a
Samoan specific variant in CREBRF that is protective for type 2 diabetes but causal for obesity has
also been identified as having evidence of selection in the Samoan population (Minster et al., 2016).
3.1.4 Objectives
The objectives of this chapter are to:
• Investigate regions that are under selection in Polynesian populations.
• Investigate regions previously associated with urate, type 2 diabetes, obesity, kidney disease, and
metabolic syndrome for signatures of selection.
3.2 Methods
The choice of individuals, and preliminary data preparation for the selection data set is detailed in
section 2.2.3. It consisted of combining 500 individuals (100 per population for each of Māori in New
Zealand (NZM), Cook Island Māori in New Zealand (CIM), Samoans in New Zealand (SAM), Tongans
in New Zealand (TON), and Europeans in New Zealand (NZC)) from the Genetics of Gout in Aotearoa
study, who had been genotyped on the Illumina CoreExome v24 SNP array with 2504 individuals from
the 1000 Genomes Project.
3.2.1 Calculation of selection and neutrality statistics
The R package PopGenome v2.2.3 (Pfeifer et al., 2014) was used to calculate the site-frequency spectrum
statistics Tajima’s D, Fay and Wu’s H , Fu and Li’s F , Zeng’s E , and FST over non-overlapping windows
of 10 kb (see section 2.1.2.1 for further details). Except for FST, the empirical distribution for each
population was used to create an upper and a lower significance threshold. The lower threshold was
the 1st percentile and less than zero. The upper significance threshold was the 99th percentile and
greater than zero. Contiguous regions of score depression or elevation were created using a rolling
window approach, whereby a condition of 15 or more windows out of a minimum of 20 consecutive 10
kb windows were required to have met a significance threshold in the same tail of the distribution.
These represent extended regions of the genome and can be indicative of a selective sweep (Carlson
et al., 2005).
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The integrated haplotype homozygosity score (iHS), number of segregating sites by length (nSL),
and cross-population extended haplotype homozygosity (XP-EHH) were calculated and normalised
using selscan v1.1.0b (Szpiech and Hernandez, 2014) as part of the selectionTools 1.1 (Cadzow et al.,
2014), pipeline as detailed in section 2.1.2.2. The default setting was used which was a maximum
gap extension of 200 kb. Significance was defined as |value| > 2.6 which was equivalent to the most
extreme ~1% of values after normalisation using frequency bins of 0.05.
3.2.2 Pathway enrichment analysis
Pathway enrichment analysis was performed by taking genes that intersected the 1st percentile windows
for the site frequency spectrum-based statistics that also had a value < 0, or genes that had a significant
marker for iHS or nSL and inputting them into Enrichr1 (Chen et al., 2013; Kuleshov et al., 2016) and
exporting the KEGG 2016 pathway table.
3.3 Results
Results will be split into two themes, the first will be regions of the genome that show evidence of
selection in the Polynesian populations. This theme will initially cover the results of the Polynesian
populations as a combined group, and then results that were specific to individual populations. The
second theme will look specifically at selection of urate and associated loci in Polynesian populations.
For reporting, there will be a focus on the 1st percentile/lower tail for the intra-population statistics as
this is the distribution end that corresponds with positive selection.
3.3.1 False discovery rate of windowed statistics
In order to control for false positives, the empirical false discovery rate (FDR) was calculated for
Tajima’s D, Fu and Li’s F , Fay and Wu’s H , and Zeng’s E . To calculate the FDR, 5000 permutations
of the genotype data were performed, each randomly shuffling the genotypes of markers by marker
position (i.e. shuffling rows only). This process re-defined the marker composition of each window,
requiring new selection statistics to be calculated for each window. This procedure therefore, generated
a new distribution for values of each selection statistic (per permutation) under the null hypothesis
of no association between marker genotype and genomic position. A similar method was used by
Teshima and colleagues (2006). For each permutation, for each statistic, the values for quantile
‘bins’ were calculated for both tails of the distribution. The ‘bins’ ranged from 0.01 to 0.1% in 0.01
increments, 0.1 to 1% in 0.1% increments, 1 to 5% in 1% increments, and 10%. The median and 95%
confidence intervals were calculated for the values of the quantile ‘bins’ across the permutations (i.e.,
the median, 2.5th and 97.5th percentiles for the values of the 1st percentile bin from all permutations).
The enrichment for each quantile bin was then calculated by comparing the number of windows that
were observed in the data compared to the number expected from the permutations. FDR was then
1http://amp.pharm.mssm.edu/Enrichr/ accessed 22 November 2017
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Table 3.1: False discovery rate for windowed frequency spectrum based intra-
population statistics by population.
Lower tail Upper tail
Population Percentile FDR (95% CI) Percentile FDR (95% CI)
Fay and Wu’s H
CIM 0.06 0.059 (0.051, 0.071) 99.4 0.571 (0.532, 0.609)
NZM 0.07 0.066 (0.057, 0.076) 99.4 0.585 (0.538, 0.625)
SAM 0.06 0.056 (0.049, 0.065) 99.4 0.570 (0.524, 0.615)
TON 0.05 0.050 (0.043, 0.059) 99.4 0.589 (0.546, 0.626)
Fu and Li’s F
CIM 0.20 0.181 (0.161, 0.206) 99.6 0.348 (0.305, 0.389)
NZM 0.20 0.170 (0.152, 0.193) 99.6 0.371 (0.327, 0.423)
SAM 0.20 0.184 (0.167, 0.205) 99.5 0.436 (0.386, 0.484)
TON 0.20 0.191 (0.175, 0.220) 99.5 0.490 (0.436, 0.554)
Tajima’s D
CIM 0.03 0.028 (0.023, 0.034) 99.8 0.165 (0.147, 0.189)
NZM 0.04 0.037 (0.032, 0.045) 99.8 0.174 (0.156, 0.194)
SAM 0.02 0.019 (0.016, 0.024) 99.8 0.191 (0.169, 0.219)
TON 0.03 0.026 (0.022, 0.031) 99.8 0.188 (0.165, 0.213)
Zeng’s E
CIM 2.00 1.000 (1.000, 1.000) 99.5 0.436 (0.405, 0.472)
NZM 2.00 1.000 (1.000, 1.000) 99.5 0.434 (0.401, 0.470)
SAM 2.00 1.000 (1.000, 1.000) 99.6 0.389 (0.361, 0.422)
TON 2.00 1.000 (1.000, 1.000) 99.6 0.389 (0.362, 0.423)
Percentile is the more conservative FDR quantile bin of the permuted data that
was equivalent to either the 1st (lower tail) or 99th (upper tail) percentile in the
observed data.
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estimated by using the value for the 1st or 99th percentile and finding the nearest conservative quantile
bin using the median, that was either larger for the lower tail, or smaller for the upper tail and
taking the inverse of enrichment for the bin (Table 3.1). As a result, the estimate will be conservative
compared to the true FDR but will still maintain FDR control.
The FDR for Zeng’s E was 1.0 for all Polynesian populations in the lower end of the distribution and
the 1st percentile of the data fell within the 2nd percentile bin from the permutations. This means
that the 1st percentile threshold from the observed Zeng’s E fell between the 1st and 2nd percentile of
the null distribution and was entirely within the 95% confidence interval. Whereas, for Tajima’s D
and Fay and Wu’s H the maximum quantile bin for the Polynesian populations in the lower tail was
0.07% (NZM), with the maximum upper confidence interval being 0.076 (NZM). For the purpose of
reporting on individual statistics, a threshold of 0.1 was applied, to reduce the expected false positive
rate to be less than 1 in 10 on average. Fu and Li’s F and Zeng’s E both had an FDR above this
threshold for the Polynesian populations and will be reported on only as additional evidence when
they overlap with other results or were in a region of contiguously depressed score (section 3.2.1).
3.3.2 Comparison with prior publications
The selection and neutrality statistics that were in the 1st percentile and < 0 were compared to regions
and genes identified in Hider et al. (2013) for East Asian Super Population (EAS) and Jonnalagadda
et al. (2017) for South Asian Super Population (SAS) as these papers had used a similar, but not
identical methodology to identify regions under selection. Hider et al. (2013) investigated selection in
the East Asian populations (Han Chinese in Bejing China (CHB), Southern Han Chinese (CHS), and
Japanese in Tokyo Japan (JPT)) of the 1000 Genomes Project in the Phase 1 release. For this they
used a non-overlapping window size of 25 kb and excluded windows with less than 10 segregating sites
and then looked at the top 1% of results. They reported regions that were significant for Tajima’s D,
Fay and Wu’s H , Fu and Li’s F , and iHS. Comparing the regions from Hider et al. (2013) with regions
that met the significance threshold for this project there were 118 of 206 regions for Tajima’s D, 15 of
151 for Fay and Wu’s H , 83 of 255 for Fu and Li’s F , and 5 of 85 for iHS (Table S1).
Of the genes reported in Jonnalagadda et al. (2017), there were 2 of 5 for Tajima’s D (DST and
SLC24A5 ), 0 of 5 for Fay and Wu’s H , and 2 of 5 for iHS (TYR and ADAM17 ) that were also
significant in this project. Jonnalagadda et al. (2017) used the same window set up as Hider et al.
(2013), but used the 1000 Genomes Project Phase 3 release for the Gujarati Indian from Houston
Texas (GIH) and Indian Telugu from the UK (ITU) populations.
In conjunction with the studies from Hider et al. (2013) and Jonnalagadda et al. (2017), Ramos (2017)
looked at evidence of selection in rheumatic disease, including gout, using the iHS results from Voight
et al. (2006) from the HapMap phase II dataset. There were three populations used which were Asian,
European, and African. When comparing the loci reported in Ramos (2017) with the iHS results,
here the equivalent populations of CHB and JPT were used to represent the Asian population, Utah
Residents (CEPH) with Northern and Western Ancestry (CEU) for European, and YRI for African.
Where the population was unknown in Ramos (2017), all of the specified populations (CEU, CHB,
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JPT, and YRI), from the 1000 Genomes Project individuals were used. Loci reported for European
had 47.8% overlap with CEU. The Asian reported loci matched 31.6% with CHB and JPT, and for
African, 23.1% of the reported loci were also found in YRI. For the loci reported with an unknown
population, 65.0% were found to match in any of CEU, YRI, CHB, or JPT.
To supplement the Ramos (2017) iHS regions, additional genes were included from Voight et al.
(2006) Table 1 to include genes that showed evidence of selection across different combinations of
the populations and were not specific to rheumatic disease. The populations covered by these genes
were CEU, CHB, CHS, JPT, and YRI. The genes included were: LCT - specific for CEU; SLC44A5 -
specific for CHB, CHS, and JPT; NCOA1, ADCY3 and SYT1 - specific for YRI; SNTG1 - specific for
CEU, CHB, CHS, JPT, and YRI; and SPAG4 - specific for CEU and YRI. All genes except SPAG4
were positive for significant iHS markers in the corresponding populations they were originally reported
in.
The differences in regions being found as significant can be partially attributed to the differing window
sizes, and the difference between sequence and chip-based genotyping for Hider et al. (2013) and
Jonnalagadda et al. (2017), and difference in markers for Ramos (2017).
3.3.3 Selection in Polynesian populations - genome-wide analysis
In this subsection results will be presented first for those that were in common between all Polynesian
populations and the sub-groups of East and West Polynesia. Following this, the results for individual
Polynesian populations will be presented. A complete table of all genes that had results meeting
the various thresholds for the various statistics used can be found in the Appendix Tables S2 (site
frequency spectrum (SFS)-based statistics), S3 (iHS and nSL), and S4 (XP-EHH).
There were 465 genes that were associated with urate and metabolic diseases from the genome-wide
association study (GWAS) catalog (see Table S7 for references), with 152 having at least a single window
from the lower tail, or SNP meeting a threshold for a single statistic in the Polynesian populations.
Genes reported here were highlighted based on three criteria: a significant haplotypic result in multiple
Polynesian populations, or having multiple statistics meeting the significance threshold in at least
a single Polynesian population, or the locus only having the main significant result in Polynesian
populations, with minimal signal in other populations, that is, multiple significant markers in Polynesian
populations and one or two in other populations.
Each Polynesian population had a similar number of windows in the 1st percentile, except for the
Western Polynesian populations with Zeng’s E where they had up to ~50% less (Table 3.2). The
Eastern Polynesian populations tended to have more independent non-consecutive regions and number
of genes that were intersected by windows than the Western Polynesian populations. However, this did
not translate into a higher number of genes that were significant in only a single population. There
were similar numbers of genes that intersected the windows that met the significance threshold in
either distribution tail between the Polynesian populations of CIM, NZM, SAM, and TON.
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Table 3.2: Number of significant regions and genes in Polynesian populations for
the intra population SFS statistics.
Lower Tail Upper Tail
Pop Windows Regions (n) Genes (n) Pop. Genes (n) Windows Regions (n) Genes (n) Pop. Genes (n)
Tajima’s D
CIM 2420 590 644 40 2420 963 466 66
NZM 2429 577 713 37 2429 954 436 42
SAM 2396 559 537 50 2396 961 479 75
TON 2380 561 508 48 2380 972 512 72
Fay and Wu’s H
CIM 2420 807 460 25 2420 895 553 57
NZM 2429 770 443 20 2429 916 573 53
SAM 2396 766 470 23 2396 895 565 36
TON 2380 764 467 41 2380 879 575 43
Fu and Li’s F
CIM 2419 655 805 72 2420 818 386 32
NZM 2429 624 966 92 2429 797 379 21
SAM 2396 620 671 79 2396 812 458 47
TON 2380 669 643 96 2380 782 467 50
Zeng’s E
CIM 2143 810 754 36 2418 959 435 24
NZM 2335 865 894 43 2428 953 431 24
SAM 1429 573 508 28 2396 895 448 28
TON 1140 476 405 11 2378 897 467 43
Regions is the number of independent non-consecutive regions the significant windows form. Genes is the number of unique
genes that the significant windows intersected. Pop. Genes is the number of genes that had significant windows intersect
in only that particular population.
3.3.3.1 Polynesian super population genome-wide selection analysis
Out of all the genes that met the thresholds, the Polynesian super population had the fewest genes
unique to a super population (Figure 3.3). The “upset plot” shows the number of genes that were in
common between super populations that had both intra-populational haplotypic and SFS evidence.
There were 111 genes that only had evidence of selection in Polynesian populations, and 11 genes that
had evidence in all super populations.
From the 1st percentile, 77 genes had at least one marker that was significant in the haplotypic tests,
and one window that intersected the same gene that was in the 1st percentile for a frequency-based
statistic and were shared between all the Polynesian populations (Figure 3.4). The number of genes
in common between the Eastern Polynesian populations that had both intra-populational haplotypic
and SFS support was 385. There were about 30% more genes for the same criteria in the Western
Polynesians, with 490 genes. Between the individual Polynesian populations, approximately one third
of the genes that met a threshold in a population were not in common with the other Polynesian
populations. The NZM population had the most genes (395) that were not shared with any of the
other Polynesian populations (Figure 3.4).
3.3.3.1.1 Prevously reported Polynesian “thrifty-genes”
There was no signal of selection for the previously reported ‘thrifty genes’ of PPARGC1A and CREBRF
(Myles et al., 2011; Minster et al., 2016). There were no markers or windows that met the significance
thresholds for any of the neutrality and selection statistics. This was consistent with the results of
Cadzow et al. (2016) for PPARGC1A. The two identified SNPs for body mass index (BMI) in Samoans
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at CREBRF, rs12513649 and rs373863828 (Minster et al., 2016) were both absent from the CoreExome
SNP array. While there was no selection signal from iHS or nSL at CREBRF (chr5:172483355-
172566291), downstream at chr5:172,800,000-173,000,000 there were four markers for SAM and seven
for TON that were significant for iHS (Figure 3.2). Rs373863828 is specific to Polynesian populations,
and therefore, important for detecting selection at CREBRF. At the same location for nSL there were
six significant markers for SAM and seven for TON. The populations from the EAS super population
had fewer significant markers for both iHS and nSL, with most of the populations having less than
three, although Chinese Dai in Xishuangbanna China (CDX) had five significant markers for iHS and
seven for nSL. The significant markers at this location in SAM were consistent with Minster et al.
(2016), were intergenic, and intersected the long intergenic non-coding RNA, CTB-164N12.1.
3.3.3.1.2 Genes with possible selection in Polynesian populations
A complete list of all of the genes that had windows in the 1st percentile and values < 0 for the
Polynesian populations can be found in table S2. A complete list of genes that had significant iHS,
nSL, or XP-EHH in Polynesian populations can be found in Appendix Tables S3, and S4.
There were 10 genes (ANO1-AS1, CCDC180, COL6A3, ESPNL, GRIP1, LINC00661, LINC01006,
NPAT, NPFFR1, and PPA1 ) for which all Polynesian populations and no other super populations had
at least one SNP with a significant iHS marker, and there were 659 genes that at least one Polynesian
population and no other super populations had selection signals for. The Eastern Polynesian populations
had 284 genes, similarly, the Western Polynesian populations had 296 genes. This compared to the
significant nSL markers where there were 4 genes (GRIP, LINC00661, PITPNC1, and SDC2 ), that
had at least one significant marker and were found in only all four Polynesian populations. Within only
Eastern Polynesian populations, there were 255 genes that had a significant marker, and within the
Western Polynesian populations, there were 244 genes only significant in that group, for nSL. There
were two genes in common that had at least one SNP in only the four Polynesian populations, when
the intersection of Polynesian specific genes for both iHS and nSL were compared. The genes were
GRIP1 (Glutamate Receptor Interacting Protein 1) and LINC00661 (Long Intergenic Non-Protein
Coding RNA 661).
3.3.3.1.3 Pathway enrichment of genome-wide selection results
Pathway enrichment analysis was performed for each intra-population statistic separately, by taking
all the genes that met the threshold for the haplotypic-based statistics, or met the lower tail of the
distribution threshold (SFS-based statistics). Pathway terms from the pathway enrichment analysis
from the Enrichr KEGG 2016 table showed there was minimal overlap in the terms that were significant
between the Polynesian populations (Table 3.3). There were more pathways in common between the
Eastern Polynesian populations (10) than the Western Polynesian populations (1). The individual
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Figure 3.2: Schematic of the CREBRF locus with flanking regions, at
chr5:172,600,000-173,000,000. Positions of the markers included on the Core-
Exome SNP array are indicated by vertical lines (top). Positions for the significant
iHS and nSL markers are shown for NZM, SAM, and TON. There were no signifi-
cant markers for CIM. Exons for genes are indicated by rectangles, and direction
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Figure 3.3: Upset plot showing the intersections of genes that had both intra-
population haplotypic and frequency spectrum-evidence at the individual pop-
ulation level and were then pooled into their super population group. The left
histogram shows the total number of genes with both haplotypic and frequency
spectrum-based evidence for each super population. The top histogram is the
number of genes that were in common between the super populations. The dots
indicate the particular set of super populations for the intersection and are ordered
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Figure 3.4: Upset plot showing the number of genes that have evidence from iHS or
nSL, and met the lower threshold from any of Tajima’s D, Fay and Wu’s H , Fu and
Li’s F , or Zeng’s E , in the four Polynesian populations. The left histogram shows
the total number of genes with both haplotypic and frequency spectrum-based
evidence for each Polynesian population. The top histogram is the number of
genes that were in common between the Polynesian populations. The dots indicate





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.4: Number of significant windows/markers by selection or neutrality
statistic by population, grouped by super population.
Lower Tail Upper Tail
Population Fay and Wu’s H Fu and Li’s F Tajima’s D Zeng’s E Fay and Wu’s H Fu and Li’s F Tajima’s D Zeng’s E iHS SNPs nSL SNPs
AFR
ACB 2452 2345 1230 2438 2453 2453 2452 2452 3590 2730
ASW 2452 2243 1355 2442 2453 2453 2453 2451 3555 2704
ESN 2424 875 780 2419 2424 2424 2423 2423 3478 2681
GWD 2435 1267 902 2435 2435 2435 2435 2435 3504 2607
LWK 2438 1210 861 2436 2438 2438 2438 2438 3788 2802
MSL 2424 1026 871 2424 2424 2424 2424 2424 3651 2629
YRI 2424 891 749 2425 2425 2426 2426 2426 3576 2785
AMR
CLM 2462 2463 2463 2221 2462 2463 2463 2463 3168 2490
MXL 2451 2451 2449 2442 2451 2451 2451 2445 3043 2313
PEL 2448 2448 2448 2447 2448 2448 2448 2448 2786 1953
PUR 2465 2463 2465 2289 2465 2465 2465 2462 3110 2585
EAS
CDX 2387 2387 2387 1013 2387 2387 2387 2384 2558 1949
CHB 2395 2395 2396 1058 2396 2396 2396 2395 2637 1918
CHS 2387 2387 2387 952 2387 2387 2387 2385 2468 1786
JPT 2377 1848 2378 788 2377 2379 2379 2377 2566 2032
KHV 2397 2398 2398 1077 2398 2398 2397 2398 2794 2025
EUR
CEU 2445 2445 2445 2365 2445 2445 2443 2445 2770 2267
FIN 2436 2436 2436 1814 2436 2436 2436 2436 2613 2205
GBR 2442 2441 2441 2277 2440 2442 2440 2440 2722 2130
IBS 2456 2456 2456 2314 2456 2456 2455 2454 2864 2185
NZC 2452 2453 2453 2448 2453 2453 2453 2453 2636 2145
TSI 2448 2449 2449 2098 2449 2449 2449 2449 2832 2185
POL
CIM 2420 2419 2420 2143 2420 2420 2420 2418 2350 1628
NZM 2429 2429 2429 2335 2429 2429 2429 2428 2345 1442
SAM 2396 2396 2396 1429 2396 2396 2396 2396 2487 1851
TON 2380 2380 2380 1140 2380 2380 2380 2378 2378 1866
SAS
BEB 2433 2436 2436 1542 2436 2436 2436 2436 2825 2218
GIH 2436 2436 2436 1425 2436 2436 2436 2435 2756 2194
ITU 2433 2420 2433 1337 2433 2433 2432 2430 2738 2230
PJL 2438 2438 2438 1597 2438 2438 2437 2438 2853 2222
STU 2434 2414 2434 1287 2434 2434 2434 2434 2809 2332
3.3.3.1.4 Regions of haplotypic selection in Polynesian populations - genome-wide
The Polynesian populations had the least number of significant SNPs for both iHS and nSL (Table
3.4). For the four Polynesian populations, the mean number of significant SNPs for iHS was 2911.3
(SD 423.4) and 2228.7 (SD 348.4) for nSL (Table 3.4). The Polynesian populations had a mean of
2390 SNPs with an iHS value that was significant, compared to 1697 for nSL. The minimum number
of SNPs that had a significant iHS was 2345 and was from the NZM population. For nSL this was also
NZM with 1442 SNPs. The maximum number of SNPs was for Luhya in Webuye Kenya (LWK) with
3788 for iHS and LWK with 2802 SNPs. Between significant SNPs for iHS and nSL there was a mean
of 1188.8 SNPs in common for the Polynesian Super Population (POL) populations, 1391.2 for EAS,
1728.9 for African Super Population (AFR), 1466.0 for European Super Population (EUR), 1562.0 for
American Super Population (AMR), and 1498.4 from SAS.
On average there were 89.5 SNPs in common between the Polynesian populations and the other
populations for iHS and 45.3 SNPs for nSL. Whereas, there was a higher number of significant SNPs in
common between the Polynesian populations with a mean of 557 for iHS and 375.8 for nSL (Table 3.5).
The Eastern/Western Polynesian split was also evident with there being a two to four-fold difference
in the number of SNPs in common between the Eastern and Western Polynesian populations for both
iHS and nSL. There were 24 genes that had at least 1 marker significant across at least 20 populations
for all Polynesian populations for XP-EHH. The Eastern Polynesian populations had 28 genes, and
the Western Polynesian populations had 49 genes.
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Table 3.5: Number of significant SNPs that were in common between populations.
iHS nSL
Population CIM NZM SAM TON CIM NZM SAM TON
AFR
ACB 69 75 85 68 24 21 29 27
ASW 57 85 92 68 25 36 24 30
ESN 47 57 81 77 15 18 36 38
GWD 84 80 70 61 19 15 16 17
LWK 81 89 95 80 22 21 18 17
MSL 57 56 141 104 24 20 25 29
YRI 67 61 83 77 23 25 30 29
AMR
CLM 80 84 113 129 35 45 59 68
MXL 91 87 104 92 56 43 60 64
PEL 72 101 97 82 37 40 63 62
PUR 59 58 99 76 27 26 33 38
EAS
CDX 80 89 154 140 71 65 127 146
CHB 115 138 189 168 74 73 98 129
CHS 98 106 215 204 76 77 109 138
JPT 113 94 123 135 90 63 86 129
KHV 91 112 248 231 56 63 118 136
EUR
CEU 62 46 73 75 30 28 26 34
FIN 71 50 99 91 32 23 38 42
GBR 71 55 79 71 31 26 26 26
IBS 50 43 64 71 27 21 27 35
NZC 62 44 66 67 26 22 20 22
TSI 54 43 75 73 23 14 24 24
POL
CIM 2670 863 330 330 1796 542 208 212
NZM 863 2671 284 260 542 1634 178 192
SAM 330 284 2939 1275 208 178 2131 923
TON 330 260 1275 2802 212 192 923 2158
SAS
BEB 84 63 93 85 46 32 45 56
GIH 72 48 94 103 23 26 44 54
ITU 86 71 84 94 37 38 55 53
PJL 98 63 97 94 41 33 53 46
STU 100 90 104 79 30 41 77 59
3.3.3.1.5 FST
FST was calculated in sliding windows of 10 kb across the genome, pair-wise between the Polyne-
sian populations and all other populations. Similar to the results for the FST calculated on entire
chromosomes (section 4.3.1.4), the mean FST using windows had the Polynesian populations most
differentiated from the AFR populations. The range of mean FST was from 0.148 to 0.203. The
Polynesian populations were least differentiated from the EAS populations with a range of FST means
from 0.051 to 0.076. Between the Polynesian populations the mean FST ranged from 0.004, between
the Western Polynesian populations of SAM and TON, to 0.029 between NZM and SAM. The Eastern
Polynesian populations had a marginally higher mean FST than the Western Polynesian populations
at 0.006. The largest maximum FST of 0.888, across four windows, was between TON and Mende in
Sierra Leone (MSL) at chr17:62455002-62495001. This same region was the maximum FST for the CIM
and NZM, and the second largest for SAM, all with MSL. The maximum FST between the Polynesian
populations was between NZM and TON, with a value of 0.346 at chr10:110685002-110695001. The
smallest maximum FST of the Polynesian populations was between SAM and TON, with a value of
0.081 at chr1:3965002-3975001.
3.3.3.2 Cook Island Māori genome-wide selection analysis
3.3.3.2.1 Pathway enrichment analysis of genome-wide selected loci in CIM
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Pathway gene-set enrichment analysis on gene lists for each statistic that met the significance thresholds
was done using Enrichr. There was a total of 10 pathways that after multiple testing correction had
significant P values (Table 3.3). Nine pathways were significant for the gene list from nSL and had a
heart and lung focus based on calcium ion movement in the form of genes for calcium transporters and
voltage-gated calcium channels. There were five genes related to calcium that were in at least five of the
pathway terms: CACNA1D, ADCY9, SLC8A1, CACNA2D2, CACNA2D3, with all of the 15 markers
except 3, being in favour of the ancestral allele. There was a single pathway that was significant from
the genes from the 1st percentile of Tajima’s D which was “bacterial invasion of epithelial cells”. This
could be due to selective pressure for bacterial resistance.
3.3.3.2.2 Contiguous regions of score depression in CIM
Looking at regions of contiguous depressed score that also had either a significant iHS or nSL marker
in them, there were a total of four regions that met this criteria. For Tajima’s D, there were two
regions. The first, a 290 kb region at chr2:24215002-24505001 intersected FAM228B and had a
single significant marker for both iHS and nSL (rs13035774). The second, was 470 kb in length at
chr11:68105002-68575001, and included LRP5, which had a single significant marker (rs634008) for
iHS. Fu and Li’s F also had a region that covered LRP5 but at chr11:68085002-68355001 and was
270 kb long. For Fu and Li’s F , there was a 250 kb region at chr16:3545002-3795001 that intersected
DNASE1 with a single marker (rs13926) for iHS and nSL, and also TRAP1 with two markers (rs13926
and rs1639150) each for iHS and nSL. Fay and Wu’s H had a single 250 kb region that intersected
MYT1L at chr2:2015002-2265001 and had four significant markers for iHS (rs4571084, rs13404264,
rs11888121, and rs13382326) and four for nSL (rs4571084, rs12470297, rs11888121, and rs13382326),
outside this region but surrounding and still within the gene.
3.3.3.2.3 Genome-wide selection from haplotypic statistics in CIM.
The significant iHS and nSL values after conversion to a P-value are shown by position across the
genome as a Manhattan plot in Figure 3.5. The conversion of the iHS or nSL value to a P value used 1
- P(|Z|), where Z was the iHS or nSL value, due to the similarity of the iHS and nSL to a Z-score. The
most extreme markers for iHS (by genomic position, -log10(P) > 4.8) were chr2: rs11683451, rs2890456,
and rs6755308; chr4: rs17060079; chr8: rs2319924; chr11: rs7931930 and rs11212617; chr20: rs647518;
chr21: rs28559700. The most extreme markers for nSL (by genomic position, -log10(P) > 4.8) were
chr4: rs1491411; chr11: rs543215 and rs1963626; chr12: rs7977414. Within the most extreme 100 iHS
values, there were 37 genes. For nSL there was 45 genes. Eighteen of these genes were in common, with
C11orf65 and CNTN4 having at least five significant SNPs each. The gene with the most significant
SNPs out of any population was CNTN4 in CIM with 27 markers having a significant iHS score. The
only other population with more than two significant SNPs was NZM with 14. There were four genes
represented in the top 100 markers that were associated with obesity or type 2 diabetes, these were:
ADCY9, ARL15, PSMD6, and ZFAND6. In total there were 124 genes that were only significant in
CIM for iHS, and 102 for nSL. There were 57 genes that had at least 20 populations with significant
markers for XP-EHH in only CIM from the Polynesian populations. ARL15 was associated with
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obesity and type 2 diabetes (Mahajan et al., 2014; Shungin et al., 2015) and RREB1 was associated
with type 2 diabetes and urate (Köttgen et al., 2013; Mahajan et al., 2014).
Figure 3.5: Manhattan plot for significant markers in CIM for both iHS and nSL.
3.3.3.3 New Zealand Māori genome-wide selection analysis
3.3.3.3.1 Pathway enrichment analysis of genome-wide selected loci in NZM
The pathway gene-set enrichment analysis from Enrichr on the KEGG 2016 pathways had 32 pathways
that were significant after multiple testing correction, this was the largest number of pathways out of
the Polynesian populations (Table 3.3). On average only 9.3% of a pathway was represented by the
genes. Thirty-one pathways were from the significant genes for nSL, with many in common with CIM.
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Calcium transporters and voltage gated calcium channels featured in many pathways that were in
common. Compared to the CIM pathway results, there were more hormone-based pathways that were
significant, such as renin secretion, oxytocin signalling pathway, adrenergic signalling in cardiomyocytes,
thyroid hormone synthesis, aldosterone synthesis and secretion, insulin secretion, and GnRH signalling
pathway. Furthermore, diabetes-related pathways were significant such as type 2 diabetes mellitus,
insulin secretion, and pancreatic secretion pathways. The genes that were shared in the most pathways
included two adenlyate cylases (ADCY8 and ADCY9 ), two phospholipase C genes (PLCB1 and
PLCB4 ), and calcium voltage-gated channel subunits (CACNA1C and CACNA1D). Similar to CIM,
there was a single pathway that was significant from the Tajima’s D list and that too was for bacterial
invasion of epithelial cells.
3.3.3.3.2 Selection from haplotypic statistics in NZM - genome-wide
The significant markers from iHS and nSL were converted to P-values and plotted on a Manhattan
plot (Figure 3.6). The most extreme markers for iHS (by position, -log10(P) > 4.8) were: chr2 -
rs2710684; chr3 - rs74823804 and rs2280162; chr8 - rs11987519; chr9 - rs2780246; chr10 - rs4075326
and rs11017145; chr16 - rs28564718 and rs3743759. For nSL, the markers were: chr4 - rs1491411; chr8
- rs11987519; chr12 - rs7977414. From the haplotypic tests for selection (iHS and nSL) there were 122
genes that were only significant in NZM for iHS, and 93 for nSL. Looking at the genes represented
by the most extreme 100 iHS and nSL markers there were 30 genes for iHS, and 40 genes for nSL.
There were 12 genes in common between the two sets (CTNNA3, WWOX, KCNS3, NRXN1, ADAM29,
VSNL1, BCCIP, BICD1, DHX32, SLC35F2, STAU2, and TENM3 ). CTNNA3 had five markers in the
top 100 for nSL (rs2441727, rs12220315, rs1911341, rs2660024, and rs10997250), and was also the gene
for NZM that had the most overall significant markers for both iHS and nSL. There were 40 genes that
had at least 20 populations with significant markers for XP-EHH in only NZM from the Polynesian
populations, only one (PAX5 ) of which was associated with obesity (Melka et al., 2012). There were
eight genes, LYST, PHIP, CTNNA3, RAD51AP2, SUPT3H, EPB41L4A, RAD51B, and VSNL1, that
had at least one significant marker for iHS or nSL, and also had a window in the 1st percentile from
three or more statistics from Tajima’s D, Fay and Wu’s H , Fu and Li’s F , and Zeng’s E .
3.3.3.3.3 Contiguous regions of score depression in NZM
The regions of contiguous depressed score from the 1st percentile of windows that also contained
markers with a significant iHS or nSL value covered three regions of the genome for NZM. Two of the
regions were for Tajima’s D, the first was 270kb at chr2:24215002-24485001, and overlapped the region
in CIM. It had a single significant marker for iHS in each of MFSD2B/FKBP1B (rs10185680), and
FAM228B (rs10197527). The second Tajima’s D region was 260 kb at chr4:106555002-106815001 and
had a single significant marker for nSL in INTS12 (rs2553453). A 200 kb region for Fu and Li’s F at
chr2:179395002-179595001 had four significant markers in TTN-AS1 for iHS (rs3731752, rs2278196,
rs72648270, and rs3813243).
No contiguous regions of score depression intersected with genes associated with urate, kidney disease,
or type 2 diabetes. There were 2 regions that intersected obesity-associated loci; for Tajima’s D
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Figure 3.6: Manhattan plot for significant markers in NZM for both iHS and nSL.
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a 320 kb region at chr16:67145002-67465001 contained KCTD19, and for Fu and Li’s F , 220 kb
at chr16:3555002-3775001 contained NLRC3. EDC4 which is associated with metabolic syndrome
(Kristiansson et al., 2012), had slightly differing regions that covered it. Tajima’s D was 330 kb
spanning chr16:67775002-68105001, and Fu and Li’s F was 320 kb spanning chr16:67775002-68095001.
3.3.3.4 Samoan genome-wide selection analysis
3.3.3.4.1 Pathway enrichment analysis of genome-wide selected loci in SAM
Only two pathways were significant for the gene-set pathway enrichment analysis using Enrichr (Table
3.3). The pathway term “ABC transporters” was significant for gene list from iHS (adjusted P =
0.0128) with 9 of 44 genes. The genes were ABCC4, ABCA5, ABCC8, ABCC5, ABCB5, TAP2,
ABCA9, ABCB8, and ABCA8. The second pathway that was significant was “long-term potentiation”
and that was from the nSL gene list (adjusted P = 0.0213) with 9 of 66 genes. The genes were PPP3CA,
GNAQ, RPS6KA1, PRKCA, CACNA1C, PLCB1, PLCB2, CAMK2G, and RAPGEF3.
3.3.3.4.2 Selection from haplotypic statistics in SAM - genome-wide
The significant markers for iHS and nSL are shown by position across the genome as a Manhattan plot
after conversion to P-values in Figure 3.7. The most extreme markers for iHS (by position, -log10(P))
were: chr1 - rs10495181; chr4 - rs12331849; chr11 - rs6578634; chr13 - rs4941616; chr16 - rs12596728.
For nSL they were: chr17 - rs11654176 and rs1860316. From the haplotypic tests for selection (iHS
and nSL) there were 110 genes that were only significant in SAM for iHS, and 90 for nSL. The genes
with the most significant markers for iHS were CDH23 and CNTN5 with 12 significant markers each.
The gene with the most significant markers for nSL was CDH23 with 16 markers. Looking at the most
extreme 100 markers for nSL there were 35 genes represented, SNX29 had the most with three markers
(rs350277, rs7201595, and rs12931604). For iHS, the gene with the most markers in the most extreme
100 was C11orf65, with three (rs425538, rs7931930, and rs11212617). There was a total of 39 genes
represented. Between the top markers for both iHS and nSL there were 10 genes that were in common
(SNX29, LINC00693, BANK1, DLC1, DUSP13, HBE1, HBG2, MYCBP2, NLRP1, and SAMD8 ).
There were ten genes that had windows from at least three of the frequency-based statistics and also
had at least a single significant marker for either iHS or nSL. The genes were DISP1 (iHS: rs2789931
and rs2789954), PARD3B (iHS and nSL: rs13000345), C4orf45 (iHS and nSL: rs11722868), NEK1
(iHS: rs4235024), CNTNAP2 (iHS: rs2620441, rs2249958, and rs17170777; nSL: rs2249958, rs17170777,
and rs10255956), CTNNA3 (iHS: rs1948946; nSL rs4297361, rs1948946, rs2764813, rs2394324, and
rs10823054), CEP112 (iHS: rs11652795; nSL rs1373074), CNTNAP5 (nSL: rs314710 and rs2602647),
SUPT3H (nSL: rs9472376), and DGKI (nSL: rs12056089). XP-EHH had 19 genes that had at least 20
populations with significant markers in only SAM from the Polynesian populations but none had been
associated with urate or related co-morbidities.
3.3.3.4.3 Contiguous regions of score depression in SAM
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Figure 3.7: Manhattan plot for significant markers in SAM for both iHS and nSL.
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There were no contiguous depressed score regions that intersected with genes associated with urate,
obesity, type 2 diabetes, kidney disease, or metabolic syndrome. Regions of contiguously depressed
score that also had significant markers for iHS or nSL in SAM covered three regions of the genome
across two statistics. Tajima’s D had two regions, the first was 400 kb at chr4:170025002-170425001
and had a single significant marker for iHS (rs4235024) nearby in NEK1. The second region was 300
kb in length and was found at chr10:76685002-76985001. It had significant markers in KAT6B (iHS
and nSL:rs3213967), and in SAMD8/DUSP13 (iHS and nSL: rs7912300 and rs10824274). Fu and Li’s
F had a single 200 kb region at chr1:26465002-26665001 that had a single significant marker for nSL in
CNKSR1 (rs2783633), and two markers for iHS and three for nSL in AIM1L (iHS and nSL:rs11247916
and rs10751735; nSL: rs4659431).
3.3.3.5 Tongan genome-wide selection analysis
3.3.3.5.1 Pathway enrichment analysis of genome-wide selected loci in TON
Pathway enrichment analysis from the Enrichr KEGG 2016 pathways produced 11 different pathways
that were significant after multiple testing correction (Table 3.3). Of the SFS based methods, only Fu
and Li’s F had a significant pathway and this was “Olfactory transduction”. There were two pathway
terms that were significant from the iHS results, these were “ABC transporters” and “ECM-receptor
interaction”. These were also significant in the nSL results, along with another eight terms (Table 3.3).
The genes that were included in the “ABC transporters” pathway from the significant markers of both
iHS and nSL were: ABCC8, TAP2, ABCA9, ABCA8, and ABCG2. From only iHS markers ABCA5
ABCA6, ABCC5, ABCB were included, and from only nSL markers, ABCB8 was included. Genes
with significant markers for both iHS and nSL in the “ECM-receptor interaction” pathway included
COL4A2, ITGB5, ITGA1, ITGA2, SPP1 and ITGB6. From only iHS markers LAMA5, TNXB, TNC,
COL6A3, and HMMR were included, and from only nSL makers, COL4A1, and ITGA9 were included.
Five of the significant pathway terms were only significant in TON out of the Polynesian populations.
3.3.3.5.2 Selection from haplotypic statistics in TON - genome-wide
The significant markers for iHS and nSL were plotted genome-wide after conversion to P-values in
a Manhattan plot (Figure 3.8). The most extreme iHS markers (by position, -log10(P)) were: chr1 -
rs12042853, rs10495181, rs4240931, and rs2800853; chr7 - rs10485976, rs6962297, rs296307, rs6969276,
rs7791859, and rs1405425; chr8 - rs4349972; chr10 - rs7097067 and rs7923688; chr11 - rs6578634; chr13
- rs4941616; chr16 rs154148 and rs350277; chr17 - rs6504539, rs1860316 and rs16976276. For nSL
they were: chr7 - rs7791859 and rs1405425; chr8 - rs2605867; chr13 - rs4941616; chr16 - rs350277. In
total there were 105 genes that were only significant in TON for iHS, and 108 for nSL. In the most
extreme 100 nSL marker scores, there were 32 genes represented with SNX29 having three markers
(rs350277, rs7201595, and rs12931604), and CDH23 having two (rs2394801 and rs10762462) from
the 100. The most extreme 100 marker scores for iHS had 30 genes represented with SNX29 having
five markers (rs350277, rs7201595, rs7198595, rs7189759, and rs12931604), PCDH15 having three
(rs4272709, rs11004106, and rs4935502), and DNAH11 having two (rs10485976 and rs1989904) of the
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100. There was an overlap between the two gene lists for the most extreme 100 of six genes, with
SNX29, and DNAH11 having the largest number of extreme markers for both iHS, and nSL. The genes
with the largest number of significant markers overall for iHS and nSL were CPNE4 (16 markers for
both iHS and nSL), SNX29 (15 markers for iHS and 16 for nSL), CDH23 (11 markers for iHS and 12
for nSL), PCDH15 (12 markers for nSL), and BANK1 (9 markers for iHS and 10 for nSL). There were
37 genes that had at least 20 populations with significant markers for XP-EHH in only TON from the
Polynesian populations, including IGF1R, JAZF1, and PEPD which had been associated with urate
or co-morbidities.
There were seven genes that had at least one significant marker for either iHS or nSL, and windows in
the 1st percentile for at least three frequency-based intra-population selection and neutrality statistics.
They were C4orf45, SUPT3H, CTNNA3, SAMD8, EXT2, LPO, and NRXN3.
3.3.3.5.3 Contiguous regions of score depression in TON
There were no contiguous depressed score regions that intersected genes associated with urate, type 2
diabetes, kidney disease, or metabolic syndrome. There was one region that intersected the obesity
associated gene CCR3 for Tajima’s D and was 260 kb in length at chr3:46035002-46295001. There were
three regions with contiguous depressed score that also had significant markers for iHS or nSL in TON.
Tajima’s D had two regions. The first similar to SAM, was at chr10:76685002-76985001 and spanned
300 kb and had significant markers in KAT6B (iHS and nSL:rs1551067 and rs3213967), SAMD8 (iHS
and nSL: rs10509355, rs10824274, and rs7912300), and in DUSP13 (iHS and nSL: rs10824274 and
rs7912300). The second region at chr17:56125002-56415001 was 290 kb and had a single significant
marker (rs9892223) for iHS in both EPX and LPO. Fu and Li’s F had a slightly shifted region that
also intersected EPX and LPO and had the same significant markers as the Tajima’s D region, but
also included RNF43/BZRAP1-AS1 - which also had a single significant marker for iHS (rs2257205).
The region was at chr17:56205002-56455001 and was 250 kb in length.
3.3.4 Selection in disease-associated genes
3.3.4.1 Selection in Polynesian populations for genes associated with urate and
metabolic disease
In order to establish if there was evidence of selection in genes associated with urate and diseases
with hyperuricaemia as a co-morbidity, loci that associated with these conditions were extracted from
the GWAS catalog (as per section 2.1.3, see Table S7 for references for each trait) and neutrality
and selection statistics that intersected these loci were collated. Table 3.6 shows the breakdown of
the number of different statistics by population that met the significance thresholds for the SFS
based statistics, the haplotype based statistics, and the overlap between the frequency spectrum
and haplotypic methods. The CIM population had the least number of genes of the Polynesian
populations that had a significant result out of the genes that were associated with urate. The
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Figure 3.8: Manhattan plot for significant markers in TON for both iHS and nSL.
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Polynesian populations had the fewest number of genes with significant iHS or nSL for obesity and the
Western Polynesian populations had the fewest number of genes for type 2 diabetes.
Figure 3.9 shows the genes associated with urate, gout and related diseases that had a significant
marker with either iHS or nSL and also had a significant window from a SFS-based statistic in at
least one Polynesian population. There were only 10 genes that met this criteria, of which, the type 2
diabetes associated gene, PTPRD, was the only gene that met the criteria, and also had significant
markers from all Polynesian populations in iHS. The obesity-associated genes GRID1, FHIT, and
ERBB4, all had windows from Fay and Wu’s H that were significant in all Polynesian populations.
ERBB4 also had significant windows for all Polynesian populations for Tajima’s D.
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Population CIM NZM SAM TON
Figure 3.9: Genes associated with urate, gout, obesity, type 2 diabetes, kidney
disease, and metabolic syndrome having both significance in intra-population SFS
and haplotypic based methods in at least one Polynesian population. Numbers
inside boxes indicate the number of significant windows (SFS methods) or SNPs
(haplotypic methods) for the population.
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Table 3.6: Number of genes with evidence of possible positive selection in super
populations from intra-population tests from urate and co-morbidities GWAS
associated loci.



















































ACB AFR 9 9 0 34 46 14 9 18 2 5 5 0 2 0 0
ASW AFR 8 5 1 31 44 11 8 21 3 10 7 2 4 3 1
ESN AFR 8 4 0 29 44 7 9 18 3 7 6 1 3 2 0
GWD AFR 5 4 0 41 43 8 9 15 3 6 6 1 4 3 0
LWK AFR 5 7 0 30 46 5 8 16 3 5 7 1 3 3 0
MSL AFR 7 10 1 35 38 10 10 11 3 6 10 2 2 3 1
YRI AFR 7 5 0 35 40 9 10 13 4 6 7 1 1 0 0
CLM AMR 10 4 1 30 36 6 8 15 1 8 3 0 2 5 1
MXL AMR 9 2 0 30 35 5 8 14 0 10 1 0 4 4 1
PEL AMR 10 3 0 29 29 6 11 18 3 6 2 0 2 2 0
PUR AMR 7 7 1 37 43 11 9 11 2 6 6 1 3 4 1
CDX EAS 4 2 0 21 37 6 11 11 3 5 3 1 1 2 0
CHB EAS 4 2 0 25 28 5 14 11 2 4 3 0 1 0 0
CHS EAS 7 2 0 22 33 6 10 10 2 5 2 0 1 1 0
JPT EAS 7 2 0 25 36 5 7 12 1 5 1 0 1 1 0
KHV EAS 2 3 0 25 34 9 6 11 2 6 1 0 1 1 0
CEU EUR 13 3 1 31 31 8 8 13 0 7 4 1 2 4 0
FIN EUR 5 3 1 27 35 5 6 14 0 5 4 1 1 3 0
GBR EUR 10 4 1 32 35 9 10 16 3 7 3 1 1 3 0
IBS EUR 9 3 0 34 38 9 8 12 1 7 2 1 1 4 0
NZC EUR 13 6 2 27 34 7 9 17 2 10 3 1 2 4 0
TSI EUR 13 4 1 27 35 11 6 14 2 6 1 0 2 7 1
CIM POL 5 1 0 29 17 2 11 9 2 5 0 0 1 0 0
NZM POL 8 1 0 31 21 5 13 10 2 4 1 0 2 3 0
SAM POL 5 4 0 27 20 4 14 4 0 7 3 0 1 1 0
TON POL 8 5 0 22 25 4 14 7 1 7 3 0 3 2 0
BEB SAS 7 3 0 25 25 5 7 13 2 10 4 1 0 5 0
GIH SAS 4 1 0 24 23 6 8 14 3 4 1 0 0 3 0
ITU SAS 6 3 0 20 24 5 6 14 2 8 2 1 1 4 0
PJL SAS 7 2 1 21 30 3 7 16 3 7 1 0 0 3 0
STU SAS 10 0 0 26 28 8 6 12 2 6 3 1 2 3 0
Hap = haplotypic. Com = combined. Combined is the number of genes that had both SFS and
haplotypic evidence.
3.3.4.1.1 Selection in Polynesian populations for genes associated with urate and gout
The 62 loci identified in the GWAS catalog (see Table S7 for references) as being associated with
urate and gout only had a small proportion with any evidence of possible selection, 18 in Polynesian
populations. In the Polynesian populations, from the intra-population neutrality and selection statistics,
there were 18 genes that had some evidence. However, there were only nine genes with haplotypic
evidence, and only one gene (RREB1 ) that had both haplotypic and SFS-based evidence. Overall,
the Polynesian populations did not have more urate genes with evidence for selection than the other
populations (Table 3.6).
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The two main effect loci for serum urate, SLC2A9 and ABCG2 both had limited evidence of selection.
SLC2A9 did not have any values for iHS or nSL because of an extended region of no recombination
leading to a large gap in the reference genome which caused the extended haplotype homozygosity
(EHH) calculation to be terminated. There was evidence with Fu and Li’s F which had windows from
SLC2A9 in the 1st percentile from TON. This was also observed with the EAS populations of CHB and
JPT. For the Polynesian populations, ABCG2 only had significant results from iHS and nSL (at the
same marker, rs2622626) for TON. With iHS, the SAS populations of GIH and ITU also had significant
values for rs2622626. For nSL, along with GIH and ITU, the other non-Polynesian populations that
had a significant value was the EAS population JPT, and the AFR population of YRI. Rs2622626 is
associated with both urate and gout (Köttgen et al., 2013). There were no Polynesian populations
with values in the 1st percentile for the frequency-based statistics, and only Esan in Nigeria (ESN) had
windows that met the threshold for Fay and Wu’s H .
Table 3.7 shows all urate and gout associated genes that had any evidence of possible selection in
the Polynesian populations. Some genes of interest included IGF1R and RREB1 which both had
significant markers with XP-EHH between nearly all Polynesian populations and many of the other
populations excepting those in the SAS super population. RREB1 is also associated with type 2
diabetes (Mahajan et al., 2014). BCAS3 had multiple windows that met the lower threshold for Fay
and Wu’s H , Fu and Li’s F , and Tajima’s D in the Polynesian populations but did not have any
significant markers for the haplotypic tests of selection.

































































BCAS3 CIM 8 4 2
BCAS3 NZM 6 9 7
BCAS3 SAM 10 1 4
BCAS3 TON 3 1
IGF1R CIM 2 3 1
IGF1R NZM 3 2 1
IGF1R SAM 2 4 5 3 1
IGF1R TON 6 4 5 6 5 5
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Table 3.7: Urate and gout associated loci that showed signs of possible selection





















































LRP2 SAM 1 1
LRP2 TON 2




MLXIPL TON 2 3










RFX3 TON 1 1
RREB1 CIM 5 3 5 6 1 3
RREB1 NZM 4 3 5 6 1 1
RREB1 TON 3 1 1 2 2
RREB1 SAM 2
SLC2A9 TON 7
XP-EHH is the number of populations from the super population that had at
least one marker significant in the gene. Integrated haplotype homozygosity
score and nSL are the number of significant markers. Fay and Wu’s H , Fu and
Li’s F , Tajima’s D, and Zeng’s E are the number of windows intersecting the
gene that met the lower threshold.
3.3.4.1.2 Selection in Polynesian populations for genes associated with obesity
There were 269 obesity-associated loci with three loci in common with urate and gout from the
GWAS catalog (see Table S7 for references). The Polynesian populations had about 30% (84) of
the obesity-associated genes showing some evidence of possible selection (Table 3.6). As a super
population, the Polynesian populations had fewer obesity-associated genes that were significant for iHS
or nSL compared to the other super populations. Genes that were associated with obesity and had
evidence across multiple populations or many significant results are included in Table 3.8. Ten loci
had evidence in all four Polynesian populations, from a combination of haplotypic and SFS statistics,
these were ABO, ARL15, CCR2, CCR3, COL6A1, ERBB4, LEKR1, PPP2R3A, RABEP1, SLC39A8,
and ZBTB38. ABO is discussed further in subsection 3.3.4.2.3 in the context of malaria. There were
nine obesity associated loci that of the Polynesian populations, the Eastern Polynesian populations
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had either the entire or the largest signal, these were ADAMTS9, ADCY9, BTNL2, CCNJL, DNAH10,
GDF5, LY86, MTIF3, and PCSK5. Conversely, eleven loci had their entire or largest signal in the
Western Polynesian populations. These were BDNF, CTSS, FER, FAM13A, GPRC5B, GRID1, JAZF1,
LRP1B, PARK2, PEPD, and TRIP11. Four of the loci, ADAMTS9, ARL15, JAZF1, and PEPD were
also associated with type 2 diabetes. FTO did have a single marker (rs4396532) that was significant
for iHS in NZM.
A contiguously depressed score region was in CIM at chr12:124195002-124505001 for Fu and Li’s F
that covered DNAH10, ZNF664, and CCDC92. Another region in CIM had a region at chr16:3545002-
3795001 and intersected NLRC3, and included the significant markers for both iHS and nSL of rs13926
and rs1639150. For Tajima’s D there were two regions of contiguous score depression that intersected
obesity-associated loci, the first in NZM at chr16:67145002-67465001 intersected KCTD19. The second
was in TON and covered CCR3 at chr3:46035002-46295001.




































































TON ADAMTS17 1 1
CIM ADAMTS9 1 2 1 3
NZM ADAMTS9 1 3
CIM ADCY9 2 5 2 2 7 6
NZM ADCY9 5 1 2 1
NZM AGBL4 1 17
NZM APOA5 1
TON APOA5 1
CIM ARL15 1 4 3 6 1 5 2 2 5
NZM ARL15 1 3 6 4 2 2
SAM ARL15 1 3 6 5 1 5
TON ARL15 1 3 6 5 3
SAM BDNF 1 1 1
TON BDNF 1 1
CIM BTNL2 7
NZM BTNL2 5
SAM BTNL2 2 3 1
SAM CADM2 2
CIM CALCRL 6 1
NZM CALCRL 4
TON CALCRL 3
CIM CCDC92 1 4 4
CIM CCNJL 2 3 3
NZM CCNJL 1 1
CIM CCR2 3 2 1 3
NZM CCR2 4 2 3 5
SAM CCR2 1
TON CCR2 1 2
CIM CCR3 1 2 1 6 5 2
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NZM CCR3 2 4 1 6 5 1 4
SAM CCR3 3 3 1 6 5 4
TON CCR3 3 3 1 6 5 7 5
NZM CDKAL1 1
CIM COL6A1 7 2 3 2
NZM COL6A1 6 1 5
SAM COL6A1 6
TON COL6A1 7 2 6 4
SAM CTSS 3 5 5
TON CTSS 1 5 4
CIM DGKG 2
NZM DGKG 1 3
TON DGKG 3
CIM DNAH10 3 1 18 7
NZM DNAH10 1 4 4 3 2
SAM DNM3 4 3
TON DNM3 3 2
SAM EFEMP1 1
CIM ERBB4 6 4 1 5 1 8 6
NZM ERBB4 7 4 4 5 1 7 2
SAM ERBB4 7 4 3 5 1 1 7 7
TON ERBB4 7 4 6 5 8 8 8
CIM EYA2 1 1 1 1
SAM EYA2 2 2
SAM FAM13A 7 1 5




SAM FER 1 2 10 4
TON FER 5 4 2 2
NZM FHIT 4 1 5
SAM FHIT 4 6
TON FHIT 1 4 4 2 5 1 1 5
SAM FNDC3B 2
TON FNDC3B 1
NZM FOXO3 1 1
SAM FOXO3 1
NZM FPGT-TNNI3K 2 3
TON FPGT-TNNI3K 1 2 1 1
NZM FTO 1
SAM GBE1 2 1
CIM GDF5 4 2 1 2
NZM GDF5 2 3
NZM GP2 1 1
TON GP2 1
SAM GPRC5B 1 1
TON GPRC5B 1
SAM GRID1 1 2
TON GRID1 2 2
SAM HSD17B12 2 1
NZM IQCK 1
SAM IQCK 1
TON ITGB6 1 1
CIM JAZF1 1
SAM JAZF1 4 3 2 1 4
TON JAZF1 5 4 5 6 1 5 1































































CIM LEKR1 7 1
NZM LEKR1 4
SAM LEKR1 6 1 1
TON LEKR1 2
CIM LEPR 1 2
SAM LEPR 1 1 2
TON LEPR 1
NZM LIN28B 1 3
NZM LINGO2 1
TON LINGO2 1
SAM LRP1B 3 7 7
TON LRP1B 1 4 4
CIM LY86 1 1
NZM LY86 4 2 2
TON LY86 1
SAM LYPLAL1 1 1
TON LYPLAL1 2 1 2
NZM MAP2K5 1 3
TON MAP2K5 1 3
CIM MSRA 1 3 2 1 2
SAM MSRA 1
TON MSRA 1 1
CIM MTIF3 1
NZM MTIF3 2
CIM NAV1 1 1
SAM NAV1 1
TON NCAM2 1
CIM NEGR1 4 5 4
NZM NEGR1 6 1
TON NEGR1 6 1 2 3
NZM NFE2L3 1
CIM NLRC3 1 3 1 5
NZM NLRC3 1 5
SAM NRXN3 1 1
TON NRXN3 6 1 1 2 3 3
NZM OR10J1 1
SAM PARK2 1 2 1 1
TON PARK2 1
NZM PAX5 3 1 5 3 3 5
SAM PCSK1 1
CIM PCSK5 1 3 1 2
NZM PCSK5 4 5 2 3 1
SAM PCSK5 1
SAM PEPD 7 2 4 6




NZM PPP2R3A 4 5
SAM PPP2R3A 2 2 1
TON PPP2R3A 7 3 1
CIM RABEP1 3
NZM RABEP1 1 1 1
SAM RABEP1 6 1 1 2
TON RABEP1 7 2 1 2
CIM RASA2 1 2
SAM RASA2 1 2
TON RASA2 1
TON RMST 1
NZM RPTOR 2 3 3 5
CIM SLC39A8 5 1
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TON TCF7L2 2 1 2
CIM TNKS 2
NZM TNNI3K 2 3




CIM ZBTB38 1 4 1
NZM ZBTB38 1 2
SAM ZBTB38 4 1
TON ZBTB38 3 7
CIM ZNF664 1 1 2
XP-EHH is the number of populations from the super population that had at least one
marker significant in the gene. Integrated haplotype homozygosity score and nSL are the
number of significant markers. Fay and Wu’s H, Fu and Li’s F, Tajima’s D, and Zeng’s
E are the number of windows intersecting the gene that met the lower threshold.
3.3.4.1.3 Selection in Polynesian populations for genes associated with type 2 diabetes
Type 2 diabetes is a co-morbidity of hyperuricemia, and had 99 genes associated from GWAS in the
GWAS catalog (see Table S7 for references), with one gene in common with urate-associated loci, and
16 genes in common with obesity. For the Polynesian populations there were 41 genes total, with 23
loci that were intersected by windows in the 1st percentile of a frequency-based statistic. There were
19 genes that had a marker with a significant value for iHS or nSL. The genes that showed evidence of
possible selection in the Polynesian populations are shown in Table 3.9. There were five genes that
showed evidence across all Polynesian populations, these were ARL15, LPP, PTPRD, SND1, and
THADA. Four genes had evidence that was mostly in the Eastern Polynesian populations, these were
ADAMTS9, PSMD6, SSR1, and ZFAND6. And the genes that mostly had evidence in the Western
Polynesians were BCL11A, JAZF1, KCNJ11, and PEPD. As previously mentioned ADAMTS9, ARL15,
JAZF1, and PEPD were also associated with obesity.
There were no regions of contiguous score depression for any of the SFS based intra-population statistics
for any of the Polynesian populations.
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Table 3.9: Type 2 diabetes-associated loci that showed signs of possible





















































CIM ADAMTS9 1 2 1 3




CIM ARL15 1 4 3 6 1 5 2 2 5
NZM ARL15 1 3 6 4 2 2
SAM ARL15 1 3 6 5 1 5
TON ARL15 1 3 6 5 3
CIM ATP8B2 1
NZM ATP8B2 1
SAM BCL11A 4 6 1 4 2 5 1





NZM CDKN2A 2 1




TON GLIS3 1 1
CIM GLIS3 1
SAM GRK5 1 1
TON GRK5 1 1
NZM IDE 1 3
TON INS-IGF2 1
TON ITGB6 1 1
CIM JAZF1 1
SAM JAZF1 4 3 2 1 4
TON JAZF1 5 4 5 6 1 5 1
SAM KCNJ11 1 1
TON KCNJ11 3 2 3
NZM LAMA1 1
SAM LAMA1 1
CIM LPP 7 2 6 5 3 1
NZM LPP 7 4 6 1 5 6 1
SAM LPP 7 2 5 4 1
TON LPP 7 3 5 4 1
SAM PAX4 1 1
SAM PEPD 7 2 4 6
TON PEPD 7 3 5 6 1
TON PPP2R2C 1
CIM PSMD6 3 2 1 1
NZM PSMD6 1 1
CIM PTPRD 6 3 5 6 5 14 4 3
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Table 3.9: Type 2 diabetes-associated loci that showed signs of possible





















































NZM PTPRD 5 3 4 5 1 5 1 1 1
TON PTPRD 7 3 4 2 1 5 5 4 1 3
SAM PTPRD 3 3
CIM RASGRP1 1
CIM RREB1 5 3 5 6 1 3
NZM RREB1 4 3 5 6 1 1
TON RREB1 3 1 1 2 2
CIM SND1 1 1 1 4
NZM SND1 1 1 7 4 4
SAM SND1 5 3 5 5 1 1
TON SND1 2 3 2 5
NZM SRR 1
CIM SSR1 2 2 5 3 2 2
NZM SSR1 4 2 5 3 2 2
SAM SSR1 1
TON SSR1 3
SAM ST6GAL1 1 1
TON TCF7L2 2 1 2
CIM THADA 6 2 6 5 8 2 1
NZM THADA 7 2 6 5 3 1
SAM THADA 7 2 6 5 3
TON THADA 7 2 6 5 7 12 8 2
SAM TP53INP1 7 1 2 2
TON TP53INP1 5 1
CIM TSPAN8 1
CIM WFS1 2
CIM ZFAND6 1 1
NZM ZFAND6 1 1
CIM ZMIZ1 5 5
NZM ZMIZ1 5 5
SAM ZMIZ1 5 4
TON ZMIZ1 5 1
XP-EHH is the number of populations from the super population that had at
least one marker significant in the gene. Integrated haplotype homozygosity
score and nSL are the number of significant markers. Fay and Wu’s H , Fu and
Li’s F , Tajima’s D, and Zeng’s E are the number of windows intersecting the
gene that met the lower threshold.
3.3.4.1.4 Selection in Polynesian populations for genes associated with kidney disease
There were 53 genes that were associated with kidney disease from the GWAS catalog (see Table S7
for references) with 11 genes having possible evidence of selection in Polynesian populations. Four
genes (DDX1, GP2, PHTF2, and WDR37 ) had markers that were significant for iHS in the Polynesian
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populations (Table 3.10). NZM had 3 markers (rs6966446, rs17158527, and rs75330800) in PHTF2,
SAM had one marker in DDX1, and TON had one marker in each of GP2 (rs7188098) and WDR37
(rs10508203). None of these loci also had windows from the SFS-based statistics that were significant.
NZM had a single marker (rs17158527) that was significant for nSL in PHTF2. SAM had a single
significant marker (rs1001116) for nSL in PRKAG2, a urate locus mentioned previously. WDR72 had
two markers, rs7182198 and rs10220852, in both TON and SAM that were significant for nSL. There
were no regions of contiguous score depression that intersected with kidney disease associated genes.
Table 3.10: Kidney disease-associated loci that showed signs of possible





















































SAM ANXA9 2 3 4
TON ANXA9 2 1 3
CIM BNIPL 1




NZM GP2 1 1
TON GP2 1




CIM SETDB1 1 1
SAM SETDB1 2 3
TON SETDB1 1 3 1
SAM SLC13A3 1
NZM WDR37 1 1
SAM WDR37 1
TON WDR37 2 1
SAM WDR72 2 2
TON WDR72 4 2
XP-EHH is the number of populations from the super population that had at
least one marker significant in the gene. Integrated haplotype homozygosity
score and nSL are the number of significant markers. Fay and Wu’s H , Fu
and Li’s F , Tajima’s D, and Zeng’s E are the number of windows intersecting
the gene that met the lower threshold.
3.3.4.1.5 Selection in Polynesian populations for genes associated with metabolic syn-
drome
In the GWAS catalog, there were 22 genes associated with metabolic syndrome (see Table S7 for
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references). In total, 9 loci had some evidence in the Polynesian populations of selection (Table 3.11).
APOA5, also associated with obesity, had a significant marker (rs3135507) in both NZM and TON
for iHS. SAM had a marker (rs12333979) that was significant for both iHS and nSL in DGKB. As
previously mentioned, NZM had a significant marker for iHS in FTO, which was also associated with
obesity and type 2 diabetes.
In the Eastern Polynesian populations there was a region of contiguous score depression for Tajima’s D
that intersected EDC4 at chr16:67835002-68115001 for CIM, and chr16:67775002-68105001 for NZM.
NZM also had a similar region for Fu and Li’s F , chr16:67775002-68095001.
Table 3.11: Metabolic syndrome-associated genes that showed signs of possible

















































NZM APOB 1 6
NZM DGKB 1








XP-EHH is the number of populations from the super pop-
ulation that had at least one marker significant in the gene.
Integrated haplotype homozygosity score and nSL are the num-
ber of significant markers. Fay and Wu’s H , Fu and Li’s F ,
Tajima’s D, and Zeng’s E are the number of windows inter-
secting the gene that met the lower threshold.
3.3.4.2 Selection in genes associated with other diseases possibly involving urate
3.3.4.2.1 Selection in Polynesian populations for genes associated with neurological dis-
orders
Urate has associations with neurological disease, such as the potential as a biomarker for the progression
of Parkinson’s disease (Wen et al., 2017). Loci that were associated with the neurological diseases of
Parkinson’s disease and Alzheimer’s disease from the GWAS catalog did not intersect with any regions
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of contiguous score depression of any SFS-based statistic. LRRK2 had significant XP-EHH for all
Polynesian populations with at least one population from each of the super populations. The Western
Polynesian populations also had markers with significant iHS and nSL (Table 3.12). Another locus,
CERS6, had each Polynesian population with significant XP-EHH markers with nearly all populations
from the AFR, AMR, EUR super population groups and approximately half of the populations from
both EAS and SAS super populations. A third locus that had significant XP-EHH markers for all
Polynesian populations was SLC2A13. All Polynesian populations had significant XP-EHH markers
with most populations from AMR and EAS super populations. NZM, CIM, and SAM also had
significant markers with nearly all populations of the SAS and EUR. Only NZM had significant markers
with the AFR populations. All Polynesian populations had significant markers for nSL at SLC2A13,
and for iHS except for NZM. VPS13C had both Eastern Polynesian populations with two significant
iHS markers (CIM: rs3784635 and rs12595158; NZM: rs3784635 and rs112236709), and windows from
the 1st percentile for Fu and Li’s F (6 windows), and Zeng’s E (9 windows for NZM and 11 for CIM).
Table 3.12: Neurological disease associated loci that showed signs of possible





















































CIM ABCA7 1 2 1 1




CIM C12orf40 3 4 3 1 3
NZM C12orf40 5 3 5 6 5
SAM C12orf40 1 4 2
TON C12orf40 2 4 2
CIM CERS6 7 2 1 5 1 1
NZM CERS6 6 3 2 6 1 1
SAM CERS6 7 4 5 6 3








TON GPRIN3 1 2
SAM HLA-DQA1 1 1
CIM LRRK2 1 3 4 5 1
NZM LRRK2 5 3 5 6 5
SAM LRRK2 6 3 5 6 1 1 2 3
TON LRRK2 1 3 4 5 3 3
CIM MS4A6A 1 2
NZM MS4A6A 1 1
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Table 3.12: Neurological disease associated loci that showed signs of possible





















































SAM MS4A6A 1 1
CIM NDUFAF2 7 1 5 5
NZM NDUFAF2 6 5
SAM NDUFAF2 4
TON NDUFAF2 4 8 6
SAM OR9Q1 3 3 5 1
TON OR9Q1 2 2
NZM PICALM 1 5 4
CIM PKP2 7 2 5 4 2
NZM PKP2 7 4 4 2 5 2 2
SAM PKP2 3 1 5 1
TON PKP2 2 1 2
TON PRICKLE1 1
NZM SIPA1L2 1 1
CIM SLC2A13 3 4 5 2 7 4 3
NZM SLC2A13 6 3 5 6 5 2
SAM SLC2A13 3 4 5 3 3 3
TON SLC2A13 2 4 3 2
CIM SNCA 2 3
NZM STK39 1 5
SAM STK39 1 2 5 4 8 4
TON STK39 5 2 7 4
SAM TMEM163 2 1
TON TMEM163 1 1
CIM VPS13C 2 5 11
NZM VPS13C 2 6 9
XP-EHH is the number of populations from the super population that had at
least one marker significant in the gene. Integrated haplotype homozygosity
score and nSL are the number of significant markers. Fay and Wu’s H , Fu and
Li’s F , Tajima’s D, and Zeng’s E are the number of windows intersecting the
gene that met the lower threshold.
3.3.4.2.2 Selection in Polynesian populations for genes associated with inflammatory
and autoimmune disorders
The list of inflammatory and autoimmune disorders was from Zhang et al. (2013) Table 2, and
included: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, celiac disease, systemic lupus
erythematosus, rheumatoid arthritis, psoriasis, multiple sclerosis, type 1 diabetes, primary biliary
cirrhosis, and vitligo. Autoimmunity is caused by the immune system attacking self rather than foreign
antigen and involves both the innate and adaptive immune response (Waldner, 2009). The genes
involved with the immune response have been suggested as possible candidates of selection (Grossman
et al., 2013). Both gout and these inflammatory and autoimmune disorders have a common cause from
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the activation of the immune system.
There were 981 genes associated with these inflammatory and autoimmune disorders, many of which
were also in common with the genes associated with urate, obesity, type 2 diabetes, kidney disease, and
metabolic syndrome, which is indicative of the immune response being part of all of these conditions.
Some of the loci that had multiple statistics, across multiple Polynesian populations indicating possible
selection were: ARHGEF3, ARL15, ATM, BLK, CCR3, CNTNAP2, DSTYK, FAM167A, FOXP1,
KCNB2, LPP, LRRK2, RREB1, SLC2A13, ALCO6A1, THADA, and XKR6 (Table S5).
All four Polynesian populations had significant XP-EHH values with populations from the AFR and
AMR super populations at the CNTNAP2 locus. The Western Polynesian populations also had
significant XP-EHH values with EUR populations. There were significant markers for iHS and nSL
for NZM and SAM. NZM had rs2620441 for both iHS and nSL, rs2249958 for iHS, and rs6952506 for
nSL. SAM had rs2249958 and rs17170777 for both iHS and nSL, rs2620441 for iHS, and rs10255956
for nSL. All Polynesians populations also had windows in the 1st percentile for Fay and Wu’s H , with
NZM having the most with 12. All Polynesian populations also had windows in the 1st percentile for
Tajima’s D that intersected CNTNAP2.
CCR2 and FCHSD2 had a higher number of significant results in the Eastern Polynesian populations,
whereas CDH23 and JAZF1 had a higher number of significant results in the Western Polynesian
populations. CCR2 and CCR3 were also associated with obesity, ARL15 and JAZF1 were associated
with obesity and type 2 diabetes, LPP and THADA were associated type 2 diabetes, and RREB1
was associated with urate and type 2 diabetes. Some of the genes had very high numbers of windows
from the 1st percentile for Tajima’s D intersect with them, such as RAD51B which was a contiguously
depressed score region for SAM, and XKR6, which was a contiguously depressed score region for CIM,
SAM and TON populations.
3.3.4.2.3 Selection in Polynesian populations for genes associated with malaria
Urate has a central role in malarial infection and triggering an immune response (Gallego-Delgado
et al., 2014). Given that immune response is a strong candidate to be under selective pressure, malaria
associated genes were looked at to see if there were signals of selection. From the GWAS catalog there
were two genes that had been associated with malaria at a genome-wide significance threshold (of three,
see Table S7 for references), that also had evidence of selection with the Polynesian populations. The
two genes that also had significant iHS scores with Polynesian populations were ABO and ATP2B4.
ABO was the only gene that had significant markers in all four Polynesian populations out of the
malaria-associated genes, and this was only for iHS. All of the markers with significant iHS in ABO
were in favour of the derived allele haplotype. CIM had two markers that were significant, the first,
rs1053878, was also significant in TON. The second marker, rs55764262, was significant in CIM, NZM,
and SAM, and was not in linkage disequilibrium (LD) with rs549446 (EAS R2 = 0.003). Rs549446
was significant in both CHS and JPT. There were no windows from the frequency-based statistics
that met the significance threshold. ABO has also been associated with obesity in GWAS (Comuzzie
et al., 2012). The marker rs8176741 had been associated with severe malaria (Timmann et al., 2012),
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rs2060762 1.000 0.600 0.449 0.688 0.723 0.492 0.490
rs11238131 0.600 1.000 0.585 0.680 0.531 0.319 0.316
rs4580999 0.449 0.585 1.000 0.674 0.510 0.611 0.607
rs3807558 0.688 0.680 0.674 1.000 0.744 0.497 0.495
rs2329371 0.723 0.531 0.510 0.744 1.000 0.707 0.698
rs1451375 0.492 0.319 0.611 0.497 0.707 1.000 0.988
rs1966839 0.490 0.316 0.607 0.495 0.698 0.988 1.000
LD was calculated in the EAS population of the 1000 Genomes
Project using LDlink (Machiela and Chanock, 2015), due to not all
markers being present on the CoreExome SNP array.
however, this marker had a significant iHS in Finnish in Finland (FIN) but no other populations. The
other SNPs that showed significance for iHS were not in LD (EAS R2 = 0.002) with rs55764262, for
which CIM, NZM and SAM all had a significant result. Both CIM and TON had a different marker
(rs1053878) that was significant for iHS in ABO.
Both SAM and NZM had SNPs that were significant for iHS in ATP2B4, SAM had rs10494845, and
NZM had rs142206068, both were in favour of the derived allele haplotype. The malaria-associated
variant was rs10900585 (Timmann et al., 2012). All three variants were not in LD with each other
(EAS R2 = 0.00). The LD was calculated using the full 1000 Genomes Project (1KGP) marker list for
EAS because rs10900585 was not on the CoreExome SNP array.
DDC encodes dopa decarboxylase and has been nominally associated at a genome-wide threshold with
malaria (Jallow et al., 2009). DDC has also been associated with BMI (Locke et al., 2015a). NZM
had significant markers for XP-EHH for nearly all other populations, CIM had fewer populations, but
across all super population other than SAS (Table 3.14). The NZM had multiple markers within DDC
for nSL. The markers were rs2060762, rs3807558, rs2329371, and rs1966839. The same markers in
addition with rs11238131 and rs4580999 were significant for iHS. A LD matrix with marker positions is
shown in Table 3.13. The marker rs1966839 (reference/derived allele = T, alternative/ancestral allele
= C) had scores from iHS and nSL in favour of the ancestral allele and was in high LD (R2 = 0.988)
with the malaria-associated rs1451375 (reference/ancestral allele = C, alternative/derived = A) where
the reference and alternative alleles correspond between the SNPs, and both are intronic variants.
Under a dominant model the A allele of rs1451375 is protective of severe malaria (OR = 0.75, CI =






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4.1 Identifying regions under selection in Polynesian populations
One of the primary objectives of this chapter was to investigate regions that were under selection in
Polynesian populations. From the intra-population statistics used, there were between 866 and 974
genes identified in the Polynesian populations that had both intra-population haplotypic and SFS
statistics that were in the 1st percentile. The regions with possible evidence of selection showed that
compared to the other super populations, the Polynesian populations had the fewest genes (111) that
only had evidence within the Polynesian super population, whereas the African populations had the
largest number of genes (457) that only had evidence in the African super population (Figure 3.3).
The Polynesian populations had similar distributions of the SFS-based statistics (explored more in
Chapter 4).
Pathway analysis on the regions with possible selection in the Polynesian populations revealed that
many of the genes that had evidence were involved with various forms of cell signalling, with many
related to calcium channels, especially in the Eastern Polynesian populations (sections 3.3.3.2.1 and
3.3.3.3.1). The majority of the pathways that had significant enrichment were from the genes that
had markers significant for nSL. There was similarity between the pathways of the Eastern Polynesian
populations, with many of the pathways in common being cardiac related. These pathways, such as
adrenergic signalling in cardio myocytes, calcium signalling pathway, hypertrophic cardiomyopathy,
and vascular smooth muscle contraction all had calcium channels as the main set of genes that were
selected (sections 3.3.3.2.1 and 3.3.3.3.1). The genes in common with these pathways were CACNA1D
(Calcium Voltage-Gated Channel Subunit Alpha1 D) which is associated with blood pressure (Lu
et al., 2015), CACNA2D2 (Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2) - also
associated with blood pressure (Warren et al., 2017), CACNA2D3 (Calcium Voltage-Gated Channel
Auxiliary Subunit Alpha2delta 3) - has an association with gout (Lai et al., 2012) but has not been
replicated in other studies, and SLC8A1 (Solute Carrier Family 8 Member A1) which is associated
with cardiac electrical activity time intervals (Arking et al., 2014). There was an association with
gout in the Polynesian GWAS performed in chapter 5 with CACNA2D3 (rs6793459, OR 0.79 95% CI
[0.68-0.90], P = 7x10-4), however it was not genome-wide significant, and this SNP was not in LD with
any of the significant iHS or nSL markers.
In the Western Polynesian populations, the only pathway that was in common between SAM and
TON was ABC transporters. There was only one gene in the ABC transporters pathway that had an
association with urate and gout from the GWAS catalog. The gene was ABCG2, which has a strong
effect for gout in Western Polynesian populations (Phipps-Green et al., 2010) and also had haplotypic
evidence in TON with iHS. One of the other genes in this pathway was ABCC4 which recently had
Western Polynesian specific variants, such as rs972711951, identified and associated with gout (Tanner
et al., 2017). There was evidence of selection at ABCC4 in CIM, NZM, and SAM (Table S3).
The gene CNTN4, encoding Contactin 4, had the highest number of significant markers in CIM and
third most in NZM for iHS. This particular locus has not been associated with urate at a genome-wide
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significance level, however there is evidence to suggest there may be an association (Chittoor et al.,
2016), but this was not observed with gout in either of the European or Polynesian GWAS analyses
performed in chapter 5 (section 5.3.2). There has also been prior selective evidence for this locus in
the Biaka Pygmy and Bantu populations, but not in more closely ancestrally related populations of
the Polynesian populations (Pickrell et al., 2009).
When looking at genes that have been associated with urate, gout and related co-morbidities, there is
no apparent difference in the number of genes showing signs of selection in Polynesian populations,
when compared to the other populations (Table 3.6). However, there were differences between the
Eastern and Western Polynesian populations for the iHS and nSL results, supporting the differences in
ancestral background. There was also evidence of selection in loci that were associated with malaria
and with type 2 diabetes and obesity, and is thus suggestive of a role for infectious disease applying
selective pressure.
3.4.2 Selection of urate associated genes
The second objective was to investigate regions associated with urate, gout and related co-morbidities
for evidence of selection in the Polynesian populations. There was evidence for selection in urate
associated loci. However, the evidence did not appear to be specific for urate itself, but for loci that are
involved in more general metabolic pathways. The main effect loci identified through GWAS, SLC2A9
and ABCG2, had limited evidence of positive selection. ABCG2 had a significant marker (rs2622626)
with iHS and nSL and only in TON from the Polynesian populations, the only other populations were
GIH and ITU from the SAS super population. This marker showing significance however might be
due to the gout prevalence of the TON sample population which was 54%. The same result is not
seen in closest population with the most similar ancestral background, SAM, where the prevalence of
gout in the sample population was much lower at 12%. Although rs2622626 has not previously been
associated with gout in East Asian populations (Zhang et al., 2016), nor did it have an association in
the Polynesian gout GWAS analysis in chapter 5 (P > 0.1).
Only RREB1 and IGFR1 had haplotypic evidence with XP-EHH across multiple other populations.
The other gene of note that did not have haplotypic evidence, but did have multiple windows in the
1st percentile across multiple statistics and all Polynesian populations was BCAS3. BCAS3 had been
previously identified as selected in Grossman et al. (2013). RREB1 was also associated with obesity
and type 2 diabetes traits. Zhang et al. (2013) had reported a variant nearby to RREB1 (rs675209) as
having evidence of selection but this particular marker was absent from the CoreExome SNP array.
There was a similar situation with obesity, type 2 diabetes, kidney disease, and metabolic syndrome,
where evidence of possible selection was found for multiple loci. The number of genes that had possible
evidence of selection was similar in the Polynesian populations to that of the other populations. An
interesting point however, was that the Western Polynesian populations had the fewest genes associated
with type 2 diabetes identified with iHS or nSL than all the other populations, despite Polynesian
populations having a high prevalence of type 2 diabetes (Winnard et al., 2013).
Other complex diseases in which urate is implicated, such as the neurological, and, inflammatory and
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autoimmune diseases, also showed multiple genes that displayed evidence of selection. One of the
‘themes’ that appeared was that genes were often associated with multiple diseases or gene lists, and
often involved with the immune system.
3.4.3 Replication of candidate thrifty-genes
There was no evidence of selection in either of the previously identified loci of PPARGC1A and
CREBRF in Polynesian populations. The CoreExome SNP array did not have rs8192678 which was
the SNP reported in Myles et al. (2011) (and not replicated in Cadzow et al. (2016)) as being a thrifty
genotype, but it did have rs1873532 which was in high LD (EAS R2 = 0.976). The lack of evidence
was consistent with the results of Cadzow et al. (2016) for PPARGC1A where there was no indication
of selection from frequency- or haplotype-based methods.
No selection signal was observed at CREBRF in any of the Polynesian populations that were tested.
One reason for this is that the CoreExome SNP array did not have the specific variants (rs12513649
and rs373863828) reported in Minster et al. (2016). Downstream from CREBRF there was a consistent
signal with what had been reported. This was only found in the Western Polynesian populations and
the populations of the EAS super population, so suggests that had the dataset contained the variants
then detection would have been possible. However, without the two markers reported in Minster et al.
(2016) it was unable to be determined if CREBRF had evidence of selection from the CoreExome data.
The pathway analysis of genes that were in the extremes for the different selection and neutrality
statistics showed that pathways involved with cell signalling (and more general in nature) were the
main results for the Polynesian populations, rather than specific metabolic pathways such as the urate
pathway. If selection had been acting on the pathways involved with urate, gout and related conditions
it would have been expected to see enrichment in genes involved with metabolic pathways. The genes
that indicated possible selection, even for obesity and type 2 diabetes, which are traditionally thought
of as being the thrifty phenotype, were genes that were largely either neurological or involved in the
immune system. NZM did have significant results for two diabetes related pathways, “Type II diabetes
mellitus_Homo sapiens_hsa04930” and “Insulin secretion_Homo sapiens_hsa04911”, however, only up
to 10% of the pathways had genes that met the significance thresholds. Of the genes that were part of
those pathways, up to 50% were genes that encoded subunits of voltage-gated calcium channels. While
some type 2 diabetes-associated individual loci show some signs of selection, it appears as if widespread
selection is not the case. Ayub et al. (2014) had a similar finding with respect to type 2 diabetes, where
there was no support for the thrifty-gene hypothesis, testing across 65 type 2 diabetes-associated loci.
As discussed in Gosling et al. (2014), the thrifty-gene hypothesis in the context of the Pacific, where
starvation during long voyages selected for thrifty-genes, does not fit with the anthropological history of
Polynesian people, where they undertook planned voyages which settled the Pacific in a speedy manner.
From the analysis results in this chapter, the thrifty-gene hypothesis appears to have none-to-minimal
support from the loci that exhibit signals of possible selection.
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3.4.4 Selection in malaria associated loci in Polynesian populations
Malaria is endemic in the southwest Pacific, extending out to the east as far as Vanuatu, with evidence
of genetic advantage against malaria of Austronesian speaking populations in Near Oceania (Clark
and Kelly, 1993). Malaria is absent, and always has been further west into Polynesia, Polynesian
ancestors would have passed through Near Oceania prior to settlement of the Pacific (Clark and Kelly,
1993). In Polynesia, even though malaria is absent, high frequencies of α-thalassaemia mutations
(protective against malaria) have been identified in populations not exposed to malaria (Hill et al.,
1985). Other malaria protective mutations, such as glucose-6-phosphate dehydrogenase deficiency and
β-thalassaemia, are present in Pacific populations in higher frequencies, though generally in island
groups where malaria remains extant (Flint et al., 1986; Cappellini and Fiorelli, 2008).
Response to infectious challenge is a key mechanism that has been thought of as a selective pressure.
Malarial infection provided a possible challenge to which urate may have been subjected to selective
pressure, and as such provided a viable candidate due to the involvement of urate with malarial
resistance (Gallego-Delgado et al., 2014). This involves precipitated urate being released from ruptured
infected erythrocytes, triggering an immune response (Orengo et al., 2009; Gallego-Delgado et al.,
2014). Three loci that were associated with malaria and identified from the GWAS catalog were
investigated for having signals of selection. Two genes that had evidence of selection in the Polynesian
populations had also been identified as being associated with obesity and type 2 diabetes. ABO and
ATP2B4 did not have strong evidence, and it came from only iHS.
The blood antigen ABO has a higher susceptibility to malaria in the A, B, or AB antigen groups, than
O (Zerihun et al., 2011). This has led to the formulation of a potential mechanism of cytoadherence
through infected red blood cells expressing PfEMP-1 and binding to the A or B antigens on other
red blood cells, enabling further infection (Cserti and Dzik, 2015). There is an increasing gradient
of A-type antigen from west to east in the Pacific, with populations in Melanesia having some of the
lowest frequencies, whereas, within Polynesia, Western Polynesian populations have lower frequencies
than Eastern Polynesian populations (Simmons, 1962). This could suggest that areas with endemic
malaria have a maintained selective pressure against the A-type antigen.
ATP2B4 encodes a plasma membrane calcium transporter, another calcium related gene with evidence
of selection in NZM, also sharing similarity with the many of the genes in the pathways from the
pathway enrichment, in that they too were calcium channels.
DDC on the other hand, which had a nominally genome-wide significant association with malaria, had
comparatively strong haplotypic evidence in the Eastern Polynesian populations. NZM had significant
XP-EHH results with every other non-Polynesian population and had six significant markers for iHS,
three of which were in the top 400 most extreme scores. Rs1966839 in DDC was in near perfect LD
with the malaria associated intronic variant rs1451375 (Jallow et al., 2009) and the protective allele
corresponded with the allele displaying a possible signal of selection.
From the obesity GWAS associated gene list, there was ADCY9, which had a very strong signal for
iHS for 7 markers in CIM and 2 markers in NZM, that were the only populations with significant
iHS values. The variant rs10775349 in ADCY9 had been associated with malaria in a candidate gene
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approach but not in GWAS (Maiga et al., 2013).
3.4.5 Study limitations
There were some technical limitations of the study that influenced the results obtained. The use of a
SNP array meant that there was an ascertainment bias built into the markers observed (Nielsen et al.,
2007). The data regarding the statistic distributions can be found in chapter 4 (sections 4.3.2.1.1,
4.3.2.2.1, 4.3.2.3.1, and 4.3.2.4.1. The quality control process for the CoreExome SNP array also has
a bias against singletons and low minor allele frequency SNPs (Guo et al., 2014). The effect of this
was seen in the right shifting of the distributions of the intra-population frequency-based statistics of
Tajima’s D, Fu and Li’s F , and Zeng’s E , all of which make use of low frequency or singleton variants
in their calculations (Tables 4.3, 4.4, 4.5, and 4.6). This shift was not observed in Fay and Wu’s H
which compared the ratio of high frequency derived and ancestral allele variants with the intermediate
frequency variants. The shift was seen in Tajima’s D, however with the African populations being
shifted to the right, such that the first percentile for many was above zero. The intermediate and
high frequency variants were over represented compared to the actual situation which will also have
had an impact on the haplotypic statistics due to haplotypes that have low-frequency variants being
altered. Further discussion on the distributions can be found in chapter 4, section 4.4.3. The effect of
using SNP array data and not sequence data, differing markers, marker density, and differing window
sizes all contributed to the up-to 65% replication of previously identified regions (section 3.3.2. For
the frequency-based statistics there was also only a FDR less than 10% in the Polynesian populations
for the 1st percentile of Tajima’s D and Fay and Wu’s H . By focussing on regions that had multiple
windows or multiple statistics the chance of it being a false positive should be reduced.
Another technical limitation that affected the haplotypes was phasing. The phasing of the haplotypes
for the Polynesian populations made use of the 1000 Genomes Project reference haplotype panel for
probabilistic phasing and could not make use of trios. This panel does not contain Polynesian-specific
haplotypes and so the phasing would be influenced by this. While the majority of common haplotypes
will be represented in this panel, haplotypes that are Polynesian-specific are not, and this introduces
incorrect haplotypes. The phasing uncertainty was unable to be taken into account for any of the
methods, this will influence the haplotypic methods of selection.
With the adaptation of the selection and neutrality tests into genome-wide usage, specifically the
sliding window approach, there was the need to balance the number of segregating sites with the
window size (Pybus et al., 2014). This balance is entirely influenced by SNP density with whole genome
sequence data offering 78 million bi-allelic SNPs in the 1000 Genomes Project Phase 3. However, the
CoreExome SNP array data had lower density, with a mean of one SNP per 9142 bases. This means
that window size needs to increase for SNP array data in order to have the same number of segregating
sites. However, as window size increases it also reduces the resolution of the genome and with it the
ability to associate a window with particular genomic features.
There was also a higher likelihood of a longer gene being reported as significant due to more windows
overlapping the genic region. Not only that, but because the window size after the statistics were
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calculated was trimmed to the central 10 kbp, this meant that SNPs in the calculation window might
not be near the actual window used, that is, up to -45 kb to +45 kb away from the edge of the defined
window used in the worst case. This would lead to some difficulty in definitive location. The flip-side
to this was that it allows for upstream and downstream effects of a SNP to be incorporated. There
was a trade-off between SNP density and window size. There were 305,214 bi-allelic SNP markers
used in this analysis from the CoreExome SNP array. This was less than the other projects such as
the HapMap project, and considerably less than the sequence data that the 1000 Genomes Project
used. The marker density may have been able to be improved though the imputation of the missing
markers using a haplotype reference panel. Ideally this analysis would have had a higher marker
density, however it was decided that it was best to remain unimputed due to both the haplotype
uncertainty at the phasing step, and the Polynesian populations not being represented in the haplotype
reference panel used for phasing and imputation. An example of why having Polynesian haplotypes
represented is important, is the finding of Minster et al. (2016), where the variant (rs373863828) had
no appreciable allele frequency outside of Polynesia. Implications from the marker density used are
the number of SNPs per window was lower than in other studies and specifically when looking at the
degradation of haplotypes there is the possibility for early truncation due to lack of data.
The method itself of using the empirical distribution and selecting the extremes for a statistic to
determine the region under selection does have precedence (Voight et al., 2006; Hider et al., 2013;
Jonnalagadda et al., 2017), however, this does assume that selection had occurred. The underlying null
distribution of the genome is also unknown. It does need to be acknowledged that using the extremes
of the distribution is likely to lead to many false positives (Teshima et al., 2006). This was somewhat
mitigated in this study by using the permutations of the actual data to calculate the empirical FDR.
Having internal replication within super populations also helps to reduce the FDR, for the Polynesian
populations this consisted of the Eastern and Western Polynesia population pairings.
Allele frequency methods, and also the haplotypic methods, may get confounded by the gout prevalences
of the Polynesian sample sets, especially the CIM and TON sets, where the prevalence of gout was up
to five-fold higher than the general population prevalence for those populations. Loci that showed
evidence in multiple populations that did not have this enrichment for the disease trait would be
expected to have more credibility. This is important to consider for the co-morbidities of gout too,
given the commonalities in associated genes.
One of the limitations of using the GWAS catalog to create gene lists for conditions is that there is
a heavy over representation of genes that are associated to disease in Europeans due to the overall
bias to GWAS research being conducted in European populations (Haga, 2010; Popejoy and Fullerton,
2016). This can mean that population-specific associations are missed (Weissglas-Volkov et al., 2013;
Minster et al., 2016). Genes that are associated with a condition can also be missed if they do not reach
genome-wide significance in a GWAS but in a candidate gene approach are significant for instance
ADCY9 being nominally significant for BMI at a genome-wide level but only significant for malaria in
a candidate gene approach.
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3.4.6 Conclusion
The first objective of this chapter was to investigate regions of the genome that had evidence of
selection in Polynesian populations. The main result regarding this objective was that the pathways
that were enriched by genes that displayed signatures of selection in Polynesian populations from the
genome-wide analysis were dominated by metabolic pathways. Of these pathways, calcium transport
and signalling was a central theme for the genes that showed evidence of possible positive selection in
Polynesian populations.
The second objective of the chapter was to investigate regions that had a previous association with
urate, gout, and associated co-morbidities. The results regarding this objective showed there was
indeed evidence indicative of selection in urate-associated loci in the Polynesian populations. The
evidence however was not specific to urate. This was shown by the fact that there was little signal
of selection appearing at the urate transporters themselves, but at the loci that were part of more
general pathways. There was also evidence of selection at other loci that were associated with the
co-morbidities, but again the signals were in genes that were for general cell functions, rather than
specific for the particular traits. The reasons for why there would be selection still remain unclear but
response to pathogenic challenge such as malaria in the case of urate is a potential mechanism.
The analysis had limiting factors with the main data using markers that originated from a SNP array,
and the ascertainment bias this introduced to the statistics, especially for those dependent on the
low-frequency variants. A second limiting factor was the use of empirical thresholds which will increase
the number false-positives. Both of these factors should temper the conclusion of selection or lack




Clustering of Selection Statistics
The previous chapter investigated regions of the genome in Polynesian populations that displayed
‘signatures of selection’, this chapter investigates the hypothesis that populations with shared ancestry
will display similar signals of selection. To test this, I will be clustering the various selection statistics
and then comparing the clusters to current population migratory history. This chapter contains data
that could be thought of as a precursor to chapter 3, however it incorporates the results from that
chapter 3 and so has been presented after.
4.1 Introduction
4.1.1 Signatures of selection
“Signatures of selection” in a population can be identified in regions of the genome that exhibit a
reduction in genetic variability (Maynard Smith and Haigh, 1974; Kaplan et al., 1989; McVean, 2007).
This reduction in genetic variation can arise when the phenotype of a neutral benefit allele experiences
a favourable change in environmental conditions, or a new allele arises conveying a selective advantage
(Hermisson and Pennings, 2005). This results in an increased frequency of both the allele, and linked
sites, within a population (Maynard Smith and Haigh, 1974). Genome-wide scans for signatures of
selection have shown that geographically similar populations share similar genetic signatures (Coop
et al., 2009; Pickrell et al., 2009). Geography can inhibit migration, leading to local adaptations
affecting the allele frequency of local populations, leaving the non-local population allele frequency
unaffected (Coop et al., 2009). New Zealand Polynesians are relatively geographically isolated, with a
recent settlement history, meaning that any signatures of selection found, and not shared with other
populations are likely to be a recent and localised adaptation.
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4.1.2 Settlement of Polynesia
The history of Polynesian migration starts with migration out of Africa (50-100 kya, Nielsen et al.
(2017)), tracking up to the Levant and Arabian Peninsula (45-55 kya) and splitting into South Asia,
Indonesia, and Australia (50kya, Kivisild et al. (1999); Quintana-Murci et al. (1999)). Concurrently
the migration to Europe was occurring (45 kya). From South Asia the migration continued with the
peopling of East Asia (20kya, Groucutt et al. (2015)). The Pacific was settled in two events, the first
was the settlement of Near Oceania (40 kya), followed by the settlement of Remote Oceania, reaching
Western Polynesia (Samoa and Tonga) during the Lapita expansion (3 kya, (Matisoo-Smith, 2015;
Skoglund et al., 2016)). Eastern Polynesia (including the Cook Islands) was then settled (1–1.2 kya,
Wilmshurst et al. (2011)). The final region of the Polynesian triangle to be settled was that of New
Zealand (NZ) by NZ Māori, occurring 800 ya (Duggan and Stoneking, 2014; Matisoo-Smith, 2015). It
is from this migration history that modern Polynesian populations come to have a shared common
ancestry with modern East Asian populations.
For largely economic reasons, during the 1950’s and 60’s there was a rural to urban migration of
people in the Pacific. As part of this, many individuals and families settled in New Zealand from
Samoa, Tonga, and the Cook Islands in search of work, and now the populations in New Zealand
largely outnumber the populations of their islands of origin (Matisoo-Smith, 2012). Within NZ, the
Polynesian populations are mostly focused within the Auckland region (Barcham et al., 2009).
4.1.3 Health disparities in Polynesian populations
New Zealand Māori and Pacific Islanders in New Zealand over the past decade have been exhibiting a
decrease in overall health (New Zealand Ministry of Health, 2016). Fruit and vegetable intake, and
physical activity has also been reported as decreasing. All the while there has been an increase in
obesity, which has an adjusted rate ratio of 1.7 for Māori versus non-Māori, and 2.4 for Pacific versus
non-Pacific (New Zealand Ministry of Health, 2016). The rate of increase in body mass index (BMI)
for Pacific Islanders was five times that of the rest of the world, and fasting plasma glucose was three
to four times higher over the 1980-2008 period (Hawley and McGarvey, 2015). The health disparities
are captured in the New Zealand statistics where Māori have a mortality rate of 1.8 that of non-Māori,
with the rates of obesity and diabetes of particular note, with the Māori standardised rate of 40.6 per
100,000, five times higher than non-Māori at 8.1 per 100,000 (New Zealand Ministry of Health, 2012).
New Zealand Polynesians have inherent elevated serum urate levels and higher prevalence of gout
(Winnard et al., 2012, 2013) and there are genetic variants in Polynesian populations associated with
increased risk of gout and elevated serum urate (Phipps-Green et al., 2010, 2016). Serum urate has
been associated with metabolic disorders (Choi et al., 2007; Choi and Ford, 2007), and genes involved
with complex diseases such as type 2 diabetes, gout, and other metabolic related disorders, have shown
evidence for selection Hancock et al. (2008); Pickrell et al. (2009); Zhang et al. (2013)].
It is hypothesised that elevated serum urate may have undergone positive selection in Polynesian
populations due to some of the beneficial properties (Gosling et al., 2014), such as its role as a powerful
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anti-oxidant (Ames et al., 1981), or as an adjuvant for the innate immune system (Opitz et al., 2009).
Serum urate has also been suggested to have a protective neurological effect against dementia, and
provides improved cognitive function with age (Euser et al., 2009). Characterisation of selection within
Polynesian populations has been largely limited to population differentiation due to population sample
sizes (Kimura et al., 2008; Mallick et al., 2016).
Here I investigate the shared ancestry for the genetic selection of serum urate and related co-morbidities
in Polynesian populations and attempt to determine whether there is a selection signature shared
among populations.
4.1.4 Objectives
The objectives of this chapter are to:
• Determine if neutrality and selection tests can be used to group populations.
• Investigate the shared selective histories of genetic loci associated with gout, urate, type 2
diabetes, obesity, kidney disease, and metabolic syndrome.
4.2 Methods
4.2.1 Data
The dataset used in this chapter is the selection dataset consisting of 31 population groups, split into
six super populations, created from marker matching the Polynesian populations genotyped on the
CoreExome single nucleotide polymorphism (SNP) array, with the 1000 Genomes Project (1KGP)
Phase 3 dataset (section 2.2.3).
4.2.2 Principal component analysis
Principal component analysis was performed on the independent genetic markers from the selection
dataset (for more detail refer section 2.1.4). The first 10 components were calculated and plotted.
4.2.3 Admixture analysis
Admixture analysis was performed on the independent genetic markers for the selection dataset.
Admixture proportions were calculated using all of the populations in the selection dataset and
cross-validation was used to identify the K value (number of theoretical ancestral populations) with
the lowest error for values of K from 1 to 15. Proportions were also calculated by first removing the
American Super Population (AMR) and Polynesian Super Population (POL) populations, calculating
the K value that provided the lowest error, through cross-validation, and then projecting these ancestral
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populations onto the AMR and POL populations, again for values of K from 1 to 15. For further
information refer to section 2.1.5.
4.2.4 Frequency spectrum
Tajima’s D, Fay and Wu’s H , Fu and Li’s F , Zeng’s E , and FST were all calculated using PopGenome
v2.2.3 (Pfeifer et al., 2014) for each chromosome. Aside from FST, these statistics were also calculated
as per section 2.1.2.1 to generate non-overlapping windows of 10 kb. For each selection test statistic,
windows were ordered by test statistic value, and the 1st and 99th percentiles of the distribution were
calculated. For the windowed approach, hierarchical clustering was then performed on a binary matrix
derived from the presence or absence of the windows in the 1st or 99th percentiles, across all populations.
Hierarchical clustering using the value calculated for each whole chromosome (i.e., treating the start
and end of the chromosome as the window boundary) used the statistic value itself to create the
distance matrix. The distance measure used was Euclidean distance and the linkage criteria was
“complete linkage” for both sets of clustering. Accuracy of the clustering was assessed by descending
the dendrogram until six groups, one for each super population, could be made, and then calculating
the maximum proportion of the individual populations of the same super population assigned to the
same cluster. Exclusivity of each cluster was calculated using the proportion of populations from a
given super population compared to the total number of individual populations assigned to that cluster.
For example, if a cluster consisted of eight populations, two from super population A and six from
super population B, then the exclusivity of the cluster would be 0.25 for super population A, and 0.75
for super population B. FST was calculated pair-wise for all populations for each chromosome.
4.2.5 Extended haplotype homozygosity
For all SNPs, integrated haplotype homozygosity score (iHS) and number of segregating sites by length
(nSL) were calculated and normalised using selscan v1.1.0b (Szpiech and Hernandez, 2014) as part of
the selectionTools 1.1 (Cadzow et al., 2014) pipeline, as described in section 2.1.2.2. Markers with an
absolute iHS or nSL value greater than 2.6 met the significance threshold, and were clustered into
genomic regions using the DBSCAN package v1.1.1 (Hahsler and Piekenbrock, 2017) in R, where
nearby SNPs were assigned the same group identifier. The search radius used was 200 kb and the
minimum number of points for a cluster was one. Cluster regions were created by taking both the
minimum and maximum position for each group identifier, population and chromosome. The distance
matrix was the result of calculating (A ∩ B)/ A and (A ∩ B) / B, where A ∩ B was the sum of the
intersection of clustered regions between population A and population B, and A and B was the sum of
the clustered regions for population A and population B respectively. Hierarchical clustering was then
performed, using complete linkage for the linkage criteria to create two sets of clusters (for an example
see Figure 4.15).
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4.2.6 Pathway enrichment analysis
Pathway enrichment analysis was performed by taking genes that intersected the clustered iHS and
nSL regions, inputting them into Enrichr1 (Chen et al., 2013; Kuleshov et al., 2016) and exporting
the KEGG 2016 pathway table. This differs from the pathway analysis in chapter 3 in that it was
performed on genes from clustered regions of significant iHS or nSL SNPs, rather than just the locus a
SNP was from.
4.2.7 Disease-associated genes
Disease associated markers and their annotated genes were downloaded from the genome-wide asso-
ciation study (GWAS) catalog2 (MacArthur et al., 2017) and filtered for association (chi-squared P
< 5x10-8). Gene lists were then created for each of the following diseases or traits; urate and gout,
type 2 diabetes, obesity, kidney disease, and metabolic syndrome by filtering the study disease trait
on keywords (see section 2.1.3 for details). Table S7 shows source disease trait and reference used to
create categories of gene lists for gout/urate, obesity, type 2 diabetes, kidney disease, and metabolic
syndrome. Selection test statistics values for each population were centred using the population median.
The gene lists from these categories were used in section 4.3.4 for hierarchical clustering using the
selection test statistic values for windows that intersected these gene regions. Complete linkage and




In order to confirm that individuals from a population were genetically similar principal component
analysis (PCA) was performed. It was expected that there would be higher genetic variation between
populations, than between individuals of a population. It was also used to confirm if the differences
between populations was likely influenced by difference in genotyping platform. The genetic variation
captured by PCA was plotted to visualise the relationship of individuals to one another (Figure 4.1).
Starting from principal component (PC) 1, each subsequent PC captured less of the variation than the
previous. Principal components for the merged 1KGP data and the New Zealand samples showed in
the first two components (which capture the most variation) that the African Super Population (AFR),
European Super Population (EUR), and South Asian Super Population (SAS) super populations all
formed separate groupings. PC 1 was responsible for separating the AFR populations from the others,
and PC 2 was largely responsible for separating the EUR and SAS from each other, and from the East
Asian Super Population (EAS) and POL populations. The EAS and POL populations were extremely
1http://amp.pharm.mssm.edu/Enrichr/ accessed 26 February 2018
2https://www.ebi.ac.uk/gwas/ accessed 19 June 2017
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similar in PC 1 but the POL populations were spread with PC 2, with the majority of the spread being
accounted for by the Eastern Polynesian populations whereas the Western Polynesian populations had
a tight grouping at -0.025 on PC 2, slightly below the EAS group. This can be observed when PC 6 is
used to separate the Polynesian populations (Figure 4.3). PC 3 separated the POL populations from
the EAS populations (Figure 4.1 B) and PC 4 separated the AMR and SAS populations (Figure 4.1
C). The Polynesian populations were split into Eastern and Western Polynesian sub-groups with PC 6
(Figure 4.3). This confirmed that the genetic variation was higher between populations, than between
individuals of a population, and indicated how genetically similar or dissimilar populations were to
each other. Populations that were thought to have a large degree of admixture also indicated as such
by the spread, and overlap with other better defined clusters.
The admixture of the AMR populations (1000 Genomes Project Consortium, 2015) was evident in
PC 1 with a large spread centred with the EUR populations. The first four PC indicated that the six
super populations could form super population clusters based on the genetic variation. There was no
distinction between the Utah Residents (CEPH) with Northern and Western Ancestry (CEU), British
in England and Scotland (GBR), and Europeans in New Zealand (NZC) populations (Figure 4.2), this
































AFR AMR EAS EUR POL SAS
Figure 4.1: A) Principal components 1 and 2 for all populations. B) Principal
components 1 and 3 for all populations. C) Principal components 1 and 4 for all



































Figure 4.3: Principal components 2 and 6 for the Polynesian populations.
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4.3.1.2 Admixture analysis
Admixture analysis is a method that can be used to infer the number of ancestral populations that
contribute to current populations by modelling the probability of the observed genotypes using
proportions of ancestral populations and the population allele frequencies (Alexander and Novembre,
2009). Proportions of theoretical ancestral populations for each population were calculated, using all
of the populations to establish the number of ancestral populations (K), that resulted in the smallest
cross-validation error. Five-fold cross-validation was used to calculate this error for K from 1 to 15.
The K value with the lowest cross-validation error was K = 11, with an error of 0.3855 (Table S6).
Admixture analysis was performed to identify the likely presence of admixture in populations, not for
quantification purposes, for cultural sensitivity reasons.
To understand the similarities in ancestral background and degree of admixture present at a population
level, the ancestral proportions for K = 11 were plotted for each individual for each population
revealing there were some clear similarities amongst the super populations (Figure 4.4). Within the
AFR populations there were three main ancestral populations, which correlated with geography, with
the East African population of Luhya in Webuye Kenya (LWK) being most different to the West
African populations (Esan in Nigeria (ESN), Yoruba in Ibadan Nigeria (YRI), Gambian in Western
Divisions in the Gambia (GWD), and Mende in Sierra Leone (MSL)). The populations of African
Caribbean in Barbados (ACB) and Americans of African Ancestry in SW USA (ASW) showed signs
of admixture with similarities to the ancestral populations in the West African populations, with
smaller proportions from the ancestral populations of LWK, and the European populations. The EAS
populations were represented by two ancestral populations. Chinese Dai in Xishuangbanna China
(CDX) was mostly one, and Japanese in Tokyo Japan (JPT) mostly the other, the remaining EAS
populations were mixtures of the two. A single ancestral population represented SAS, but there were
indications of admixture with the ancestral populations of the EUR and EAS populations. In the
EUR populations there was again two main ancestral populations, they correlated with North and
South Europe. One ancestral population was mostly in Finnish in Finland (FIN), and the other mostly
in Toscani in Italia (TSI) and Iberian Population in Spain (IBS). GBR, CEU, and NZC were all
extremely similar in proportions of the two and ancestral populations. The AMR populations were
mostly differing proportions of the ancestral population that TSI had, and an ancestral population
that was only in the AMR populations. There were also small proportions of the ancestral populations
that made up the West African populations. The POL populations had two ancestral populations,
one found in the East Polynesian populations, and the other in the West Polynesian populations. All
Polynesian populations had indications of small amounts of admixture with the ancestral populations
of the EUR populations, with the East Polynesian populations having a higher amount than the
West Polynesian populations. This analysis was consistent with the results of the PCA, and other
admixture analysis (Hellenthal et al., 2014; 1000 Genomes Project Consortium, 2015), but also showed
that there were sub-groups within the super-populations. The low level of admixture in the Polynesian











































































































Figure 4.4: Proportions of ancestral populations as inferred from ADMIXTURE,
using K = 11. Ancestral population (AP) represents a particular theoretical
ancestral population. Q is the ancestral proportion. Individuals in the sample
populations are represented on the x-axis.
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4.3.1.3 Whole chromosome clustering
In order to establish at a summary genome level how similar populations were by selection and neutrality
statistic were, clustering on each statistic summarising each chromosome was done. Clustering on
the full chromosome results for all chromosomes from PopGenome (Figure 4.5) did not group the
populations of each super population together, with the exception of Fay and Wu’s H , which grouped
all super populations, although it split the AMR populations into two subgroups. Tajima’s D grouped
the EUR and most of the SAS super populations, and had smaller sub-super population groupings of
two to three populations. Cook Island Māori in New Zealand (CIM), Māori in New Zealand (NZM),
and Samoans in New Zealand (SAM) were grouped with two AMR populations, (Peruvians from Lima
Peru (PEL) and Mexican Ancestry from Los Angeles USA (MXL)), and this group was the least
similar to the others. There was no clear pattern to the clustering order of Fu and Li’s F , although it
did have a few small groups of the same super population of no more than three individual populations.
The CIM and SAM populations were grouped together for both statistics. Zeng’s E clustered the AFR
populations together and this cluster was the least similar to the other populations. There was also a
grouping of the EAS populations which had the Western Polynesian populations as part of it. This











































































































































































































































































































































































































































































































































Figure 4.5: Hierarchical clustering of the populations using selection test statistics
for each entire chromosome. Clustering was performed using Euclidean distance
for the distance measure and complete linkage for the linkage criteria. Selection
test statistic is in the label for each dendrogram. Coloured by super population.
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4.3.1.4 FST
Hierarchical clustering performed on the pair-wise FST for the whole chromosomes between each
individual population grouped all of the super populations, except AMR into their correct groups
(Figure 4.6). The AFR populations were most similar to each other but least similar to the rest of the
populations. The Polynesian populations were grouped together and were sub grouped into East and
West Polynesian. The largest differentiation was between CIM and ESN (mean FST = 0.203), whereas
the smallest differentiation was between CEU and NZC (mean FST = 3.42x10-4). The mean FST for
POL and AFR was 0.184; POL and AMR was 0.110; POL and EAS was 0.065; POL and EUR was
0.128; POL and SAS was 0.095. This shows that the POL populations were least differentiated from


































































































































Figure 4.6: Hierarchical clustering on chromosomal FST using Euclidean distance
and complete linkage. Coloured by super population.
4.3.2 Hierarchical clustering of distribution extremes
Hierarchical clustering of the distribution extremes for each population was done to investigate if
there was a similarity between populations and the genetic regions that had the most extreme scores.
For the frequency spectrum methods, the 1st and 99th percentiles of windows (i.e., distribution tails)
by statistic value were calculated, and a binary matrix of sharing of significant windows between
populations was used for the clustering. This was done with the premise being that the extremes
would represent regions that had a similar selective pressure based on geographic similarity, or selective
pressure that operated on a shared ancestral population. For the haplotypic methods, the proportion of
regions that overlapped between populations was used to create the distance matrix for the hierarchical
clustering. The groups created by the clustering were then assessed for the number of populations from
a super population that were assigned the same cluster. Having all populations correctly grouped into
their super population was only completely achieved by clustering using the lower tail of Fay and Wu’s
H . If an allowance is made for the two AMR populations to be grouped with the EUR populations, as
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in the chromosomal FST clustering, then both haplotypic methods and six of the clustered tails of the
frequency spectrum-based methods clustered populations into their respective super populations.
There were differing numbers of windows used for each population, ranging from a minimum of 2388 to
a maximum of 2488. The mean number of windows per population was 2444.7 (SD 22.9) and was due to
multiple windows having the same value. Table 4.1 and Table 4.2 show the proportion and exclusivity
of the clusters respectively, for the clustering of populations by cutting the dendrograms to create
six groups, based on the number of super populations. Proportions were calculated independently
for each super population based on the cluster group with the maximum number of populations
from a particular super population, whereas, exclusivity of each cluster was calculated by using the
proportions of populations from a given super population assigned compared to the total number
of individual populations assigned to that cluster. Clustering based on the windows of the extreme
tails of the selection statistic distributions resulted in a higher number of the individual populations
being clustered into their super populations than for the chromosome-wide selection statistics, and the
clusters were also more exclusive to the super populations. This shows that the aggregate frequency
spectrum-based selection and neutrality statistics do not capture the population differentiation, but
that the extremes for each population do replicate the grouping that population differentiation had
with FST.
The following subsections will cover the distributions for the frequency-based statistics calculated
genome-wide in windows to highlight that populations within a super population had similar distri-
butions, but between super populations there were differences. For each statistic there will also be a
description of the clustering that was done on the 1st and 99th percentiles, and make note of any of
the metabolic disease associated loci from chapter 3 that met the selection thresholds that were found
in windows from the distribution extremes. There is a subtle difference between the windows that
were deemed of interest in chapter 3, and the windows in the extremes of the distributions, in that the
latter does not have the greater or less than zero condition. Each statistic also represents different
‘partitions’ of the frequency spectrum with Tajima’s D representing low versus intermediate frequency
variants, Fu and Li’s F representing singletons versus intermediate frequency variants, Fay and Wu’s
H representing intermediate versus high frequency derived variants, and Zeng’s E representing low
versus high frequency variants.
4.3.2.1 Tajima’s D
4.3.2.1.1 Tajima’s D distributions
The distributions of the genome-wide Tajima’s D values showed that there were differences between
each population, and super population (Figure 4.7 and Table 4.3). The Tajima’s D means for the
Polynesian populations were the smallest of the super populations at 2.003 (SD 1.049) with 1.875
(SD 1.073) for CIM, 1.929 (SD 1.042) for NZM, 2.061 (SD 1.041) for SAM, and 2.151 (SD 1.016) for
Tongans in New Zealand (TON) (Table S9). The means of the Polynesian populations were lower than
all of the other populations except PEL and MXL, indicating that overall the Polynesian populations
had a higher proportion of low frequency to intermediate frequency variants. The SAS populations
104
Table 4.1: Proportion of populations clustered into their corresponding super
population by selection and neutrality statistic. Proportions were calculated
independently for each super population based on the cluster group with the
maximum number of populations from a particular super population.
Type AFR AMR EAS EUR POL SAS
Fu and Li’s F
Chromosome 0.57 0.50 0.60 0.50 0.75 0.80
Lower Tail 0.71 1.00 1.00 1.00 0.75 1.00
Upper Tail 1.00 0.50 1.00 1.00 0.50 1.00
Urate/Gout 1.00 1.00 0.80 0.83 0.75 1.00
Type 2 diabetes 1.00 0.75 1.00 1.00 0.50 1.00
Obesity 1.00 0.75 1.00 1.00 0.50 1.00
Kidney Disease 1.00 1.00 1.00 0.33 1.00 1.00
Metabolic Syndrome 0.57 0.75 1.00 1.00 0.50 1.00
Fay and Wu’s H
Chromosome 1.00 0.50 1.00 1.00 0.75 1.00
Lower Tail 1.00 1.00 1.00 1.00 1.00 1.00
Upper Tail 1.00 0.50 1.00 1.00 1.00 1.00
Urate/Gout 1.00 0.75 1.00 1.00 1.00 1.00
Type 2 diabetes 1.00 0.50 1.00 1.00 0.50 1.00
Obesity 1.00 0.75 1.00 1.00 1.00 1.00
Kidney Disease 1.00 1.00 0.80 1.00 0.50 1.00
Metabolic Syndrome 1.00 0.75 1.00 1.00 1.00 1.00
Tajima’s D
Chromosome 0.71 0.25 0.60 1.00 0.50 0.80
Lower Tail 1.00 0.50 1.00 1.00 1.00 1.00
Upper Tail 1.00 0.50 1.00 1.00 1.00 1.00
Urate/Gout 1.00 0.75 1.00 1.00 1.00 1.00
Type 2 diabetes 1.00 0.50 1.00 1.00 0.50 1.00
Obesity 1.00 0.75 1.00 1.00 1.00 1.00
Kidney Disease 1.00 0.50 1.00 1.00 1.00 1.00
Metabolic Syndrome 1.00 0.75 1.00 1.00 1.00 1.00
Zeng’s E
Chromosome 0.57 0.75 1.00 1.00 0.50 0.60
Lower Tail 1.00 0.50 1.00 1.00 1.00 1.00
Upper Tail 1.00 0.50 1.00 1.00 1.00 1.00
Urate/Gout 1.00 0.75 1.00 1.00 1.00 1.00
Type 2 diabetes 1.00 0.50 1.00 1.00 1.00 1.00
Obesity 1.00 0.50 1.00 1.00 1.00 1.00
Kidney Disease 1.00 1.00 0.80 1.00 0.75 1.00
Metabolic Syndrome 1.00 0.75 1.00 1.00 1.00 1.00
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Table 4.2: Mean exclusivity of clusters for a given super population by selection
and neutrality statistic. Exclusivity of each cluster was calculated by using the
proportions of populations from a given super population assigned compared to
the total number of individual populations assigned to that cluster
Type AFR AMR EAS EUR POL SAS
Fu and Li’s F
Chromosome 0.25 0.23 0.47 0.67 0.40 0.28
Lower Tail 1.00 0.36 1.00 0.55 0.55 1.00
Upper Tail 1.00 0.58 1.00 0.46 1.00 0.38
Urate/Gout 1.00 0.40 0.62 0.55 0.88 0.50
Type 2 diabetes 1.00 0.61 1.00 0.43 1.00 0.36
Obesity 1.00 0.61 1.00 0.43 1.00 0.36
Kidney Disease 1.00 0.67 0.56 0.78 0.44 1.00
Metabolic Syndrome 0.64 0.21 1.00 0.86 1.00 0.45
Fay and Wu’s H
Chromosome 1.00 0.44 1.00 0.50 0.88 0.42
Lower Tail 1.00 1.00 1.00 1.00 1.00 1.00
Upper Tail 1.00 0.62 1.00 0.75 1.00 1.00
Urate/Gout 1.00 0.69 1.00 1.00 1.00 0.62
Type 2 diabetes 1.00 0.58 1.00 0.46 1.00 0.38
Obesity 1.00 0.67 1.00 0.67 1.00 1.00
Kidney Disease 1.00 1.00 0.65 0.55 0.57 0.45
Metabolic Syndrome 1.00 0.69 1.00 1.00 1.00 0.62
Tajima’s D
Chromosome 0.61 0.28 0.31 0.86 0.50 0.34
Lower Tail 1.00 0.62 1.00 0.75 1.00 1.00
Upper Tail 1.00 0.62 1.00 0.75 1.00 1.00
Urate/Gout 1.00 0.69 1.00 1.00 1.00 0.62
Type 2 diabetes 1.00 0.58 1.00 0.46 1.00 0.38
Obesity 1.00 0.69 1.00 1.00 1.00 0.62
Kidney Disease 1.00 0.62 1.00 0.75 1.00 1.00
Metabolic Syndrome 1.00 0.69 1.00 1.00 1.00 0.62
Zeng’s E
Chromosome 1.00 0.64 0.71 0.55 0.34 0.39
Lower Tail 1.00 0.62 1.00 0.75 1.00 1.00
Upper Tail 1.00 0.62 1.00 0.75 1.00 1.00
Urate/Gout 1.00 0.69 1.00 1.00 1.00 0.62
Type 2 diabetes 1.00 0.62 1.00 0.75 1.00 1.00
Obesity 1.00 0.62 1.00 0.75 1.00 1.00
Kidney Disease 1.00 0.44 0.75 1.00 0.75 0.56
Metabolic Syndrome 1.00 0.69 1.00 1.00 1.00 0.62
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Table 4.3: Summary statistics for Tajima’s D by super population.
Super Population Mean SD Min 1st Percentile Median 99th Percentile Max
AFR 2.378 0.717 -1.785 0.362 2.454 3.730 4.610
AMR 2.228 0.948 -2.252 -0.522 2.376 3.850 4.827
EAS 2.348 0.985 -2.642 -0.628 2.521 3.966 4.863
EUR 2.321 0.977 -2.200 -0.603 2.491 3.929 4.884
POL 2.003 1.049 -2.559 -0.977 2.160 3.824 4.837
SAS 2.442 0.891 -2.274 -0.257 2.590 3.948 4.772
had the highest mean Tajima’s D overall at 2.442 (SD 0.891). The AFR populations were the only
populations with the 1st percentile above zero, but also had the smallest overall maximum value of
4.610. The EUR populations had the highest maximum Tajima’s D value at 4.884. The smallest
Tajima’s D value of -2.642 came from the Kinh in Ho Chi Minh City Vietnam (KHV) population of
the EAS super population. The AFR population had the smallest range (6.395), whereas the EAS
super population had the largest (7.506). The POL population had the second largest (7.396). The
distribution for Tajima’s D should normally centre on zero, however, a right shifted distribution of
Tajima’s D, such as all distributions in Figure 4.7, can be attributed to ascertainment bias from using
a SNP array, where there is a bias against low frequency markers.
The clustering of the individual populations for the 1% most extreme values from each of the lower
and upper tails of the Tajima’s D distribution both showed the East/West split in the Polynesians
(Figure 4.8). But the clustering also showed that the Polynesian populations were most similar to
each other. Both tails placed the Polynesian cluster closest to the EAS cluster, consistent with the
migration history. The main groupings are of the populations that were designated as the same super
population, although the AMR super population in both tails has been split into two. The mean
number of unique windows per population was 274.5 (SD 153.1) in the upper tail, compared with
202.4 (SD 101.2) in the lower tail, indicating a higher degree of window sharing in the 1st percentiles
of populations. The groupings for both the upper and lower tails exclusively grouped each of the AFR,
SAS and POL super populations. The AMR super population was split into an exclusive group of
MXL and PEL, and a group of Colombians from Medellin Colombia (CLM) and Puerto Ricans from
Puerto Rico (PUR) which was shared with the EUR super population. All clusters, except the AMR -
EUR cluster, were each exclusive to a single super population.
4.3.2.1.2 Clustering Tajima’s D 1st percentile
In the lower tail, the number of windows that were unique to the Polynesian super population was 2188,
representing 11.1% of all windows in the lower tail that were used. This compared to super population
unique window numbers of 4825, 1085, 2114, 1250, 1119 for the AFR, AMR, EAS, EUR, and SAS
super populations respectively. Of the unique windows for Polynesian populations, 267 were specific to
CIM, 266 were specific to NZM, 300 were specific to SAM, and 404 were specific to TON. The Eastern
Polynesians had 699 unique windows with 166 of those shared between CIM and NZM, whereas the
Western Polynesians had 950 windows, with 246 shared between SAM and TON. There were 314
windows where all the Polynesian populations shared a window with a non-Polynesian population.
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Figure 4.7: Plot of the distribution of Tajima’s D by population. Triangles indicate
the minimum and maximum values. Dots indicate the 1st and 99th percentiles for
each population.
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Figure 4.8: Hierarchical clustering of Tajima’s D using the upper and lower 1%
of the distribution. A and B Dendrograms representing the clusters of Tajima’s
D lower and upper tails respectively, using hierarchical clustering with Euclidean
distance and complete linkage, and coloured by super population. C and D Plots
representing the windows present in each population from the lower and upper
tails respectively. A blue line represents presence of a window, white represents
the absence of a window in the 1% of the distribution for a population.
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And 3130 windows, intersecting 1268 genes, where at least one Polynesian population shared a window
with a non-Polynesian population (Table S13). There were 32 genes that had windows that were in the
1st percentile for all four Polynesian populations. Cell signalling as an immune response, such as the
Toll-like receptor cascades, were the main pathways this list of genes covered, although this was largely
due to PPP2CB and NOD1. Two other genes in the list were CCR3 and ARL15, both of which are
associated with obesity related traits (Comuzzie et al., 2012; Shungin et al., 2015), and the latter also
associated with type 2 diabetes (Mahajan et al., 2014).
4.3.2.1.3 Clustering Tajima’s D 99th percentile
The upper tail had a total of 3036 windows, or 13.5% that were unique to the Polynesian populations.
This compares to super population unique window numbers of 4626 (AFR), 1774 (AMR), 2476 (EAS),
1952 (EUR), 1274 (SAS). Eastern Polynesians contributed 985 unique windows, with CIM having 491
unique windows and NZM having 494 windows. The Western Polynesians had 1279 unique windows.
497 were from only SAM and 533 from only TON. There were 291 windows where all the Polynesian
populations shared a window with a non-Polynesian population. And 2807 windows, intersecting 1098
genes, where at least one Polynesian population shared a window with a non-Polynesian population
(Table S14).
In both tails the clustering was being driven by a small subset of the regions; this can be seen in
Figures 4.8 C and D, where most of the regions that the Polynesian populations have are not shared
with the other populations. It can also be seen that the regions that the Polynesian populations do
have in common are also shared with the EAS populations. This is reflected in the dendrograms in
Figures 4.8 A and B.
4.3.2.1.4 Metabolic disease-associated genes in the extremes of Tajima’s D
Specifically focusing on the 465 genes that were associated with urate, gout, obesity, type 2 diabetes,
kidney disease, and metabolic syndrome from the GWAS catalog (Tables S7 and S8), from the clustering
of the extremes, there were a total of 32 genes that had at least one of the Polynesian populations
having at least one window in the 1st percentile. This dropped to 6 genes that had windows in the 1st
percentile for at least one Polynesian population, and also in the 1st percentile of other populations.
Some examples of this were CCR3, which had windows in the 1st percentile for all four Polynesian
populations, and the same windows were also in the 1st percentile as the EAS populations of CDX and
KHV. ARL15 had windows that were only from the four Polynesian populations. And DNAH10 had
windows that were in the 1st percentile of the EAS populations except CDX, as well as the Eastern
Polynesian populations, CIM and NZM. In the 99th percentile there were 39 genes associated with the
metabolic diseases that had windows in the Polynesian populations, of those, 9 genes had windows
in the 99th percentile for Polynesians and the 99th percentile of other populations. Some examples
include ADCY3 which had multiple windows with POL, EUR, EAS, and SAS. And NEGR1 which
had windows from both the EAS and POL populations.
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Table 4.4: Summary statistics for Fay and Wu’s H by super population.
Super Population Mean SD Min 1st Percentile Median 99th Percentile Max
AFR 0.028 0.913 -8.113 -2.782 0.183 1.400 1.812
AMR -0.761 1.366 -11.167 -5.098 -0.507 1.240 1.817
EAS -1.040 1.551 -11.374 -5.977 -0.743 1.232 1.860
EUR -0.812 1.415 -13.060 -5.306 -0.546 1.259 1.789
POL -1.283 1.648 -11.692 -6.395 -0.982 1.162 1.732
SAS -0.704 1.348 -11.022 -5.031 -0.453 1.271 1.827
4.3.2.2 Fay and Wu’s H
4.3.2.2.1 Fay and Wu’s H distributions
Comparing genome-wide Fay and Wu’s H revealed that the POL super population had the lowest
mean (-1.283), 1st percentile (-6.395), median (-0.982), 99th percentile (1.162), and maximum values
(1.732) (Figure 4.9 and Table 4.4). Within the POL group, the minimum Fay and Wu’s H value for
a Polynesian population was from NZM, whereas the maximum value was from SAM. EAS was the
second lowest for mean (-1.040), 1st percentile (-5.977), median (-0.743), and 99th percentile (1.232),
but had the largest maximum (1.860). The EUR super population had both the smallest minimum and
largest range (14.850). The AFR super population were the only group to have a positive mean (0.028),
they also had the smallest range and variation (SD 0.913). This indicates that the AFR populations
have a deficit of moderate-to-high frequency derived alleles, whereas the POL and EAS populations
have the most windows with the highest excess of moderate-to-high frequency derived alleles.
The clustering of Fay and Wu’s H (Figure 4.10) had the main groupings the same as the defined super
population groups, with the exception of the upper tail where the AMR super population was split in
half. The Polynesian populations were clustered together in both the lower and upper tails for Fay
and Wu’s H . In both tails the Polynesian cluster also had the East/West split within the group. The
Polynesian population group was closest to the EAS populations with 1631 windows from the upper
tail and 2212 windows from the lower tail in common between at least one Polynesian population and
one EAS population.
4.3.2.2.2 Clustering Fay and Wu’s H 1st percentile
The clustering of the lower tail assigned all the individuals into their super populations and each of
the groups were exclusive to their super population. There were a total of 15,628 windows in the lower
tail, with 1546 windows specific to Polynesian populations. This compared to 3767 windows for AFR,
679 windows for AMR, 1081 windows for EUR, and 1375 windows for EAS. The Eastern Polynesian
populations had 561 windows, of those, 230 were specific to CIM and 189 were specific to NZM. The
Western Polynesian populations had 593 windows, with 156 specific to SAM and 283 specific to TON.
The mean number of windows specific to an individual population was 135.6 (SD 72.8) in the lower
tail. There were 595 windows with all Polynesians that also shared with a non-Polynesian population.
And 3208 windows, intersecting 885 genes with at least one Polynesian population that also shared
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Figure 4.9: Plot of the distribution of Fay and Wu’s H by population. Triangles
indicate the minimum and maximum values. Dots indicate the 1st and 99th
percentiles for each population.
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Figure 4.10: Hierarchical clustering of Fay and Wu’s H using the upper and lower
1% of the distribution. A and B Dendrograms representing the clusters of Fay
and Wu’s H lower and upper tails respectively, using hierarchical clustering with
Euclidean distance and complete linkage, and coloured by super population. C
and D Plots representing the windows present in each population from the lower
and upper tails respectively. A blue line represents presence of a window, white
represents the absence of a window in the 1% of the distribution for a population.
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with a non-Polynesian population (Table S15). There were 38 genes that had windows that were only
in the four Polynesian populations and no others.
4.3.2.2.3 Clustering Fay and Wu’s H 99th percentile
In the upper tail of the Fay and Wu’s H distribution, the clustering assigned all of the individual
populations into their super populations with only AMR being split. The CLM and PUR populations
were clustered as part of the EUR group. Exclusivity was also high with all clusters except the EUR -
AMR being exclusive to a single super population. Of the 20,659 windows, 2545 windows were from
Polynesian populations only. The Eastern Polynesian populations had 1119 specific windows, of those,
404 were unique to CIM and 371 were unique to NZM. The Western Polynesian populations had 925
unique windows, of these, 305 were specific to SAM and 332 specific to TON. The mean number of
unique windows for all populations was 226.4 (SD 144.1). There were 344 windows with all Polynesians
that also shared with a non-Polynesian population. And 2731 windows, intersecting 1176 genes, with
at least one Polynesian population that also shared with a non-Polynesian population (Table S16).
The 1st percentile has many of the regions in the Polynesian populations in common with the EAS
populations (Figure 4.10). Whereas, in the 99th percentile there were more regions that were only from
the Polynesian populations that were not in common with any other populations. This shows that the
regions with high frequency derived alleles are in common with the EAS populations, indicating they
possibly originated prior to the Polynesian migration.
4.3.2.2.4 Metabolic disease-associated genes in the extremes of Fay and Wu’s H
Of the genes that were in the windows of the 1st percentile, there were 30 genes that were in the list
of genes of metabolic disease associated genes and also had windows that intersected them from the
Polynesian populations. Thirteen of those genes were for windows from Polynesian populations, as
well as others. Some examples of these genes were RASA2 and ERBB4, and both are associated with
obesity traits and involved in signalling pathways. RASA2 had windows only from CIM and NZM.
ERBB4 had windows from all four Polynesian populations, as well as the populations of EAS - except
JPT.
There were 25 genes that were in the 99th percentile that were also in the list of genes of metabolic
disease associated genes. Some examples of genes that had windows in both Polynesian and other
populations in the 99th percentile include SHROOM3, RBMS1, and UBE2E2. SHROOM3 was an
example of a gene that had windows in common from all the other super populations, except EAS.
RBMS1 had multiple windows for across all Polynesian populations, but not other super populations.
And UBE2E2 had multiple windows across the Polynesian populations, as well as the populations
of EAS and SAS. SHROOM3 was an example of a gene associated with kidney disease, with its role
being in the development of the kidney (Khalili et al., 2016).
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Table 4.5: Summary statistics for Fu and Li’s F by super population.
Super Population Mean SD Min 1st Percentile Median 99th Percentile Max
AFR 1.992 0.543 -4.068 0.243 2.050 2.982 4.072
AMR 1.891 0.694 -4.809 -0.342 1.998 3.055 3.953
EAS 1.955 0.663 -5.262 -0.108 2.044 3.110 3.934
EUR 1.899 0.744 -5.048 -0.528 2.025 3.100 4.013
POL 1.719 0.754 -4.498 -0.685 1.844 2.970 4.040
SAS 2.012 0.643 -4.068 -0.055 2.104 3.107 3.921
4.3.2.3 Fu and Li’s F
4.3.2.3.1 Fu and Li’s distributions
The distributions of Fu and Li’s F were all centred above zero, with the lowest mean being that of
POL at 1.719 (Figure 4.11 and Table 4.5). The POL populations also had the lowest 1st percentile
(-0.685), median (1.844), and 99th percentile (2.970). Conversely, the SAS populations had the highest
mean (2.012), median (2.104), and were equal with the AFR populations with the highest minimum
(-4.068). The AFR populations were the only group to have a positive 1st percentile (0.243). The EAS
populations had the lowest minimum (-5.262), but the highest 99th percentile (3.110) and the largest
range (9.195). This pattern was similar to what was seen with Tajima’s D.
Clustering on the 1% Fu and Li’s F from each tail of the distribution (Figure 4.12) had 13851 windows
in the upper tail (Figure 4.12 B and D) and 30798 windows in the lower tail (Figure 4.12 A and C).
The mean number of unique windows per population was 120.6 (SD 102.8) in the upper tail, compared
with 467.2 (SD 202.1) in the lower tail. Both tails clustered the EAS populations into their own
exclusive cluster.
4.3.2.3.2 Clustering Fu and Li’s F 1st percentile
Clustering on the lower tail windows grouped the majority of the individual populations together into
their super populations. The Polynesian populations were grouped together as a West Polynesian
group and the CIM population. The NZM population was grouped with the MXL and PEL as part of
a larger group with the EUR super population. Exclusivity of clusters was reasonable with four of
six being exclusive. There were a total of 30,798 windows with 2722 windows specific to Polynesian
populations. This compared to 6337 windows for AFR, 1322 windows for AMR, 2635 windows for
EUR, and 4168 windows for EAS. The Eastern Polynesian populations had a total of 926 unique
windows, 483 were unique to CIM and 407 were unique to NZM. The Western Polynesian populations
had 1538 unique windows. Of these, 565 were unique to SAM and 811 to TON. There were 15 genes
that overlapped windows in the 1st percentiles of all four Polynesian populations (Table S17). Of
these genes, three (OR4C11, OR4C15, and OR4C16 ) were involved with the significantly enriched
“Olfactory transduction_Homo sapiens_hsa04740” pathway (adjusted P = 0.044).
4.3.2.3.3 Clustering Fu and Li’s F 99th percentile
115
Figure 4.11: Plot of the distribution of Fu and Li’s F by population. Triangles
indicate the minimum and maximum values. Dots indicate the 1st and 99th
percentiles for each population.
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Figure 4.12: Hierarchical clustering of Fu and Li’s F using the upper and lower
1% of the distribution. A and B Dendrograms representing the clusters of Fu
and Li’s F lower and upper tails respectively, using hierarchical clustering with
Euclidean distance and complete linkage, and coloured by super population. C
and D Plots representing the windows present in each population from the lower
and upper tails respectively. A blue line represents presence of a window, white
represents the absence of a window in the 1% of the distribution for a population.
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Clustering on the windows from the upper tail put the super populations into their own groups, but
also split the AMR populations into two separate groups. The Polynesian populations were also
clustered into an East/West split of 2 separate exclusive clusters. Exclusivity of clusters was high
with five of the six clusters being exclusive to a single super population, however one cluster contained
half of the AMR populations (CLM and PUR) and all of the EUR and SAS populations. There were
a total of 13,851 windows with 1804 windows specific to Polynesian populations. This compared to
2020 windows for AFR, 896 windows for AMR, 777 windows for EUR, and 953 windows for EAS. The
Eastern Polynesian populations had a total of 795 unique windows with 314 only from CIM and 228
from NZM. From the Western Polynesian populations there were 687 specific windows. There were
267 specific to SAM and 276 specific to TON. There were 101 genes that overlapped windows in the
99th percentiles of all four Polynesian populations (Table S18).
4.3.2.3.4 Metabolic disease associated genes in the extremes of Fu and Li’s F
There were 50 genes that were in the list of genes of metabolic disease associated genes and also had
windows in the 1st percentile, that intersected them from the Polynesian populations. Some examples
of these genes were MAFC1, DNAH10 and SLC2A9. MAFC1 had six windows, some of which were in
common with the AMR and AFR populations. DNAH10 had 18 windows, with about half being in
common with the populations of EUR, EAS, SAS, and AMR. The urate transporter SLC2A9 had
multiple significant windows in TON, JPT, and Han Chinese in Bejing China (CHB).
There were 41 of genes that were in the 99th percentile for Polynesians. Some examples were HLA-B,
PTPRD, LIPC, SHROOM3, and ABO. HLA-B was in common with all the super populations, although
only half of the populations of AFR. PTPRD was mostly only the four POL populations with a few
windows that were in common with a population for either SAS or AMR. LIPC had windows in
common for all Polynesian populations, and also shared with EAS, SAS, and AMR. SHROOM3 was
in the Eastern Polynesian populations, but also in common with EAS, and to a lesser degree EUR and
AMR and AFR. ABO was in the Eastern Polynesian populations and also in common with EAS, SAS,
and AFR.
4.3.2.4 Zeng’s E
4.3.2.4.1 Zeng’s E distributions
Similar to Tajima’s D, all of the distributions for Zeng’s E appear to have been shifted to the right,
indicating a potential bias against low frequency variants (Figure 4.13 and Table 4.6). The AFR
populations had the lowest overall distribution, with the lowest mean (1.850), 1st percentile (-0.096),
median (1.838), 99th percentile (3.910), maximum (6.511), and range (8.093). The EUR populations
that had the lowest minimum (-1.866) and the highest maximum (8.544), which also meant the largest
range (10.410). The highest mean of 2.642 was from EAS. The POL populations had the second
highest mean (2.559), median (2.535), 99th percentile (5.194), and maximum (7.827).
Zeng’s E for both extremes of the distribution (Figure 4.14), clustered all populations except AMR
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Figure 4.13: Plot of the distribution of Zeng’s E by population. Triangles indicate
the minimum and maximum values. Dots indicate the 1st and 99th percentiles for
each population.
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Figure 4.14: Hierarchical clustering of Zeng’s E using the upper and lower 1%
of the distribution. A and B Dendrograms representing the clusters of Zeng’s E
lower and upper tails respectively, using hierarchical clustering with Euclidean
distance and complete linkage, and coloured by super population. C and D Plots
representing the windows present in each population from the lower and upper
tails respectively. A blue line represents presence of a window, white represents
the absence of a window in the 1% of the distribution for a population.
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Table 4.6: Summary statistics for Zeng’s E by super population.
Super Population Mean SD Min 1st Percentile Median 99th Percentile Max
AFR 1.850 0.860 -1.581 -0.096 1.838 3.910 6.511
AMR 2.346 0.994 -1.684 0.012 2.340 4.754 7.652
EAS 2.642 1.001 -1.577 0.352 2.620 5.135 7.602
EUR 2.452 1.024 -1.866 0.024 2.453 4.904 8.544
POL 2.559 1.065 -1.613 0.122 2.535 5.194 7.827
SAS 2.463 0.968 -1.763 0.192 2.458 4.812 7.354
into their respective super populations. The AMR population was split into CLM and PUR which was
grouped with the EUR populations, and MXL and PEL which were grouped as a separate exclusive
cluster. The groupings of all super populations was the same for both tails, however, in the dendrogram
the difference comes from where the AMR populations were relative to the other super populations
with the MXL and PUR populations changing slightly in how close to the SAS group they were.
Exclusivity of clusters was high with only the AMR -EUR group not being exclusive to a single super
population.
4.3.2.4.2 Clustering Zeng’s E 1st percentile
There were a total of 14,052 windows, with 1371 windows specific to Polynesian populations in the
lower tail. This compared to 3002 windows for AFR, 605 windows for AMR, 976 windows for EUR,
and 1149 windows for EAS. There were a total of 444 windows specific to the Eastern Polynesian
populations, with 191 specific to CIM and 130 specific to NZM. The Western Polynesian populations
had 618 unique windows, 204 were unique to SAM and 250 unique to TON. The mean number of
unique windows was 119.5 (SD 64.1) in the lower tail. There were 36 genes that intersected windows
that were only in the four Polynesian populations and no other populations (Table S19). None of these
genes were associated with urate or co-morbidities.
4.3.2.4.3 Clustering Zeng’s E 99th percentile
In the upper tail there were a total of 13,684 windows with 1320 windows specific to Polynesian
populations. This compared to 2909 windows for AFR, 584 windows for AMR, 900 windows for EUR,
and 1200 windows for EAS. The Eastern Polynesian populations had 467 unique windows, the CIM
had211 unique windows, and NZM had 141 unique windows. The Western Polynesian populations had
594 unique windows. Of those, 204 were unique to SAM and 264 unique to TON. The mean number
of unique windows per population was 113.5 (SD 64.3)
4.3.2.4.4 Metabolic associated diseases in the extremes of Zeng’s E
There were 34 genes that were in the list of genes of metabolic disease associated genes and also had
windows in the 1st percentile, that intersected them from the Polynesian populations. Some examples
of these genes are MACF1, AGBL4, DACH1, and RBMS1. MACF1 had windows that were in the 1st
percentile of all populations. AGBL4 and DACH1 had windows in nearly every population except for
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most AFR populations. RBMS1 was only in the 1st percentile for the Western Polynesian populations
SAM and TON. Windows of the 99th percentile in the Polynesian populations that intersected the
metabolic disease associated genes tended to also be found in the populations of EAS, and many also
were in common with all other populations but not many were in common with the AFR populations.
There were 37 genes that were in the 99th percentile for Polynesians. Some examples were CHST8,
ERBB4, FHIT, PTPRD, and HMGA2. CHST8 had windows that were in the 99th percentile for the
four Polynesian populations, as well as the populations of EAS with a couple of populations of both
SAS and EUR too. ERBB4 had windows that were in both POL and EAS populations. FHIT had
windows for the Western Polynesian populations, SAM and TON and most of the populations from
EAS and SAS. PTPRD had windows from the Eastern Polynesian populations of CIM and NZM,
these windows were also in common with populations mostly from EUR, while some other windows
were in common with the Eastern Polynesian populations and AFR. HMGA2 had windows in all of
the super populations except AFR.
4.3.2.5 Summary of clustering on extremes regions
Clustering of the windows using that fell in the lower 1% and upper 99% of the distributions for
grouped the populations of the POL super population together in all instances except the lower tail of
Fu and Li’s F . There were no windows that were present for a single population in the 1st percentile for
all frequency-based statistics. The same applied for the 99th percentile. Pooling the windows for each
population within a super population for the 1st percentile, across all intra-population frequency-based
statistics used, had 16 genes. The AFR superpopulation had PHF7 ; EAS had ALMS1, OPLAH,
EXOSC4, GPAA1, CYC1, and SHARPIN ; EUR had NTN3 ; POL had FANCM and ALMS1 ; and
SAS had ABHD14A, ACY1, ABHD14B, TBC1D24, and NTN3. EAS and POL had ALMS1, a kidney
function-associated locus (Pattaro et al., 2016) in common, and EUR and SAS had NTN3 in common.
There were no windows in the 99th percentile that when populations were pooled as super populations
were present in all four frequency-based statistics.
4.3.3 Hierarchical clustering of selected haplotypic regions
A similar approach as with clustering of the frequency spectrum-based statistics was used to investigate
similarities in regions that had evidence of possible selection in the intra-population haplotypic based
selection methods. To do this, the significant iHS or nSL results were clustered into regions (Table
S21), and the percentage of bases overlapping between populations was calculated in these regions. The
proportion of shared regions, based on region overlap, was used to cluster populations, given the total
region that was significant for a single population. This was to investigate if there was a commonality
between populations in the haplotypic regions that had evidence for selection, the hypothesis being
that populations in similar geographic regions would have had a similar environmental exposure, and
therefore have similar regions of the genome under selective pressure. Another possibility was that the
selective pressure was in a shared ancestral population.
Clustering on the proportion of shared regions (see section 4.2.5) for both iHS (Figure 4.15) and nSL
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(Figure 4.16) grouped the individual populations into their super populations, with the exception of
the AMR populations which were split into two separate groups. The order of populations differed due
to each population having a different total for the size of region that was significant. Both iHS and
nSL gave similar groupings and had similar proportions of selected regions shared.
4.3.3.1 iHS
For the iHS significant regions, the populations with the least regions shared between them were CIM
and CLM, with 3.0% shared. The populations that had the largest proportion of region shared was
NZC and CEU with 56.7% shared. Looking specifically at the proportion of regions shared between
Polynesian populations, for the Eastern Polynesian populations there was NZM with 34.5% of regions
shared with CIM, and CIM shared 35.6% of regions with NZM. In the Western Polynesian populations,
SAM shared 43.8% of regions with TON, but TON shared 45.3% of regions with SAM. Out of all the
significant iHS regions for Polynesian populations, only 1.7% were in common across all Polynesian
populations. The Eastern Polynesians accounted for 59.9% of the regions from all of the Polynesian
populations while the Western Polynesian populations made up 50.1%.
The proportion of significant iHS regions the Polynesian populations shared with AMR was 14.5%,
AFR was 14.5%, EAS was 12.9%, EUR was 10.4%, and SAS was 9.6%. This was lower than the
mean (20.3%) for proportion of regions shared between the other super populations. The Polynesian
populations were clustered together with a high proportion of shared significant regions. The Eastern
Polynesians had on average 35.0% in common, and the Western Polynesian populations had 44.6%.
However, shared regions between the Eastern and Western Polynesian populations was 14.2% on
average. Of the clustered regions of significant iHS that were in common between all of the POL
populations, 70 genes intersected the regions. These genes were part of 57 pathways in the Kyoto
Encyclopedia of Genes and Genomes (KEGG) 2016 pathways in Enrichr, but none were significantly
enriched. Regions that were in common between NZM and CIM had 392 genes that intersected, and
were involved with 174 pathways. Again, no pathways were significantly enriched. For the regions that
were in common between SAM and TON, there were 502 genes that intersected the regions. They
belonged to 223 pathways, with only a single pathway significantly enriched (Benjamini-Hochberg
adjusted P = 0.023) with seven of 44 genes (ABCA5, ABCC8, ABCC5, TAP2, ABCA9, ABCB8, and
ABCA8 ). That pathway was “ABC transporters_Homo sapiens_hsa02010”.
4.3.3.2 nSL
The clustering results using regions of significant nSL gave the same groupings as iHS (Figure 4.16).
This similarity was also seen with the differences in individual populations, where NZC and GBR had
the highest percentage of shared regions at 59.9%. NZM and Bengali from Bangladesh (BEB) shared
the lowest percentage of regions at 0.5%. The percentage of the significant nSL regions the Polynesian
populations shared with AMR was 10.0%, AFR was 10.4%, EAS was 11.6%, EUR was 7.6%, and
SAS was 7.0%. This was lower than the mean (16.5%) proportion of region sharing between super
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Figure 4.15: iHS Clustering: A. Dendrogram from hierarchical clustering based
on proportion of significant iHS regions shared between populations, coloured by
super population. B. Heatmap showing the proportion of significant iHS regions
shared. The population listed on the axis is used as A in the calculation = (A ∩
B)/ A. Axes have been ordered according to the hierarchical clustering.
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significant regions. The Eastern Polynesians had on average 36.5% in common. NZM shared 38.3% of
regions with CIM, whereas CIM shared 34.6% of regions with NZM. The Western Polynesians had
40.4% of regions shared on average. SAM shared 39.1% of regions with TON, but TON shared 41.8%
of regions with SAM. However, between the Eastern and Western populations, region sharing averaged
11.2%. Of the regions from all of the Polynesian populations, the Western Polynesian populations
made up 56.7%. The Eastern Polynesians made up 51.0%. The total percentage of regions common
for all Polynesian populations was 1.4%. This shows that within the Eastern or Western Polynesian
groups there was a larger proportion of regions that were similar for significant nSL, than between the
Eastern and Western groups.
The regions that were in common for significant nSL between all of the POL populations intersected
27 genes. These genes were part of 10 pathways, but none were significantly enriched. Regions that
were in common between NZM and CIM had 230 genes that intersected, and were involved with
160 pathways. A single pathway, “Glycosaminoglycan degradation_Homo sapiens_hsa00531”, was
significantly enriched (adjusted P 9.223 x 10-3) with four of 19 genes (HPSE2, HYAL1, HYAL2, and
HYAL3 ). The regions that were in common between SAM and TON intersected 319 genes. There
were 197 pathways that these genes were part of but none were significantly enriched.
4.3.3.3 Metabolic disease associated genes
In the clustered-significant regions of both iHS and nSL (Table S21) there were 405 independent regions
that overlapped with genes associated with urate and metabolic diseases from all populations, for
Polynesian populations the number of regions was 104. iHS had 337 regions, while nSL had 329, and
in common between the two statistics were 261 regions. The regions of the Polynesian populations
covered 433 SNPs for iHS and 301 for nSL, with 149 in common between them. For the genes that had
significant regions in Polynesian populations, 8 regions intersected genes that had been associated with
urate and gout, 67 with obesity, 30 with type 2 diabetes, 6 with kidney disease, and 5 with metabolic
syndrome.
Using the significant SNPs for these iHS and nSL (as in Chapter 3) there were a total of 204 SNPs
that were significant in a Polynesian population and also significant in at least one other population
for iHS, and 93 for nSL (Table S3). The number of SNPs that were significant in both iHS and nSL in
the Polynesian population was 48.
The urate associated gene ABCG2 had a single SNP (rs2622626) that was significant in TON that
was in common for significance for iHS in two other populations, Gujarati Indian from Houston Texas
(GIH) and Indian Telugu from the UK (ITU), both were from the SAS super population. The situation
was the same for nSL, but with the addition of JPT.
The SAM and TON populations had multiple SNPs in common that were significant for both iHS and
nSL. An example is in LRP1B, where there were three SNPs: rs10173806, rs4591293, and rs2890615.
Rs2890615 was also significant in ESN and Southern Han Chinese (CHS).
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Figure 4.16: nSL Clustering: A. Dendrogram from hierarchical clustering based
on proportion of significant nSL regions shared between populations, coloured by
super population. B. Heatmap showing the proportion of significant nSL regions
shared. The population listed on the axis is used as A in the calculation = (A ∩
B)/ A. Axes have been ordered according to the hierarchical clustering.
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TSI, and GBR. FHIT also had a single significant SNP, but this was in the NZM, CHB, CHS, CDX,
KHV, and PEL populations. Of the metabolic disease genes, ERBB4 and FHIT were also found by
Pickrell et al. (2009) in the Human Genome Diversity-CEPH Panel using iHS and cross-population
extended haplotype homozygosity (XP-EHH).
One of the main regions, chr20:33470694-34556005, had 11 significant SNPs in Polynesian populations
as well as up to 16 other populations, contained the obesity-associated gene GDF5 and the neighbouring
genes CEP250 and UQCC1. The majority of the significant SNPs were for the ancestral allele. Both
rs1570841 and rs4911502 were significant in the populations of AMR (CLM, MXL and PUR), EAS
(CDX, CHB, CHS, JPT, and KHV), EUR (CEU, FIN, GBR, IBS), POL (CIM, NZM, and TON),
and SAS (BEB and ITU. Both SNPs were for the ancestral allele. Four SNPs, rs4911178, rs4911494,
rs6087704, and rs6087704, intersected both GDF5 and UQCC1, and were significant for the derived
alleles in the CIM and JPT populations.
4.3.4 Disease-associated gene clustering
To assess if there was specificity of selection for the metabolic disease gene lists or if the population
groupings could be obtained from any list of genes, clustering was performed using the actual statistic
values for the genes. These values were median-centred to account for the population specific shifting
of distributions which would have accounted for the majority of difference in the distance calculation.
Gene lists were chosen for metabolic-related disease and compared to lists of random genes (section
4.3.5.2) to assess clustering specificity to metabolic disease.
4.3.4.1 Clustering of median-centred window values for urate and gout-associated genes
There were 62 loci that had an association with urate or gout at a genome-wide significance level
in the GWAS catalog. This mapped to 435 windows for each of the frequency-based selection test
statistics. Tables S22, S23, S24, and S25 contain the median centred values for the windows used in
the clustering. All statistics (Tajima’s D, Fay and Wu’s H , Fu and Li’s F , and Zeng’s E) grouped
most of the super populations correctly and nearly all clusters had good exclusivity for each single
super population (Tables 4.1 and 4.2). Tajima’s D, Fay and Wu’s H , and Zeng’s E also had an
Eastern/Western Polynesian population sub group within the Polynesian group (Figure 4.17). Unlike
the FST clustering, the AMR populations were grouped together for Tajima’s D, Fay and Wu’s H , and
Zeng’s E . The EAS and POL populations were closest for Tajima’s D, Fu and Li’s F , Fay and Wu’s H ,
and Zeng’s E .
One of the trends across all of the statistics, was that within a super population, the range of values
within a gene were very similar, but between super populations there could be completely different
directions. There was also variation between loci, in terms of which populations had overall more
positive or negative windows. INHBB was an example of a locus with Fay and Wu’s H that showed
similarity in scores of populations with similar ancestry, such as between the POL and EAS which
were positive, SAS was near zero but slightly positive, EUR and AMR were near zero but slightly
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negative, and AFR was more negative (Table S23). Another example was RREB1, where for Tajima’s
D, the POL populations were sitting around -2 , with the EAS populations slightly less negative, and
the other populations having windows that were around zero (Table S22). A similar pattern was seen
in RREB1 with Fu and Li’s F (Table S24). With Zeng’s E , SLC22A12 and SLC22A12 both had
AFR, EAS, and POL negative, and AMR, EUR, and SAS positive (Table S25). And both SLC17A1
and SLC17A4 had all populations with negative Zeng’s E , except the POL populations, which were
positive. SLC2A9 tended to be overall more negative in value for all statistics for both POL and EAS









































































































































































































































































































































































































































































































































Figure 4.17: Dendrograms created from hierarchical clustering applied to windows
from the 62 loci associated with urate and gout. Coloured by super population.
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4.3.4.2 Clustering of median-centred window values for obesity-associated genes
The GWAS catalog had 269 loci associated with obesity, this was represented by 4099 windows and
the clustering resulted in the groupings of super populations (Figure 4.18). Exclusivity of a single
super population to a cluster was also high with the notable exception being the AMR populations
of CLM and PUR often being part of the EUR cluster (Tables 4.1 and 4.2). Tables S26, S27, S28,
and S29 contain the median centred statistic values for the windows used in the clustering. The
Polynesian super population cluster was also closest to EAS in all selection statistics and also had an
Eastern/Western sub-grouping within the POL group.
Much like the urate-associated genes, the same trend of within a super population, genes had similar
values, but there could be completely different directions of statistic between super populations held.
Some examples of this included LEPR and FOXE1, where for Fay and Wu’s H , Tajima’s D, and Fu
and Li’s F , for the EAS and POL populations the windows were mostly negative, whereas for the
other populations they were close to zero or even positive. ARL15 was an example of a locus that all
populations had a range of values, but the POL populations was the negative most for all statistics,
and in Tajima’s D, Fay and Wu’s H , and Fu and Li’s F the EAS populations showed similarity with
the POL populations in the values of the statistics in being overall quite negative.
4.3.4.3 Clustering of median-centred window values for type 2 diabetes-associated genes
The GWAS catalog had 99 genes associated with type 2 diabetes. These were represented by 1471
windows and clustering of the type 2 diabetes associated genes grouped the individual populations
into their super population groups. For all clustering the AMR populations were split, with CLM and
PUR grouped with the EUR populations for Tajima’s D, Fay and Wu’s H , and Zeng’s E (Figure 4.19).
Tables S30, S31, S32, and S33 contain the median centred statistic values for the windows used in
the clustering. The POL populations were assigned two exclusive groups through the cutree method
that created an Eastern/Western Polynesian split for Tajima’s D, Fay and Wu’s H , Fu and Li’s F ,
and Zeng’s E . Fay and Wu’s H and Zeng’s E had a similar pattern to the groupings of the whole
chromosome FST clustering.
Again, most of the loci that were associated with type 2 diabetes followed the same trend of values
within a super population being similar, and differences between the super populations. An example
where this was not the case was SSR1, where all populations, except the Eastern Polynesian populations
were very similar and close to zero, whereas the Eastern Polynesian populations were negative in all
statistics, but not extreme enough to be in the 1st percentile.
4.3.4.4 Clustering of median-centred window values for kidney disease-associated genes
The GWAS catalog had 53 genes associated with kidney disease, this was represented by 390 windows.
The clustering of the kidney disease-associated genes grouped the individual populations into their
super population groups for AFR and SAS using Tajima’s D, Fay and Wu’s H , Fu and Li’s F , and










































































































































































































































































































































































































































































































































Figure 4.18: Dendrograms created from hierarchical clustering applied to windows










































































































































































































































































































































































































































































































































Figure 4.19: Dendrograms created from hierarchical clustering applied to windows










































































































































































































































































































































































































































































































































Figure 4.20: Dendrograms created from hierarchical clustering applied to windows
from the 53 loci associated with kidney disease. Coloured by super population.
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Fu and Li’s F but were clustered together for Fay and Wu’s H and Zeng’s E (Figure 4.20). Tables S34,
S35, S36, and S37 contain the median centred statistic values for the windows used in the clustering.
Tajima’s D clustered populations from AFR, EAS, POL, and SAS into super population specific and
exclusive clusters.
The same trend as for the other gene lists still stood with the kidney disease gene list. Although for
Fay and Wu’s H and Zeng’s E there was a higher similarity between TON and KHV than with the
other populations of their respective super populations. This was largely driven by ALMS1, where
TON, KHV, and the populations of AFR, were negative, and the other populations were positive for
Zeng’s E and the opposite was the case for Fay and Wu’s H .
4.3.4.5 Clustering of median-centred window values for metabolic syndrome-associated
genes
The GWAS catalog had 22 genes associated with metabolic syndrome, this was represented by 234
windows. The clustering of the metabolic syndrome associated genes grouped individual populations
into their super population groups for Tajima’s D and Fay and Wu’s H (Figure 4.21). Tables S38,
S39, S40, and S41 contain the median centred statistic values for the windows used in the clustering.
For Fu and Li’s F , the Polynesian populations were assigned two exclusive clusters that followed the
Eastern/Western Polynesian split. Zeng’s E clustered the individual populations, except for PEL, into
their super populations. The Polynesian populations were grouped into entirely exclusive clusters
for all statistics. The same trends of within super populations having similar statistic values and
differences between super populations still held in the gene list for metabolic syndrome.
4.3.5 Random draws
4.3.5.1 Random windows
It is possible that obtaining the population groupings by clustering the most extreme windows for each
statistic, could have occurred by chance. To assess this, 10,000 iterations of random resampling of
2500 windows per population was undertaken, and these windows were then clustered. This was done
so that the extreme tail clustering could be compared to the random windows to see if the extreme
window clustering performed better in exclusivity and proportion of super population clustering than
by drawing windows at random. The maximum proportion of populations being clustered into their
designated super population was then calculated when the tree was cut to have six groups (K = 6), one
for each super population. The mean proportion of populations grouped into their super population
was less than 0.5 for all super populations, with an overall mean of 0.282 (Table 4.7). This compared
to a mean proportion of 0.916 for the clustering of the extreme windows, this implies that there is
similarity in the regions of extreme score within a super population, and differences in these regions
between super populations. Based on the results of the admixture analysis, K = 11 was also tested










































































































































































































































































































































































































































































































































Figure 4.21: Dendrograms created from hierarchical clustering applied to win-
dows from the 22 loci associated with metabolic syndrome. Coloured by super
population.
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Table 4.7: Proportion of individual populations assigned to their super population
by hierarchical clustering across 10000 iterations of 2500 randomly drawn windows.
Super Population Min Mean Std. Dev Max Prop50 (%) Total Complete (n)
AFR 0.286 0.389 0.103 0.857 2.1 0
AMR 0.250 0.451 0.147 1.000 11.9 32
EAS 0.200 0.429 0.118 1.000 3.6 6
EUR 0.167 0.395 0.102 0.833 5.6 0
POL 0.250 0.450 0.147 1.000 11.8 30
SAS 0.200 0.423 0.116 1.000 3.3 2
Prop50 is the percentage of the iterations that had at least 50% of each super population
assigned the same cluster. Total complete is the number of iterations all populations of a
super population were assigned the same cluster
remainder of this section will report on K = 6, as this reflects the number of super populations used
for the non-randomised data.
Not a single random draw grouped the all individual populations into all of their respective super
populations. Only the populations of the AFR and EUR super populations did not each get fully
grouped into a cluster. Grouping at least 50% of a super population was at best 12% of the draws
but for the larger super populations (AFR, EAS, EUR, and SAS) it was on average 4% of the draws.
There were only eight random draws that had all super populations each having half or more of their
individual populations assigned to the same group. The mean exclusivity of the random draws was
low, ranging from 0.26 to 0.32 and there were no random draws in which the Polynesian populations
were all grouped together as a Polynesian exclusive cluster.
Compared to the clustering on the extreme tails, the random windows had poorer exclusivity of clusters
with a mean exclusivity of 28%. The populations were clustered into their super populations rarely for
the random windows and did not have multiple super populations being clustered as the clustering of
the extremes returned (Table 4.7). This indicates that there is a degree of similarity of regions that
are in the extremes of the distributions and the populations who share them. This is largely due a
minimum degree of differences in similarity being needed in order for hierarchical clustering to be
effective for clustering. When windows are drawn at random the differences, or distances, between
populations is likely to be equivalent, so the hierarchy is flatter, meaning small differences have very
large changes to the groupings.
4.3.5.2 Random genes
In order to assess whether the clustering from gene lists was specific to the disease associated genes
used, lists of random genes were created by selecting genes from a list containing all annotated genes,
and then clustered. Random gene lists were generated with either 25 or 100 randomly selected genes,
100 times each. Hierarchical clustering was then performed on the median centred statistic value based
on the population, for windows that intersected genes from the random gene lists for Tajima’s D, Fay
and Wu’s H , Fu and Li’s F , and Zeng’s E . The number of times the Polynesian super population was
completely clustered ranged from 5 to 78 (Table 4.8). The Polynesian super population was completely
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Table 4.8: Percentage of draws from randomly selected genes for completely
clustered super populations.
Statistic Genes (n) POL Complete (%) All Complete (%) All Complete excl. AMR (%)
Fay and Wu’s H 25 57 5 49
Fu and Li’s F 25 13 0 0
Tajima’s D 25 51 8 44
Zeng’s E 25 60 7 52
Fay and Wu’s H 100 78 5 75
Fu and Li’s F 100 5 0 1
Tajima’s D 100 74 3 73
Zeng’s E 100 75 6 75
clustered more often with the lists of 100 genes for Tajima’s D, Fay and Wu’s H , Fu and Li’s F ,
and Zeng’s E compared to the lists of 25 genes. The number of times all populations were clustered
completely was less than 10%. However, if the AMR super population was not included then it became
56 for the 100 genes, and 36.3 for the 25 genes. Fu and Li’s F did not perform well at clustering the
Polynesian populations into their super population, and only achieved this less than 13% of the time.
Clustering all populations was not achieved by Fu and Li’s F . The other frequency spectrum statistics
clustered the Polynesian populations into their super population for at least 50% of the time and
did better with more genes. Clustering of the other super populations was similar to the Polynesian
super population when the AMR populations were not included. This indicates that clustering from
disease associated gene lists is not specific to particular genes, but they contain similar discriminatory
information as other lists of genes, which is likely to be capturing allele frequency differences between
populations. This was evident from that fact that if the AMR populations are excluded, by chance
the super populations were correctly clustered at least 50% of the time, and this increased to ~75%
when more genes were used (Table 4.8). It also indicates that genes (even when randomly selected) are
better at clustering the super populations than randomly drawn windows.
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4.4 Chapter discussion
4.4.1 Use of selection and neutrality statistics to group populations
Other studies have previously shown the relationships between Polynesian and other Pacific populations,
most often with mitochondrial DNA and Y chromosome markers (Kayser, 2010; Duggan et al., 2014;
Hudjashov et al., 2017, 2018). Autosomes have also been used to explore Polynesian origins and
relationships between Pacific populations, though generally with rather small sample sizes (Largest
Polynesian population size: 24 Kimura et al. (2008); 9 Hudjashov et al. (2017); 30 Hudjashov et al.
(2018)). This study is the first to compare four Polynesian populations, two of East, and two of West
Polynesian ancestry, and of similar sample sizes to those of the 1000 Genomes Project. The analysis is
important because it adds new evidence of the genetic relationship between the Polynesian populations
and other populations. This is important, as (in addition to purely academic reasons) understanding
the ancestry of populations helps to inform and reduce the stigma of genetic diseases (Sankar et al.,
2006), and to inform about the etiology of modern metabolic disease.
In Chapter 3 (section 3.4), it was noted that the populations had population specific-distributions
for the frequency spectrum-based selection and neutrality statistics. The tails of the distributions
contain the most extreme values and are therefore most likely to be the loci that have undergone
selection - specifically the negative tail is of interest for positive selection. It was thought that perhaps
the tails could be used to group the individual populations using an unsupervised method - in this
case, hierarchical clustering - and reassemble the super populations. The first test used the entire
chromosome and created a summary statistic that was used to create clusters. It was successful in
re-assembling the super populations using FST which is a measure of population differentiation, and
had previously been used within the 1KGP dataset to establish how differentiated the 1KGP samples
were from each other (1000 Genomes Project Consortium, 2015). The population groupings were
also the same as in the PCA that was used to select the individuals for the selection analysis (Figure
4.1). Both the FST results and PCA (for the subject selection) confirmed the genetic relatedness and
differentiation of the Polynesian populations in a global context, as being most similar to the East
Asian populations (Kayser et al., 2008). It also confirmed that within Polynesia, the differentiation
between Eastern and Western Polynesia, was consistent with the out of Africa human migration and
subsequent Polynesian expansion (Matisoo-Smith, 2015; Skoglund et al., 2016; Nielsen et al., 2017;
Hudjashov et al., 2018).
4.4.1.1 Clustering of aggregate statistics
The whole chromosome summary using the intra-population frequency spectrum neutrality and selection
statistics had varying levels of success in re-assembling the super populations. Fu and Li’s F had
mini-groups of 2-3 populations that were part of the same super population, but these mini-groups
were not closely linked to the other groups of the same super population. These two statistics are based
on singletons, and it is likely that these are not well represented in the markers of the CoreExome
chip itself, or the quality control that the New Zealand samples underwent. During the quality control
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process, a singleton was more likely to be removed, or less likely to be rescued, upon manual inspection
depending on the predefined cluster boundaries for the probe intensities in Genome Studio. This would
lead to an under-representation of the singletons that actually might be present in the populations.
Overall, it was found that the clustering of selection and neutrality test statistics for entire chromosomes
did not resemble the grouping that clustering on FST produced.
4.4.1.2 Clustering of extreme windowed statistics
Compared to the entire chromosome summaries, using windows from the extremes of the distribution
was effective at clustering the individual populations into their super population groups. Fay and
Wu’s H was the only statistic that grouped all individual populations into their corresponding super
populations, whereas Tajima’s D and Zeng’s E had the same split of the AMR populations as with the
FST clustering. The clustering of populations into their super populations was not seen when random
windows were used for clustering, indicating that there is a degree of commonality in the extreme
windows within a super population group. This would mean that there was similarity in the windows,
and therefore regions of the genome that were represented in the extremes of the distributions between
the populations of a super population. It also suggests that because these regions differ between
super populations that these regions may have been influenced from the out of Africa migration and
subsequent population movements. The haplotypic based methods of iHS and nSL clustered into super
populations and had the AMR population split too. There was not a high amount of region sharing
outside of each super population, again showing similarity within super populations but not between.
Allele sharing between populations is moderate for common SNPs, and more so for continental groups,
but is minimal for rarer frequencies, due to population divergence (Gravel et al., 2011). This helps to
explain both of the patterns observed with site frequency spectrum (SFS) based statistics for both the
extremes and gene clustering. With the extremes, many of the super populations had windows that
were not in the extremes of the other populations, these formed the ‘blocks’ in the heatmap, showing
that there were regions of the genome that differed in extremity between super populations. This was
most evident with the AFR populations, which had the majority of windows for each statistic not in
common with the extremes from the other populations.
The extremes of the distributions represent different types of selection or demographic events and are
different depending on the selection test statistic being used (Tajima, 1989; Fu and Li, 1993; Fay and
Wu, 2000; Zeng et al., 2006). The upper end of the distribution is able to be compared as all of the
values that it encompassed were positive in value across all populations for all statistics and represent
the same types of selection or demography.
The clustering of the most extreme windows represents, other than a similarity in allele frequencies
between populations, a pattern that is consistent with the out of Africa model of human migration
(Mallick et al., 2016; Pagani et al., 2016). And represents the influence of selection, drift, population
expansions, migrations, bottlenecks, introgression, and admixture following the population divergences
over history.
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4.4.1.3 Clustering on genic regions
Clustering from gene lists for the frequency spectrum-based selection and neutrality statistics consis-
tently grouped the individual populations into their super populations, although there was inconsistency
for the AMR populations. This inconsistency could be the influence of admixture in the AMR popula-
tions, between the PCA analysis and the admixture analysis (sections 4.3.1.1 and 4.3.1.2), it was clear
that the four AMR populations were less homogenous than the other super populations. With the
exception of the AMR populations, the clustering of populations using windows or haplotypes was
consistent with previously reported results (Pickrell et al., 2009; 1000 Genomes Project Consortium,
2015). The grouping of populations was also seen with random lists of genes. This would indicate
that the commonalities with populations for a gene are not specific to a disease, but instead, a general
locus by locus similarity.
4.4.2 Potential shared selective histories for loci associated with urate and
metabolic disease
The “Out of Africa” model of human migration can be useful in explaining differences between modern
populations and potential time points when these differences may have arisen. Under a neutral
model the differences in allele frequency between populations are due to genetic drift (Kimura, 1979b).
Demographic events such as bottleneck, migration, expansion, and admixture also contribute to the
differences in allele frequencies found between populations (Wright, 1951). Conversely, selection acts in
a targeted manner, therefore if the selection occurred post population split then it would be expected
to look neutral in one population but not in the other. However, if the selective event happened in an
ancestral population of the two then, dependent on time since divergence, it would be expected to be
observed in both populations (Hermisson and Pennings, 2017). It is also possible to have ‘parallel’
selection, where both populations experience independent selection (Tennessen and Akey, 2011). Using
a coalescent approach to identify the common intermediate ancestral populations, if for example, a
genomic region identified as under selection in the Polynesian populations was also found in the East
Asian populations, but not the Europeans, it could be inferred that the selective pressure was likely
after the migration from Europe to East Asia. In looking at modern disease, a potential approach to
understanding the differences in disease burden between modern populations is to look at the genetic
differences between populations with shared ancestry.
The current metabolic disease burden in the Polynesian populations is higher than other populations
(Winnard et al., 2012, 2013). This higher disease burden could possibly have arisen due to environmental
changes and selective pressure on Polynesian populations after the migration into the Pacific. As
found in Chapter 3, however, there was limited evidence for selection, especially in the overlap between
haplotypic and SFS-based methodologies, in the genes that were associated with urate and associated
metabolic diseases (Table 3.6). Three approaches were taken to investigate the potential of a ‘shared
selective’ history of the loci associated with urate and metabolic disease. These were: investigating
the loci that were in either the 1st or 99th percentile, investigating the loci that were in the clustered
regions for the significant SNPs of the haplotypic statistics, use of iHS and nSL, and finally, hierarchical
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clustering of the median-centred values for windows that intersected the loci associated with urate and
metabolic disease.
For the SFS-based statistics, many of the windows in either the 1st or 99th percentile for the POL
populations that intersected the genes associated with metabolic disease were not in common with
other populations. The windows that were in common, were usually with the EAS populations. This is
consistent with the migratory history of the Pacific and the shared ancestry the Polynesian populations
have with East Asia.
4.4.2.1 Clustering on median-centred gene values
The clustering based on the median-centred values of the statistics was able to reassemble the super
population groups. Again, the similarity of the allele frequency spectrum-based on geography appeared
through urate and metabolic disease genes. Both exclusivity and the proportion of populations clustered
correctly were very high for nearly all populations for the four site-frequency statistics, across the
metabolic disease gene lists (Tables 4.1 and 4.2). This indicated that there was sufficient similarity
between populations of a super population, and differences between super populations that the statistic
values were discriminatory. However, the groups were also reassembled with the random draws of
genes, with an increase in the number of completely grouped super populations when more genes were
used. This showed that the particular genes themselves were not specific to the clustering but the
frequency distributions in genes were different and the number of genes influenced the discrimination
of populations during clustering.
The simplest explanation of why similar clustering occurred with the gene lists is that with the tests of
neutrality or selection that rely on the frequency spectrum, populations that are similar geographically
and/or ancestrally, also have a similar allele frequency to each other (Gravel et al., 2011). This would
explain why, with Tajima’s D, Fay and Wu’s H , and Zeng’s E , which are based on comparing ratios of
low, intermediate and high frequency variants, all were clustered into their super population groups.
4.4.2.2 Clustering of extreme value windows
The differences in the extremes of the distributions for the site-frequency spectrum statistics showed
that they could be used to cluster the populations into their super populations. The differences
and commonalities in the genes that had evidence of association with a metabolic disease, in the 1st
percentiles of the statistics for the Polynesian populations, were almost exclusively isolated to only the
Polynesian populations. The 1st percentile represents the values with the highest likelihood of being
under selection. The windows that were in common with other populations were, for the most part,
only found in the populations of EAS. The windows or SNPs that were significant in the Polynesian
populations within the metabolic disease gene lists were usually limited to commonality with the paired
ancestrally similar population (CIM and NZM, or SAM and TON). Windows were more likely to be
in common between populations for the 99th percentiles where this represented an increase in high
frequency variants.
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4.4.2.3 Clustering of haplotype-based statistics
For the haplotypic statistics, there were commonalities between some of the significant SNPs. The
SNPs that were in common were more often in pairs of either SAM and TON, or CIM and NZM. The
SNPs that were significant for a Polynesian population were more likely to have also been significant
in an EAS population than the other super populations. The regions created from the clustering of
significant SNPs also showed that within the super populations there was a higher commonality than
between super populations. This would suggest that, similar to Coop et al. (2009), geographically
similar populations are subjected to similar selective environments. The time to the most recent
common ancestor of two populations also affects the detection of shared regions as the more time that
has passed, the more recombination will have an opportunity to break down the haplotype.
4.4.3 Limitations
The technical limitations of this dataset based on the markers from the CoreExome SNP array raised
in section 3.4.5 also apply to this analysis. Particular to the analysis in this chapter is how the
clusters were determined. The cutree method implemented in R (R Core Team, 2017) that was used
to slice the dendrograms, creating the groups used to assess the proportions and exclusivity of the
clustering was relatively crude and did not always agree with the clusters that were ‘visually apparent’
in the dendrogram, although ‘visually apparent’ could be partially attributed to confirmation bias.
Hierarchical clustering was chosen as the clustering algorithm over K-means because the branching
nature could be thought of as a metaphor for the population migration histories. It is also possible that
different linkage and distance criteria for the clustering algorithm may have produced different clusters.
However, a brief investigation of this, using each of the distance and linkage measures implemented by
the hclust method in R indicated that any differences in clusters would likely be minor (data not
shown).
The cutree method also required that K clusters be returned regardless of what the tree actually
looked like, and K < n. The use of K = 6 was chosen due to there being six super populations,
however, CLM, PUR, MXL, and PEL being classed as a single super population was not reflected
in the clustering of the chromosome-wide FST. Many of the selection tests split AMR into 2 groups,
CLM/PUR and MSL/PEL. This pairing is consistent with what had previously been found from
similarity of admixture and FST (Gravel et al., 2013; 1000 Genomes Project Consortium, 2015). These
AMR populations had also been identified as being admixed and so it was interesting that for the upper
tail of Fu and Li’s F they were clustered with the NZM population, which is also known to be admixed,
mostly with New Zealand European (Hollis-Moffatt et al., 2012; Gravel et al., 2013). Because these
AMR populations were still included, and the requirement for six clusters, this affected the exclusivity
measurement of clusters. The proportion measurement was also affected because sometimes a super
population was spread across multiple but exclusive clusters. An example of this was the Polynesian
populations and the 99th percentile of Fu and Li’s F where the Eastern Polynesian populations were an
exclusive cluster, and the Western Polynesian populations were an exclusive cluster. This meant more
clusters were assigned to Polynesian populations than should have been (under the K = 6 assumption
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there would be one cluster per super population), and for six clusters to remain, the SAS populations
ended up combined with the EUR populations, based on the distance and linkage criteria used for the
clustering.
The only statistic that consistently did not cluster the Polynesian populations was Fu and Li’s F .
Fu and Li’s F is based on singletons, and for the clustering, the 1st percentile windows was a sparse
matrix of windows that were in common between populations. The sparsity of the matrix influenced
how well the clustering performed due to the lack of windows that were in common between any pair
of populations. At the extremes of similarity (e.g., very similar or very dissimilar), the clusters are
disproportionately influenced by only a few windows, which means a large amount of information
was not being used for the differentiation of populations. As the lower tail represents an excess of
singletons, this is likely to have been impacted by using SNP array data as there was a very strong
bias against singletons during the quality control protocol (Guo et al., 2014). In this situation, because
the data has reduced singletons, the distribution for Fu and Li’s F was shifted to the right, with the
upper tail representing a deficit of singletons (Fu and Li, 1993). This shift now means there is an
under representation of regions in the lower tail.
As reported in section 3.3.1, only the false discovery rate (FDR) for the Polynesian populations was
below 10% for the 1st percentiles of Tajima’s D and Fay and Wu’s H for the frequency spectrum-based
statistics. This means that while the extremes would be considered the most likely ends of the
distribution that would contain regions of the genome that had been selected, this cannot be claimed
with confidence. Therefore, the mechanism through which they became the extremes of the distribution
is possibly through selection, however, other neutrality mechanisms are still valid. While it is true
that the extremes may include selected loci, it is also true that because of the use of a distribution
proportion threshold, there will always be windows or SNPs that would be identified as possibly being
under selection (Teshima et al., 2006). This means that while there were similarities in the extremes of
the distributions for the frequency-based statistics, they are not necessarily under selection, and based
on the FDR calculated from the permutations, they are likely to be false positives.
Another limitation was a lack of ‘internal replication’, for example, the Eastern and Western Polynesian
pairs, where a region would only meet the threshold for significance in a single population and not in
the paired population. This could also just be a side effect of discretising a continuous distribution,
and especially for values sitting close to the threshold it is easy to imagine a situation where in one
population it was significant and the other it was not. An alternative approach could have been to
rank all of the windows based on statistic value and determine differences and similarities in rank
order between populations.
The rightwards shift in the distributions of Tajima’s D, Fu and Li’s F , and Zeng’s E largely is
influenced by the low frequency variants and singletons being under-represented. This effect is due to
the ascertainment bias on the SNP arrays, where there is an excess of common alleles, when compared
with sequence data (Ramírez-Soriano and Nielsen, 2009). This shift was more noticeable in the AFR
populations with the 1st percentile being above zero for Tajima’s D and Fu and Li’s F . This meant
that the windows that were being compared were not always the going to be inferring the same type
of selection or population demographic events as those that were from below zero. The rightward
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shift would not have affected all genes in a uniform manner - the impact will be different for different
genes, based on the frequency of the markers they contain. This means that it cannot be assumed
that the genes in the 1st percentile for the AFR populations are the equivalent in terms of ranking by
statistic value, to those in the other populations. Nor can it be assumed that the distribution that
was observed using the markers from the CoreExome would be the same that would be observed from
using sequencing data.
Grouping based on the clustering of the significant results in iHS or nSL may falsely link SNPs into a
‘region of significance’. The 200 kb limit was the maximum distance that selscan by default would allow
the calculation of the extended haplotype heterozygosity to extend across a gap of information before
terminating. The calculation of region sharing also does not take into account the directionality of
the selection. For example, one population might have favoured the ancestral allele, whereas a second
favoured the derived allele, the region sharing calculation treats these as being the same and would
consider them a shared region.
4.4.4 Conclusions
It can be concluded that the extremes of the distributions for the intra-population selection and
neutrality statistics can be used to group populations into their super populations. There was similarity
in the regions in the extremes of the selection and neutrality statistics for the populations of a super
population, but limited commonality in the extreme regions between super populations. Random
regions of the genome had varying levels of commonality between populations but was lower than the
regions with extreme selection and neutrality statistic values.
Genes that are associated with disease performed well at grouping populations into their super
population groups with hierarchical clustering. However, this was not specific to metabolic disease
associated genes, but applied to random sets of genes, with an increase in number of genes improving
the clustering. This suggests the result was not specific to the loci used, and instead was due to allele
frequency similarities between populations.
In all combinations of clustering of selection and neutrality statistics used, the East Asian populations
were the most similar to the Polynesian populations. There was additional evidence of the differences
and similarities of the Polynesian populations, between the Eastern and Western Polynesian’s, which
reflected the migration history . And there was evidence of regions having a shared ancestry between
these populations, along with evidence of a common ancestral population with the modern East Asian
populations.





Selection and Association Studies
This chapter investigates the performance of different gout case definitions on a genome-wide association
study (GWAS). It also looks at how selection statistics could be used for the prioritisation of variants
from a GWAS.
A subset of these results were published as part of Cadzow et al. (2017); the gout definition testing,
heritability of gout, and the replication of the Köttgen et al. (2013) results for gout, using the UK
Biobank data. The results and discussion from that paper have been included and expanded on here.
5.1 Genetic associations with Gout
5.1.1 Performance of gout definitions
Genome-wide association studies provide a statistical framework on a genomic scale for an association
analysis between a phenotype of interest, and the genotypes of a genetic marker, generally using linear
regression for a continuous trait, or logistic regression for a dichotomous trait (Lee et al., 2011; Zuk
et al., 2012). The association test, in a GWAS context, is repeated for all available markers across the
genome. In epidemiological studies the use of an accurate case definition is important (Olijhoek et al.,
2007), however, there is variation in the gout definitions used from the multi-purpose cohort studies
that are used for genetic analysis. Multi-purpose cohort studies are cohorts that are collected in a way
that enables the use of the data to answer many different research questions; some well known cohorts
include the Wellcome Trust Case-Control Consortium (WTCCC) cohort, the Atherosclerosis Risk in
the Community (ARIC) study, and the Framingham Heart Study (FHS) (Investigators, 1989; Burton
et al., 2007; Splansky et al., 2007).
The use of a consistent case definition is also important for genetic analyses using multiple cohorts.
If the definition is consistent then it is possible to combine the genetic data from each cohort and
performing the GWAS, allowing for increased sample size and therefore increased power. Another
common way of combining genetic association studies is through meta-analysis. In both instances,
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having the same case definitions across studies reduces the variation. The power of genetic case-control
studies increases with accurate case definition. The use of gold-standard case definitions means that
there are the maximum number of genuine cases, and the maximum number of disease-free controls
(Colhoun et al., 2003). For gout, the gold standard case definition is the presence of mono-sodium
urate crystals in the synovial fluid of the joint (Wallace et al., 1977), measurement of which is not
possible for multi-purpose cohorts. A substitute for crystals in the synovial fluid is the American
College of Rheumatology (ACR) criteria (Wallace et al., 1977). These criteria require a minimum
of six of twelve conditions to be met for an individual to be classed as a ‘case’. It is uncommon for
multi-purpose cohorts to report either the gold-standard, or ACR criteria, but instead, for a self-report
diagnosis of conditions and diseases to be reported.
The UK Biobank is a publicly available data set consisting of 500,000 individuals, mostly of European
ancestry, from around the United Kingdom, aged between 40 and 69. It contains genetic, health, and
lifestyle information. As part of the UK Biobank collection process, participants filled in detailed surveys
on health and lifestyle questions, provided biological samples, and provided access to administrative
health records. The UK Biobank includes the self-report diagnoses that were collected by survey
at the time of recruitment, but it also has hospital admission information, for both primary and
secondary diagnosis. This collection of both self-report information combined with hospital admission
information provides a unique opportunity in a large cohort to investigate possible gout definitions
and their influence on GWAS.
5.1.2 Genetic associations for gout in Polynesian populations
As has been previously mentioned (sections 1.7.2, 4.1), New Zealand Polynesians have a higher
prevalence of gout and metabolic disease (Winnard et al., 2013). Of the 28 genetic variants associated
at a genome-wide significance threshold with serum urate levels that have been previously reported in
European populations, 17 also had significant associations with gout (Köttgen et al., 2013). In the
Polynesian populations of New Zealand, association with gout has been replicated for nine of these
variants, with some Polynesian-specific effects being noted (Phipps-Green et al., 2016). The inherent
higher prevalence of gout in Polynesian populations, combined with a lack of adequate sample sizes to
perform GWAS with sufficient power to detect loci (other than the main effect loci of ABCG2 and
SLC2A9 ), means that alternative approaches are needed to find additional evidence to reduce the
number of potentially false negative results. Traditionally meta-analysis of GWAS has been used to
boost statistical power, or trans-ancestral meta-analysis can be used to incorporate differing linkage
disequilibrium (LD) patterns between ancestries when performing meta-analysis (Morris, 2011).
5.1.3 Use of selection statistics to inform GWAS
GWAS in the last few years have utilised larger and larger cohorts, in a quest to discover the source
of ‘missing heritability’ (Visscher et al., 2012; Yang et al., 2017). The requirement for larger cohorts
comes from the inverse relationship between effect-size and statistical power. The source of missing
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heritability is thought to be found in the polygenic effects of many small effect genetic variants and
unmarked uncommon variants of stronger effect sizes (Spencer et al., 2009). GWAS also suffer from the
need to control the false positive rate and as such have a stringent significance threshold for association
(Fadista et al., 2016). One of the side-effects of this threshold is that variants that have a true effect
but due to cohort size do not reach statistical significance are lost in the ‘noise’ of the GWAS signal.
One of the possibilities to be able to identify such variants is to use a combination of of selection
statistics with GWAS to prioritise GWAS results (Ayodo et al., 2007; Casto and Feldman, 2011; Field
et al., 2016a).
5.1.4 Objectives
The objectives of this chapter are to:
• Test performance of gout definitions on GWAS.
• Investigate the use of selection statistics in conjunction with GWAS.
5.2 Methods
5.2.1 European Gout GWAS
This GWAS was performed using the interim data release from the UK Biobank (approval number
12611) downloaded November 2015. There was genetic information for 152,249 individuals. For the
GWAS itself, it was limited to be only people who had self-reported an ethnic background of British,
Irish, or ‘any other white background’ to limit the effect of genetic ancestry confounding the analysis.
Inclusion criteria were: European ethnicity, aged between 40 and 69 years, and having genome wide
genotypes available. The exclusion criteria used were: mismatch between self-reported sex and genetic
sex, genotype quality control failure, relatedness, or either a primary or secondary hospital diagnosis
of kidney disease (International Classification of Diseases, Tenth Revision (ICD-10), codes I12, I13,
N00-N05, N07, N11, N14, N17–N19, Q61, N25.0, Z49, Z94.0, Z99.2), participants aged 70 years and
over, and those with kidney disease, because these are risk factors for secondary gout.
Individuals from the UK Biobank cohort were genotyped on an Axiom array with 820,967 markers
(Affymetrix, Santa Clara, CA, USA). The genotypes were phased using SHAPEIT3, and then imputed
using IMPUTE2 with both the UK10K impute reference panel1, and the haplotype reference consortium
impute panel (McCarthy et al., 2016), to bring the total number of single nucleotide polymorphisms
(SNPs) to approximately 73.3 million. Genotyping, phasing, and imputation were performed by the
UK Biobank.
A replication cohort was created from the full UK Biobank genetic dataset by using the same criteria
as for the interim release but with the participants from the interim release excluded. Genotypes for
1https://www.uk10k.org
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these individuals were downloaded in March 2018. The number of individuals in this replication cohort
was 261132.
5.2.1.1 Gout definitions
Four main classification criteria were used to define gout cases. Hospital defined gout involved either a
primary or secondary hospital diagnosis for gout (ICD-10 code M10, including sub-codes). Self-report
of gout was defined as reporting having gout at the time of the study interview with a nurse, in response
to the question “In the touch screen you selected that you have been told by a doctor that you have
other serious illnesses or disabilities, could you now tell me what they are?”2. Use of urate lowering
therapy (ULT) used self-report data for the use of allopurinol, febuxostat, or sulphinpyrazone, and not
having a hospital diagnosis of leukaemia or lymphoma (ICD-10 codes C81-C96). Winnard defined gout
was based on Winnard et al. (2012) and consisted of a hospital diagnosis of gout, or self-report of gout
specific medication (ULT or colchicine). The largest number of people were classified through either
self-report or the use of urate lowering therapy (Figure 5.1). Additional exclusion criteria were applied
to participants not classified as having gout from these definitions in order to remove possible cases
from the control cohort. The criteria were cortico-steroidal use, non-steroidal anti-inflammatory drug
use or probenecid use. The UK Biobank replication cohort used the gout definition of self-reported
gout or self-reported ULT use to define cases.
Confidence intervals for proportions of each gout definition out of the combination of all gout definitions
were calculated using the prop.test function from the stats package in R.
5.2.1.2 Gout association test
A GWAS was performed using logistic regression in Plink1.9b (Chang et al., 2015; Purcell and Chang,
2015) for each gout classification, with age, sex, and body mass index (BMI) as co-variates. The
association results for each GWAS were then compared with the 30 SNPs reported in Table 1 of
Köttgen et al. (2013) that had previously been associated with urate and gout in a cohort of >140,000
Europeans.
5.2.1.3 Heritability
For each gout classification, the genetic component of heritability explained was calculated. This was
done by first randomly selecting 10,000 controls and then combining this same subset with cases from
each of the gout classifications. The genetic variance was calculated for each chromosome separately
and then combined. The dichotomous case-control phenotype was transformed onto a continuous
liability scale using the restricted maximum likelihood analysis function in the GCTA software (v1.26.0,
Yang et al. (2011b)) and a general population prevalence of gout of 2% (section 2.1.6). The liability
scale operates on a liability threshold model whereby an unseen continuous trait has a threshold above
2http://biobank.ctsu.ox.ac.uk/crystal/docs/Interview.pdf accessed 28 May 2018
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which one is a case (Lee et al., 2011; Zuk et al., 2012). Heritability estimates were compared using the
formula h1 - h2 and the standard error (SE) calculated using formula (5.1).
SE =
√
SE21 + SE22 (5.1)
5.2.2 Polynesian Gout GWAS
A multi-cohort gout dataset was assembled by combining individuals from the Genetics of Gout,
Diabetes, and Kidney Disease in Aotearoa cohorts and the Ngāti Porou Hauora Charitable Trust
cohort. Genotyping on the Infinium CoreExome v24 bead-chip was performed at the University of
Queensland (Centre for Clinical Genomics) for the Genetics of Gout, Diabetes, and Kidney Disease
in Aotearoa cohorts and at AgResearch (Invermay Agricultural Centre) for the Ngāti Porou Hauora
Charitable Trust cohort. The genotype quality control procedures described in section 2.2.2.1 were
applied per cohort, and then as necessary after combining the cohorts. The genotype quality control,
and combining of cohorts were performed by Dr Tanya Major, Merriman Lab. Principal component
analysis (PCA) was performed on the combined dataset with the first 10 components outputted and
used as covariates to adjust for population substructure in the GWAS.
The GWAS for gout using individuals with Polynesian ancestry was conducted by Dr Tanya Major
(Merriman Lab) using Plink v1.9b32. Gout affection was determined by the ACR criteria (Wallace
et al., 1977), or a doctor diagnosis, or if enrolled in a gout drug trial. All participants were older than
18, and provided informed written consent. Exclusion criteria included unknown gout affection status,
non-Polynesian self-reported ancestry, or a mismatch between self-reported ancestry and principal
component analysis (PCA) clustering. The GWAS was adjusted for age, sex, and the first ten principal
components (PCs) calculated from 2,858 ancestry informative markers (as identified by Illumina and
used in Guo et al. (2014)). Markers were removed if the minor allele frequency was less than 0.01, or
had a Hardy-Weinberg Equilibrium (HWE) chi-squared exact test P < 1x10-6.
5.3 Results
5.3.1 UK Biobank
5.3.1.1 Participant and association model characteristics
There were genome-wide genotype data available for 105,421 participants, after applying the inclusion
and exclusion criteria. The mean BMI for all participants was 27.36 kg/m2, the mean age was 56.97
years, and 50.82% were male. A breakdown by affection status for anthropomorphic traits, drug use,
and gout classifications is provided in Table 5.1.
Prior to performing the GWAS analyses using the different classifications for gout, the best model
(determined by Akaike information criterion (AIC) (Akaike, 1974)) for phenotype co-variate adjustment
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was determined by logistic regression. Known co-variates for gout included age, sex, and BMI. Each of
these co-variates were tested individually and together. Each covariate had a significant association
with gout on their own: age (P = 8.72× 10−88), sex (P = 8.26× 10−247), and BMI (P = 1.84× 10−271).
In the combined model, with all three covariates there was an AIC for the model of 19558.30 compared
to single variable models for age (AIC 22706.05), sex (AIC 21041.80) and BMI (AIC 22001.03). Based
on the lower AIC for the combined model, age, sex, and BMI were used as the covariates in the GWAS
for gout.
5.3.1.2 Performance of gout classification criteria
There were a total of 2432 individuals that had any classification of gout and 102,989 controls. Of
those with any classification of gout, there were 382 with a hospital diagnosis, 1652 with urate
lowering therapy, 1861 with the Winnard criteria, and 2066 with self-reported gout. The overlaps in
classification between each group can be seen in Figure 5.1. There was considerable overlap between
the self-report, urate lowering therapy, and Winnard classifications with 1242 individuals meeting all
three classifications. There were 571 (27.6%) of 2066 participants who could only be defined through
self-report. And for hospital diagnosis, 126 (33.0%) of 382, did not meet the self-report of gout, or
ULT use definition criteria.
The prevalence of gout from all definitions was 2.4%. This ranged from the lowest prevalence of gout
of 0.36%, from the hospital diagnosis definition, through to the highest of 2.18%, by self-report of gout
or ULT usage in the study population (Table 5.2). The UK Biobank replication cohort had a total of
5065 cases and 256,067 controls.
Table 5.1: Clinical details of participants in the UK Biobank.
Replication
Case Control Case Control
n 2432 102989 5065 256067
Male (%) 97.88 52.94 98.22 54.75
Mean Age (SD) 60.18 (6.67) 56.9 (7.93) 59.88 (6.96) 56.94 (7.98)
Mean BMI (SD) 30.82 (4.89) 27.28 (4.7) 30.64 (4.97) 27.13 (4.61)
Gout medication
Febuxostat 0 0 0 0
Allopurinol 1651 0 3633 0
Sulphinpyrazone 9 0 22 0
Colchicine 63 0 135 0
Gout classification
Hospital 382 0 1381 0
Self-report 2066 0 4553 0
Winnard 1861 0 3932 0
ULT 1652 0 3610 0































Figure 5.1: An “upset plot” showing the number of samples (left) and intersections




















































































































































































































































































































































































































































5.3.1.3 Replication of Köttgen et al. (2013) urate associated loci
Analysis of the 30 reported urate-associated SNPs from Köttgen et al. (2013) revealed similar odds
ratios (ORs) for all gout definitions (Figures 5.2 and 5.3, Table 5.3). Experiment-wide significance
was defined as P < 0.0017, and genome-wide significance as P < 5x10-8 (Fadista et al., 2016). There
were differing numbers of SNPs that had a significant association with gout, both at genome- and the
experiment-wide thresholds between the gout definitions used. Meeting genome-wide significance, there
were five SNPs (one in each of ABCG2, GCKR, SLC17A3, SLC22A12, and SLC2A9 ) for both the
self-reported gout or ULT usage definition and the self-reported gout definition, four SNPs (ABCG2,
GCKR, SLC22A12, and SLC2A9 ) for the ULT usage definition, three SNPs (ABCG2, GCKR, and
SLC2A9 ) for the Winnard definition, and two SNPs (ABCG2 and SLC2A9 ) for the hospital diagnosis
definition. For all definitions, the effect size and strength of association was larger for ABCG2 than
SLC2A9. At the experiment-wide significance threshold, there were 13 SNPs for the self-reported gout
or ULT use definition, 12 SNPs for the self-reported gout definition, 11 for ULT use definition, 10 for






























Figure 5.2: Plot showing odds ratios (95% CI) for the two largest effect SNPs re-
ported in Köttgen et al. (2013) based on gout definitions, rs2231142 and rs12498742.
Original Kottgen reported odd ratio are shown as red circles. The reported Kottgen











































































































































Figure 5.3: Plot showing odds ratios (95% CI) for the 28 SNPs reported in
Köttgen et al. (2013) based on gout definitions. Original Kottgen reported odds
ratios are shown as red circles. The reported Kottgen odds ratio was inverted
to maintain consistency of reported effect allele (A1) for the following markers:
rs2307394, rs2079742, rs7224610, rs7188445, rs1178977, rs6770152, rs7193778,
rs164009, rs653178, rs2078267 and rs478607.
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5.3.1.4 Heritability explained
To see if there was a difference between gout classifications in the genetic component of the variance
explained by an additive model in gout, heritability estimates were calculated for each gout classification.
To do this, 10,000 controls were randomly selected and were used with each different gout criteria, and
heritability estimates for each chromosome were calculated using GCTA 1.26.0 (Yang et al., 2011b).
The heritability estimates were 0.289 (SE 0.034) for the self-report of gout or ULT use definition, 0.283
(SE 0.036) for the self-report of gout definition, 0.282 (SE 0.040) for the Winnard definition, 0.308 (SE
0.044) for the ULT use definition and 0.236 (SE 0.160) for the hospital diagnosis definition. There
were no statistically significant differences between the heritability estimates for any of the different
classifications. The heritability estimates for gout were similar to the estimates of genetic variance of














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.2.1 UK Biobank gout definitions GWAS
The total number of genome-wide significant SNPs was 397 for the hospital definition, 2044 for the
self-reported gout definition, 1396 for the ULT use definition, 1411 for the Winnard definition, and
2310 for the self-reported gout or ULT use definition. There was considerable overlap between the
definitions in the SNPs that met the nominal significance threshold of P < 1x10-5 (Figure 5.4). There
were five main regions of the genome that had peaks of association with gout. These were at GCKR on
chromosome 2, SLC2A9 and ABCG2 on chromosome 4, the SLC17A1-SLC17A3 region on chromosome
6, and the SLC22A11-SLC22A12 region on chromosome 11 (Figure 5.5). Only the peaks at SLC2A9
and ABCG2 reached genome-wide significance under the hospital definition.
There were a total of ten top SNPs from seven genes that were associated with gout at a genome-wide
significance threshold, across the definitions used (Table 5.4). The top SNP for each locus differed
between definitions for GCKR and SLC2A9, and SLC22A12. GCKR had the top SNP (rs780093) for
self-report of gout, self-report of gout or ULT use, or ULT, whereas the top SNP for the Winnard
definition was rs780094. The top SNP was rs9994216 in SLC2A9 for the self-reported gout definition,
and rs4697701 for the ULT usage, self-report of gout, and the Winnard definitions. SLC22A12 had
rs11231837 for the top SNP for the self-reported gout and self-reported gout or ULT use definitions,
whereas rs7929627 was the top SNP for the ULT usage, and Winnard definitions. None of the top
SNPs were the same as reported by Köttgen et al. (2013) in Table 1. This can largely be explained by




































Figure 5.4: Overlap of markers that reached nominal genome-wide significance
between the different gout classifications. The upper histogram indicates the size
of the intersection and the left histogram indicates the total number of nominally
significant SNPs by gout definition.
Figure 5.5: Manhattan plot for association with gout, adjusted for age, sex and
BMI using the self-reported gout or ULT usage gout definition. The dotted line
indicates the genome-wide significance threshold level of 5x10-8. The genome-
wide significant peaks in order are GCKR (chr2), SLC2A9 and ABGC2 (chr4),
SLC17A1-SLC17A3 (chr6), and NRXN2-SLC22A12 (chr11).
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Table 5.4: Top genome-wide significant SNPs by gout definition in the UK
Biobank cohort.
Chromosome Definition Gene name Marker A1 A2 OR [95% CI], P
2 Self-report GCKR rs780093 T C 1.316 [1.235-1.403], 1.990 x 10-17
2 Self-report or ULT GCKR rs780093 T C 1.293 [1.217-1.374], 7.827 x 10-17
2 Winnard GCKR rs780094 T C 1.276 [1.193-1.364], 1.057 x 10-12
2 ULT GCKR rs780093 T C 1.286 [1.198-1.38], 3.666 x 10-12
4 Hospital ABCG2 rs4148155 G A 2.126 [1.777-2.543], 1.544 x 10-16
4 Self-report ABCG2 rs4148155 G A 2.279 [2.106-2.466], 2.844 x 10-93
4 Self-report or ULT ABCG2 rs4148155 G A 2.234 [2.071-2.409], 2.970 x 10-96
4 Winnard ABCG2 rs4148155 G A 2.185 [2.009-2.376], 1.125 x 10-74
4 ULT ABCG2 rs4148155 G A 2.302 [2.109-2.513], 1.121 x 10-77
4 Hospital SLC2A9 rs734553 G T 0.5603 [0.459-0.6838], 1.218 x 10-8
4 Self-report SLC2A9 rs9994216 G G 0.548 [0.5025-0.5975], 3.162 x 10-42
4 Self-report or ULT SLC2A9 rs4697701 A G 0.5646 [0.5219-0.6108], 5.547 x 10-46
4 Winnard SLC2A9 rs4697701 A G 0.5796 [0.5316-0.6319], 3.883 x 10-35
4 ULT SLC2A9 rs4697701 A G 0.5725 [0.5223-0.6276], 1.207 x 10-32
6 Self-report SLC17A1 rs1165195 T G 0.8093 [0.7585-0.8636], 1.683 x 10-10
6 Self-report or ULT SLC17A1 rs1165195 T G 0.8034 [0.7552-0.8547], 4.176 x 10-12
6 Winnard SLC17A1 rs1165195 T G 0.8175 [0.7634-0.8753], 7.601 x 10-9
6 ULT SLC17A1 rs1165195 T G 0.8162 [0.7592-0.8776], 3.926 x 10-8
6 Self-report SLC17A3 rs1747550 A G 0.8186 [0.7675-0.873], 1.090 x 10-9
6 Self-report or ULT SLC17A3 rs1747550 A G 0.8087 [0.7606-0.8599], 1.221 x 10-11
6 Winnard SLC17A3 rs1747550 A G 0.8254 [0.7712-0.8833], 2.894 x 10-8
6 ULT SLC17A3 rs1747550 A G 0.8186 [0.7618-0.8796], 4.873 x 10-8
11 Self-report NRXN2 rs10897521 T C 1.337 [1.24-1.443], 5.729 x 10-14
11 Self-report or ULT NRXN2 rs10897521 T C 1.341 [1.247-1.441], 1.699 x 10-15
11 Winnard NRXN2 rs10897521 T C 1.31 [1.209-1.42], 4.063 x 10-11
11 ULT NRXN2 rs10897521 T C 1.345 [1.236-1.464], 5.585 x 10-12
11 Self-report SLC22A12 rs11231837 T C 1.319 [1.223-1.423], 7.494 x 10-13
11 Self-report or ULT SLC22A12 rs11231837 T C 1.326 [1.234-1.425], 1.521 x 10-14
11 Winnard SLC22A12 rs7929627 G A 1.298 [1.198-1.406], 1.660 x 10-10
11 ULT SLC22A12 rs7929627 G A 1.333 [1.226-1.45], 2.022 x 10-11
A1 is the effect allele.
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5.3.2.2 Polynesian GWAS
The GWAS for gout in the Polynesian populations of New Zealand had a total of 2402 individuals,
with a mean age of 48.6 (SD 14.9), was 60.5% male, and had a mean BMI of 35.0 (SD 8.35). A break
down by gout affection is shown in Table 5.5. There were only two markers that met the threshold
for genome-wide significance, rs2725215 (risk allele = T, OR = 1.939, 95% CI = 1.567-2.40, P =
1.162 x 10-9), located in PKD2, and rs2231142 (risk allele = T, OR = 2.306, 95% CI =1.891-2.81, P
= 1.570 x 10-16), located in ABCG2. The LD r2 between these two markers was 0.58 (Polynesian
Super Population (POL)). Two other markers reached the nominal significance threshold, rs2728108
(ABCG2 ) and rs11034401 (chr11 inter-genic). Other genes that had SNPs that were close to the
nominal significance threshold, in the 10-5 < P < 10-4 range contained some previously associated
genes/regions for urate and gout such as SLC2A9 and the region containing IBSP, MEPE, PKD2,
and ABCG2, all on chromosome 4 (Figure 5.6). Of the 39 SNPs in the 10-4 > P > 10-5 range, only
rs3775948 in SLC2A9, rs7698623, rs2725220 and, rs1871744 in ABCG2, rs6481407 in BICC1, and
rs6041522 in LOC105372532, had associations of P < 0.05 in the UK Biobank gout GWAS, with only
rs3775948 being genome-wide significant (P = 9 x 10-43).
5.3.3 Comparison of haplotypic selection with gout GWAS
In order to determine if additional loci (which did not meet the significance threshold in GWAS),
had extra information from the selection tests that could prioritise the GWAS results, the gout
GWAS and selection results were combined. The “European Ancestry” combination, combined the
GWAS performed in the UK Biobank using the self-reported gout or ULT usage with the haplotypic
selection results for the British in England and Scotland (GBR) population. The “Polynesian Ancestry”
combination, combined the Polynesian gout GWAS with the haplotypic selection results for the
Polynesian populations of Cook Island Māori in New Zealand (CIM), Māori in New Zealand (NZM),
Samoans in New Zealand (SAM), and Tongans in New Zealand (TON). All of the analyses were
restricted to the markers of the CoreExome SNP array. A new threshold for the combinations was used
that required an |integrated haplotype homozygosity score (iHS)| > 2 or |number of segregating sites
by length (nSL)| > 2 and a GWAS P < 2 x 10-4. the iHS and nSL threshold was selected because |iHS|
or |nSL| > 2 is equivalent to P < 0.05, since the statistics are very similar to a Z-score. A “probability
score” for the combined statistics was calculated using Scorecombined = PGWAS x Pselection, where
Pselection was given by 1 - P(|Z|), and Z was the iHS or nSL value. With the Polynesian populations,
Table 5.5: Clinical details for participants of the Polynesian gout GWAS.
Controls Cases
n 1182 1222
Mean Age (SD) 44.14 (15.26) 52.95 (13.2)
Mean BMI (SD) 33.35 (8.12) 36.62 (8.26)
Sex (% Male) 43.9 81.4
Mean age is reported in years. BMI is reported in kg/m2.
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Figure 5.6: Manhattan plot for gout GWAS, adjusted for age and sex, in Polynesian
ancestry individuals showing -log10(P) for the association test by genomic position.
The solid line indicates the genome-wide significance threshold of P = 5 x10-8, the
dashed line indicates the suggestive significance threshold of P = 10-5.
the maximum |value| was used. The combined threshold was set as Scorecombined < 5 x 10-8, to mirror
the GWAS significance threshold.
5.3.3.1 UK Biobank GWAS and haplotypic selection in GBR
When the results from the UK Biobank GWAS for gout (using the self-reported gout or ULT usage
definition) and the iHS and nSL results for the GBR population were combined, there was only one
SNP, rs12638016 (intergenic), with an |iHS| > 2.6 (equivalent to the most extreme 1%) that also had
P < 10-5 in the GWAS. If the significance threshold for iHS was reduced to |iHS| > 2 (approximately
the 5% extreme most values), then there were three SNPs, all located at SLC22A12 or within 1 kb,
that were genome-wide significant in the GWAS (rs505802, rs9734313, and rs559946), and four SNPs
that were nominally significant. There were 176 SNPs that had an |iHS| > 2 and a gout GWAS of P <
0.01. This decreased to ten SNPs, when the GWAS P threshold was reduced to 2 x 10-4 (Table 5.6).
Only the variants in SLC22A12 replicated in the UK Biobank replication cohort.
Using a threshold of |nSL| > 2 and a nominally significant P < 10-5, two SNPs were identified, both
on chromosome 6 (Table 5.6). The first was rs4712972, located in SLC17A4. The second was rs501220,
located in SLC17A3. If the thresholds were relaxed, there were 158 SNPs that had a |nSL| > 2 and a
gout GWAS P < 0.01. This decreased to seven, when a GWAS P threshold of 2 x 10-4 was used (Table



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.3.2 Polynesian GWAS and haplotypic selection in Polynesian populations
Combining the results of the GWAS for gout in Polynesians with the results of the iHS analysis
produced a single marker that met the threshold of an |iHS| > 2.6 and a GWAS P < 5 x 10-8; that SNP
was rs2725215, located in PKD2. Rs2725215 also had a |nSL| > 2.6. Both iHS and nSL thresholds
were only met for TON. There were 1604 SNPs that had a GWAS P < 0.05 and an |iHS| > 2; this
reduced to 11 at the combined threshold of |iHS| > 2 and P < 2 x 10-4 (Table 5.7). Combining the
nSL results with the GWAS, there were 1502 SNPs that had a GWAS P < 0.05 and a |nSL| > 2; this
reduced to 14 at the combined threshold of |nSL| > 2 and P < 2 x 10-4 (Table 5.7).
At the combined threshold of |iHS| > 2 or |nSL| > 2 and a GWAS P < 2 x 10-4, there were seven
SNPs, located within IBSP, PKD2, ABCG2 and PPCDC, found with both iHS and nSL (Table 5.7).
CHN2 and SLC39A11 only had SNPs that met the nSL threshold. Out of all of the SNPs that met
the combined threshold, ten SNPs had evidence from both iHS and nSL. Rs12908919 (PPCDC ) was
the only SNP that showed significance in multiple populations (SAM and TON) and had support from
both iHS and nSL (Table 5.7), whereas, there were six SNPs that had support from only the TON
population, for both iHS and nSL. The loci represented were different to the SNPs in the European
ancestry GWAS and selection analysis.
The region containing IBSP, PKD2, and ABCG2 had multiple SNPs that met the suggestive significance
threshold. Of those, six SNPs had evidence of both selection and association (Figure 5.7, Table 5.7).
The selection signal came only from the Western Polynesian populations, with no indication in the
Eastern Polynesian populations of selection in this region. The recombination rate in this region had
intermittent small spikes, with three of the variants in PDK2 having an LD R2 > 0.4 with rs2231142
(calculated using East Asian Super Population (EAS)). These variants also had an association with gout
that met the suggestive significance threshold. Only the variants from PKD2 and ABCG2 replicated
their association from the UK Biobank replication cohort.
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Figure 5.7: Locus zoom plot of Polynesian gout GWAS results for the region
chr4:88,600,000-89,200,000, covering IBSP, PKD2, and ABCG2. Points indicate
SNP association with gout by genomic position in the Polynesian gout GWAS.
Linkage disequilibrium with rs2231142 is indicated by colour. Recombination rate
in the East Asian super population of the 1000 Genomes Project is indicated by
the blue line. The dashed line indicates the Genome-wide significance threshold P



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.1 Performance of gout definition
The UK Biobank had a larger number of cases for the gout GWAS than Köttgen et al. (2013). This
increase in cases reflects the increase in strength of association that was seen. A similar comparison of
gout definitions was performed using data from the study for updated gout and classification criteria
(SUGAR) with 983 rheumatology patients with known gout affection and definitions derived from
epidemiology studies used in the Global Urate Genetics Consortium GWAS of hyperuricaemia and gout
were tested for sensitivity and specificity (Dalbeth et al., 2016). In the SUGAR paper, the definition
that provided the highest specificity (82%) and sensitivity (72%) was self-reported gout or on ULT
when tested against the mono-sodium urate crystal identification as the gold standard. Consistent with
this, the work presented here found that the self-report of gout or ULT use definition also provided the
highest precision from the definitions used, and supports the use of this definition in genetic studies
when better gout classification methods are not available, such as ACR criteria or mono-sodium urate
crystal identification.
The different definitions of gout used in this study may represent the different disease presentations or
patient populations. Not all patients were captured by all criteria, and the Winnard definition was not
as good as self-report of gout or ULT, despite a similarity in definitions, and had lower precision in the
genetic association. The hospital diagnosis definition had the lowest prevalence and was restrictive,
making it the least likely to capture most people with gout. One third of the people that met this
definition did not meet any of the self-report definitions, for gout, and/or ULT usage. There is a
number of reasons that might explain this. Firstly, the hospitalised population may have a different
disease presentation from those in the community identified by self-report or ULT use. Secondly, a
diagnosis of gout made in a hospital may subsequently be revised to a different diagnosis; this is not
taken into account with the current methodology. Therefore, when self-report information is available
it is recommended that the self-report of gout or ULT use be used as the way to define cases.
Each of the gout definitions tested had genome-wide significance for SNPs associated with gout in
ABCG2 and SLC2A9. These two genes encode proteins that transport urate in the gut (ABCG2) and
proximal tubule of the kidney (SLC2A9). The large effect sizes in the association with gout, show
similarity with their large effect sizes in the control of serum urate levels (Köttgen et al., 2013).
Heritability estimates for the variance attributed to the additive effects of common SNPs for gout of
0.282-0.308 (excluding the hospital definition) were in line with those reported by Köttgen et al. (2013),
with the same approach using the GCTA software of 0.27 to 0.41 for serum urate levels. There was also
no statistically significant differences between the heritability estimates for the different definitions.
The comparability between the heritability estimates for gout and serum urate by common genetic
variants suggest the genetic heritabilities of serum urate levels and gout is similar. However, also
contributing to the risk of gout are environmental factors, such as diet and medications. Because the
estimates are constructed under an additive model, it does not account for the non-additive variance,
such as gene-gene or gene-environment interactions, or rare variants, or the effect of structural variants
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such as copy number variation.
5.4.2 GWAS and selection
The main peak of association in the Manhattan plots (Figures 5.5 and 5.6) for the GWAS analyses of
both the UK Biobank, and the New Zealand Polynesians was ABCG2, this was consistent with previous
GWAS analyses for gout, compared to GWAS for serum urate which has the strongest association with
SLC2A9 (Okada et al., 2012b; Köttgen et al., 2013; Nakayama et al., 2017). Combining the haplotypic
selection results for iHS and nSL from the GBR population with the UK Biobank gout GWAS showed
additional evidence at SLC22A12, PTPN11, SLC17A3, SLC17A4 , and ADAM10. However, from
the GWAS those genes had already met the suggestive significance threshold of P < 10-5. All except
ADAM10 had previously been reported as being significant at a genome-wide threshold for association
with serum urate levels (Köttgen et al., 2013). ADAM10 had not been previously associated at a
genome-wide threshold with either gout or serum urate levels, but had previously been reported as a
strong candidate for positive selection (Deschamps et al., 2016). ADAM10 is involved in the innate
immune system with the Notch signalling pathway, but also becomes down-regulated during interaction
with the extracellular proteins PfSEL1/PfSEL2 of P. falciparum (Singh et al., 2009). The strength of
association weakened in the replication UK Biobank cohort for all loci that had been identified, with
most showing no signs of significance except SLC22A12, which increased in strength of association.
The combination of the New Zealand Polynesian gout GWAS with the haplotypic selection statistics
of iHS and nSL from the Polynesian populations of CIM, NZM, SAM, and TON did not have any
corroboration with the equivalent combination of analyses in the European ancestry cohort. The TON
population was the main source of the selection statistics that met the threshold, this could be due to
the high proportion of gout patients (> 50%) that were included in the sample. Between the iHS and
nSL based results, there was a high degree of overlap in the SNPs that met the thresholds for both,
although nSL had three SNPs that did not meet the threshold in iHS.
The IBSP/PKD2/ABCG2 region has been associated with both gout and urate levels (Yang et al.,
2010a), but often just the lead SNP of rs2231142 is reported, as it has the strongest association
and is one of the most likely causative variants due to the Q141K amino acid change that leads
to a reduction in expression and a less efficient transporter (Woodward et al., 2009). The IBSP
locus encodes bone sialoprotein, which is involved with bone development (Kerr et al., 1993). Loci
nearby such as MEPE and SPP1, encode proteins with similar structure and functions, suggesting a
shared evolutionary history (Rowe et al., 2000). In the presence of urate crystals, as with gout, IBSP
expression is reduced and affects osteoblast differentiation (Chhana et al., 2011). PKD2 is involved
with kidney disease (Mochizuki et al., 1996; Hildebrandt, 2010), and Polynesian populations have a 3.5
fold higher incidence of end-stage renal disease, compared to Europeans (Collins et al., 2017). For
all the variants that had both selection and GWAS signal at PKD2, the selection signal was for the
ancestral allele, which was also the risk allele for gout. The selection signal was absent in the Eastern
Polynesian populations, which displayed selection statistics in favour of the derived/protective gout
alleles at PKD2. As previously discussed (section 3.4), many of the loci that have evidence suggesting
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selection in Western Polynesian populations are calcium channels. The IBSP/PKD2/ABCG2 region, is
functionally involved with calcium, bone sialoprotein has a high affinity for calcium (Kerr et al., 1993),
and PKD2 has some homology with calcium channels, containing domains that are consistent with
calcium binding (Mochizuki et al., 1996), again demonstrating this calcium-related selection pattern.
5.4.3 Limitations
In the analysis of the different gout definitions, there was a difference between the the definitions in
the number of SNPs that had a significant association with gout, with the hospital diagnosis definition
having the fewest. One of the key differences between the definitions was the number of cases defined
for each, ranging from 382 to 2295, which will have impacted on the power for each GWAS to detect
associations. Similar to the GWAS results from the different gout definitions, the differences between
heritability estimates of the different definitions may too be impacted by the differing numbers of
cases. Due to computational reasons, only a sub-sample of the controls was used in the calculation
of the heritability estimates. The use of all of the controls may have changed the results of the
heritability analysis. Another limitation of the definitions was the lack of ‘gold standard’ to which the
definitions could be compared, and therefore sensitivity and specificity were unable to be calculated
for each definition. The ancestry of the UK Biobank samples included for the gout definitions were
European, this means that results and conclusions from the definition and heritability analysis may
not be applicable to other ancestral backgrounds.
With the combination of the selection statistics with the results of the gout GWAS analyses, the
variants that were able to be compared were limited by the selection analysis, where the selection
results were only from the markers that were available on the CoreExome SNP array. This is despite
the UK Biobank GWAS being conducted on an imputed dataset, where there were results for 9.3
million markers after filtering. This compared to the total number of 236,868 markers for which there
were iHS or nSL results. It is possible that if there were iHS and nSL results for a greater number
of markers, more loci may have been prioritised. The Polynesian GWAS was limited by sample size,
and also in the number of markers for which there were both association and selection results. The
marker density of the CoreExome SNP array could have been improved through imputation, however,
for Polynesian populations, the public haplotype reference panels lack representation of Polynesian
populations. This means that Polynesian specific variants (such as rs373863828, Minster et al. (2016))
and therefore haplotypes, are not incorporated in the imputation, and as a result the imputation
accuracy suffers (Howie et al., 2011).
The combination of the Eastern and Western Polynesian populations into a single grouped population
for the GWAS may also affect the results, as there are population specific effects, even between similar
ancestral backgrounds such as the East and West Polynesian populations. Such differences with respect
to gout have been seen with ABCG2 (Phipps-Green et al., 2010). This was similar to what was
observed in the selection results at the extended locus including IBSP, PKD2, and ABCG2 displaying
a difference between Eastern and Western Polynesian populations. One method to take into account
these differences between the Eastern and Western Polynesian populations, would be to perform the
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GWAS separately in each and then meta-analyse the results.
5.4.4 Conclusions
The analyses in this chapter for performance of the case-definition for gout association studies showed
that in the absence of the gold-standard of observing urate crystals in the synovial fluid, or the ACR
criteria, it is recommended using the self-report or ULT definition, as this gave the best performance in
estimating the cohort gout prevalence, out of the definitions tested in this analysis. It was also shown
that incorporation of selection analyses with GWAS does provide evidence for additional variants
associated with gout. Despite these associations already mostly being nominally significant from
GWAS, the selection analyses do provide an avenue for prioritisation of GWAS results but only
appeared to further enhance evidence at known loci, rather than aid in discovery. Further work such
as incorporating multiple selection statistics, and the use of whole genome sequenced data or imputed






This thesis set out to investigate the role of genetic selection in the genome of modern Polynesian
populations, and its effect on urate and metabolic disease. There were three main objectives that were
covered. The first was to identify and characterise positive selection within Polynesian populations
with regard to metabolic diseases such as gout, obesity, type 2 diabetes, kidney disease, and metabolic
syndrome. The second was to investigate the shared ancestral history of Polynesian populations in
genomic regions relevant to metabolic disease. The third was to investigate the impact of alternative of
gout definitions in association studies, and to incorporate the use of selection statistics into association
analyses.
6.1.1 Evidence of selection in Polynesian populations
Chapter 3 utilised multiple selection and neutrality statistics, based on haplotypic and frequency
spectrum methodologies, to establish regions of the genome that exhibited ‘signals of selection’. The
findings of Chapter 3, specifically identified regions of the genome in Polynesian populations that
had evidence suggesting that positive selection had played a role. The characterisation of these
regions through pathway analysis indicated that metabolic functions dominated in the pathways with
enrichment of genes that had evidence of possible selection. However, only fractions of the pathways
were enriched. The majority of the genes in these pathways were enriched for significant markers
from nSL. The Eastern Polynesian populations had a greater number of enriched pathways than the
Western Polynesian populations. Many of the genes in the pathways enriched in the Eastern Polynesian
populations were involved with signalling, specifically with calcium.
The enriched pathway in common between the Western Polynesian populations was ABC transporters.
The loci, ABCG2 and ABCC4, that encode for two ABC transporters, have previously had genetic
variants identified that increase risk of gout in Western Polynesian populations (Phipps-Green et al.,
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2010; Tanner et al., 2017). ABCC4 has also had a Western Polynesian specific SNP (rs972711951)
identified that associated with gout (Tanner et al., 2017), and there was evidence of possible selection
at this locus, from CIM, NZM, and SAM.
The loci that exhibited ‘signatures of selection’ in Polynesian populations, that were also associated
with urate were limited, and there was minimal evidence for the main effect loci for urate and gout of
SLC2A9 and ABCG2. Instead the loci that indicated possible selection included RREB1, IGFR1 and
BCAS3, none of which are urate transporters but instead are involved with more central metabolic
pathways. The other metabolic diseases of obesity, type 2 diabetes, kidney disease, and metabolic
syndrome all had a number of associated loci that also had evidence of possible selection. Some of
these loci were associated with multiple traits, and had an immunological function. This points to a
potential relationship of these loci being influenced by pathogenic challenge, that results in influence
on metabolic diseases. One example of this potential relationship could be loci that were associated
with obesity and type 2 diabetes, that were also associated with malarial infection. One of the genes,
DDC, that was putatively associated with malaria, had one of the strongest iHS signals in NZM.
Due to urate having a central role in malaria infection and functioning as an adjuvant for the innate
immune system (Ames et al., 1981; Opitz et al., 2009), as well as previously having been identified
a selective pressure applied to the genome, malaria associated genes were investigated for signals of
selection in Polynesian populations. Three loci that had associations with malaria, to varying degrees,
showed possible evidence for selection through haplotypic statistics, these were ABO, ATP2B4, and
DDC. The blood antigen locus of ABO, has a suggested mechanism for how a red blood cell displaying
the type A or B antigen may increase cytoadherence with a malaria infected cell, increasing the
infectivity of Plasmodium falciparum (Cserti and Dzik, 2015). However, this may be limited in benefit
to regions that have a high frequency of O type such as Melanesia, and not for Polynesian populations
(Simmons, 1962; Zerihun et al., 2011).
Unfortunately, two previously identified loci (PPARGC1A and CREBRF) which had been posited as
thrifty-gene candidates, were unable to be verified, or rejected as having under-gone selection due to
the absence of the markers (or surrogates) that had previously been reported. The selection signal had
been specific to those markers.
6.1.2 Shared ancestry of selected loci
Chapter 4 was an investigation into the genetic similarities of populations in the regions that lay in the
extremes of the selection and neutrality statistic distributions. This chapter added to the evidence that
the modern-day Polynesian populations had genetic similarities to modern day East Asian populations,
and from the migration and settlement histories have a shared ancestry. There was also evidence
from all the clustering methodologies that while the Polynesian populations were most similar to each
other in a global context, there were in fact genetic differences between the East and West Polynesian
populations, a finding also reported by Hudjashov et al. (2018).
The principal component analysis, used to partition the variance of the genetic data, where each
subsequent principal component captures smaller amounts of variance, showed that the first four
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components could be used to explain the genetic variation that separated the populations into their
geographically based super population groups. The first component captured the difference of the
African Super Population (AFR) populations and all the other populations. The second component
captured the difference between the European Super Population (EUR) populations and the EAS, South
Asian Super Population (SAS), and POL populations. The third component captured the variation
responsible for separating the EAS from the POL populations. And the forth component captured the
genetic variation that separated the SAS and American Super Population (AMR) populations from
each other, and other populations.
The selection and neutrality statistics showed that populations within a super population were most
similar to one another, with the greatest differences being between super populations. There was also
evidence of a shared ancestry in both the frequency spectrum of variants, as well as with haplotypes
that was consistent with the Out of Africa migration and subsequent population movements. There was
not however a specific signal for selection that appeared in the Polynesian populations for urate or any
of the metabolic disease associated loci, but instead a commonality between the frequency spectrum of
similar geographic populations. The extremes of the frequency-based selection and neutrality statistics
showed that there was similarity in the regions of the genome within a super population, but the regions
that were in the extremes differed between super populations. This suggested that local adaptations
were geographically restricted (Gravel et al., 2011).
6.1.3 Incorporation of selection analyses into GWAS
Chapter 5 investigated the use of gout definitions that were common amongst multi-purpose cohorts
and assessed the performance of multiple definitions. It was found that the best definition was that of
self-reported gout or self-report of ULT usage, when the ACR criteria or observation of urate crystals
in the synovial fluid is not available. The use of selection statistics in prioritisation of GWAS loci
revealed that there were several loci that had possible evidence of selection that were “in the noise”
of the GWAS signal, however, these loci were limited to previously identified regions, with the new
suggestive associations failing to replicate.
6.2 Significance
Investigations of selection in different populations have yielded several population-specific genetic
adaptations. Some examples of adaptations with evidence of selection include lactase in European
populations (Bersaglieri et al., 2004), pigmentation in South Asian populations (Jonnalagadda et al.,
2017), altitude adaptations in Tibetans (Huerta-Sánchez et al., 2014), adaptations to climate in
Greenlanders (Fumagalli et al., 2015), and most recently adaptations for diving in the Bajau people
(Ilardo et al., 2018).
The health disparities that affect Polynesian populations, such as the high burden of metabolic
diseases like obesity, type 2 diabetes, renal disease, and gout are important to understand and address.
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Determining the origin of population genetic differences has the potential to lead to new insights for the
biological model. Looking at genetic selection can help explain how these population genetic differences
came to be. This thesis is the first to conduct a genome-wide scan for regions of genetic selection, and
to identify and characterise selection through a range of selection statistics, in multiple Polynesian
populations. The population sample sizes are also some of the largest for Polynesia compared to other
studies (Friedlaender et al., 2008; Kimura et al., 2008; Skoglund et al., 2016; Hudjashov et al., 2018).
From these genome-wide selection scans, there was evidence of metabolic pathways being enriched for
genes displaying signals of selection. But importantly, the genes that were associated with urate and
gout that displayed the most evidence of possible selection, were not urate transporters, but genes
that also had associations with other metabolic diseases.
Research into the genetic ancestry of populations, and in particular Polynesian populations is still a
current research focus (Hudjashov et al., 2018; Matisoo-Smith and Gosling, 2018). The research in
this thesis (in particular chapter 4) added to the current knowledge by comparing genome-wide SNP
data and selection statistics, finding there was additional evidence of similarity in ancestry between
modern-day Polynesian populations, and modern-day EAS populations. The regions that showed signs
of possible selection had varying degrees of similarity between populations, some were only seen in
East or West Polynesian populations, while others had signal that was shared with other populations,
with sharing with EAS being the most common.
Recommendations around the use of gout definition in genetic studies, when the gold-standard gout
diagnosis or other clinical based criteria (ACR criteria) are not available. When individual level genetic
data is available, this can assist in pooling genetic data between studies, rather than performing
meta-analysis. The heritability of gout was also confirmed to be similar to that of urate.
The incorporation of selection statistics provided another method to prioritise variants from GWAS.
Exploring additional options such as these is important, especially when sample sizes for GWAS in
Polynesian populations are unlikely to ever be large enough to have the power to detect all of the
small effect loci that contribute to complex genetic diseases such as gout. The analysis of combining
selection statistics with GWAS indicated it has potential by aiding in providing additional evidence for
known loci but did not aid in the discovery of new gout-associated variants. Broadening the types of
selection statistics used might provide different results.
6.3 Study limitations
One of the major limitations of this research project was the reliance on SNP array data. Ideally
whole genome sequencing would have been used, however, Polynesian populations are generally under-
represented in large sequencing projects. A clear demonstration of the benefit of using sequence data
over SNP array data is with the CREBRF variant, where rs373863828 was specific to Polynesian
populations (Minster et al., 2016; Krishnan et al., 2018) and not represented in my analysis. Using
SNP array data impacted on all aspects of the selection statistics analysis. The marker density of the
SNP array meant that the windowed statistics had a small number of markers per window, compared
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to the HapMap data, with whole genome sequence data giving the highest density. This meant that
the minimum number of markers of four was conveying signal for 100 kb regions of the genome.
The data from the CoreExome SNP array could have been imputed, however, due to the Polynesian
specific variant, and therefore haplotypes not being present in the reference panel haplotypes, the
imputation quality would be affected. The impact of this, beyond the potential for false haplotypes
to be introduced is still unknown. The trade-off benefit of having an increased density of markers
versus the increased probability of incorrect haplotypes has not been quantified, as the specificity of
haplotypes in Polynesian populations is unknown.
Another limiting factor for the analyses in chapters 3, 4 and 5, was the focus on positive selection.
This focus came from the hypothesis that urate had been beneficial in the past. However, other types
of selection are also relevant to complex genetic diseases, and influence the genome (Andrés et al.,
2009; Daub et al., 2013). On top of selection, there is also the possibility of random genetic drift,
population expansions, bottlenecks, and migrations that all play a role in shaping the genome.
The statistics used in this thesis have a wide range of time-frames they are powered for, however, many
of the differences that are being looked at are in the < 10kyears ago (ya) time frame, so some of these
methods might not be powered appropriately. In addition, the nature of the SNP array data means
that some of the newer methods are not necessarily applicable, for instance singleton-density score
(Field et al., 2016b). This is especially true where the SNP array data are missing very low frequency
variants due to an ascertainment bias in the markers on the SNP array, and from subsequent quality
control procedures that might have been implemented.
Using the GWAS catalog provided a convenient method to incorporate many of the known genetic
associations found from GWAS into the selection analysis. There were a few effects from this approach
that will have influenced the results in the analyses involving the GWAS catalog derived gene lists.
First, the associations were only for GWAS, and did not report on associations that were found in a
non-GWAS setting, such as candidate genes, so some true genetic associations may have been missed.
The impact of this on the conclusions is likely to be small, given that a trend being searched for was a
systematic selection signal across pathways (section 3.3.3.1.3). Given the number of genes in a pathway
that showed signs of selection and the pathway sizes involved, missing a few loci per pathway is unlikely
to have made this systematic selection signal appear. Secondly, there is the fact that a large proportion
of the GWAS that have been done and reported in the GWAS catalog are for European populations
(Haga, 2010; Popejoy and Fullerton, 2016), and the focus of this research was in Polynesian populations.
The result of this will be population-specific associations that are missed, so incorporation of other
association information, such as candidate genes or curated gene lists would be beneficial. The use of
the GWAS catalog, while extremely useful in terms of defining of gene lists, may have ‘cast a wide
net’ for genes with associations, than perhaps an expertly curated candidate-gene list. By having an
extended list, this may have increased the ‘noise’ in the selection signals which meant that trends in
the loci that showed signs of selection for a trait were harder to distinguish.
The technicalities of annotating gene information onto SNPs and genomic regions can be challenging,
especially with regard to annotation of intergenic regions where there might be no clear nearest gene.
Consideration also needs to be given to the functional impact of variants on expression, or the effects
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of regulatory elements such as DNAse hypersensitivity sites. The incorporation of this information
was limited, but with new annotation and analysis pipelines being developed (Ferrero, 2018), future
work will benefit from including these features in the analysis.
Selection is not the only explanation for genetic differences between populations. Other causes, such
as random genetic drift, migration, population expansions or bottlenecking can also contribute to
these differences. In order to boost the confidence that the signal’s that were seen were the result
of selection, the analysis would have benefited from population simulations using models that may
best explain the population history (Yuan et al., 2012). Extensions to simulation techniques could
include training machine learning algorithms or deep learning on simulated data and applying the
model predictions to real data (Pybus et al., 2015; Sheehan and Song, 2016; Schrider and Kern, 2018)
6.4 Future directions
Future work in this area would include the generation of a high-quality set of Polynesian whole-genome
sequences that could be used to remove the ascertainment bias introduced through the SNP arrays.
High quality sequences could also be used to supplement the reference haplotype panels that are
currently available to include haplotypes that are specific to Polynesian populations which could then
be used improved haplotype phasing, and for imputation of Polynesian specific variants.
If sequence data were available, then the use of some of the newer statistics such as the population
branching statistic (Yi et al., 2010), singleton density score (Field et al., 2016b), and levels of exclusively
shared differences (Librado and Orlando, 2018) could be made use of, which are designed for detecting
selection on more recent time-scales.
Comparing the present day East Asian and Polynesian populations with ancient Polynesian DNA
could prove useful in determining areas of the genome that differ, to refine the regions of the genome
that have changed since population divergence, and subsequent changes in the Polynesian populations.
Comparisons with Denisovan and Neanderthal data could also be used to investigate the impact
introgression has had on the Polynesian populations, or if regions that showed signs of selection were
also similar to regions of introgression.
Investigating the use of selection statistics with GWAS could still prove fruitful if other statistics
and methodologies were incorporated that allowed for cross-population comparisons, especially in
situations where there are differences in the disease prevalence between populations. This could be
further improved by inclusion of expression quantitative trait loci information, and regulatory elements
to assess if the markers and regions identified in the selection analyses have known impact on gene
expression, or are tissue specific. Furthermore, replication of this analysis in other sample Polynesian
populations, and the use of population simulations would be beneficial to increase the confidence in
the regions that displayed evidence of possible selection.
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6.5 Conclusion
Overall, it was shown that there was evidence suggesting positive selection in Polynesian populations
with some of the regions including loci associated with urate and metabolic diseases. Further evidence
was shown for the modern-day Polynesian populations being most similar to modern day East Asian
populations, with there being a degree of similarity in the regions displaying signatures of selection. It
was also shown that selection statistics could be used to group populations of similar ancestry.
Identification of additional gout-associated loci in GWAS was limited when selection statistics were
incorporated, but the number of statistics used was not exhaustive, so expansion of the statistics used,
particularly cross-populational statistics, may yield different results. It is also shown that the use of
self-reported gout or ULT usage to define gout-cases in a case-control genetic association study gave
the best performance, in the absence of the gold-standard gout diagnosis, or ACR criteria.
This thesis has provided identification and characterisation of regions of the genome that displayed
“signatures of selection” in Polynesian populations, that was previously unavailable. It has also provided
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A1.2 Genes in 1st percentile for Polynesian populations for frequency
based statistics
Table S2: All genes that had a window in the 1st percentile and value < 0 from a
Polynesian population. Table can be found in the electronic supplement as file
Appendices/03-intrasfsPol.csv
A1.3 Significant iHS and nSL markers in Polynesian populations
Table S3: Significant markers for iHS and nSL in Polynesian populations. Table
can be found in the electronic supplement as file Appendices/03-ihsnsl-genes.csv
A1.4 Significant XP-EHH markers in Polynesian populations
Table S4: Genes that had a significant XP-EHH value in Polynesian populations.
Table can be found in the electronic supplement as file Appendices/03-xpehh-
Pol.csv
A1.5 Inflammatory and auto-immune genes with significant results in se-
lection statistics for Polynesian populations
Table S5: Loci associated with various inflammatory and autoimmune diseases that































































NZM AHI1 1 6
TON AHI1 1 1
CIM AHR 2
NZM AKAP11 1
CIM AMT 3 2
NZM AMT 3 1
TON AMT 7 1 4 2
SAM ANXA3 1
CIM APEH 2
TON APEH 1 3
243
Table S5: Loci associated with various inflammatory and autoimmune diseases that


























































CIM ARAP1 7 2 5 5 2 5 1
NZM ARAP1 2 1 5 4 2 5
SAM ARID5B 1 3 4
CIM ARID5B 1
SAM ATF6B 1 4
CIM ATF6B 2
NZM ATF6B 3 2
TON ATF6B 4
CIM ATG16L2 2 5 5 2 5
NZM ATG16L2 1 3 2 3
CIM ATM 7 3 5 6 1 3 6 6
NZM ATM 3 8 6
SAM ATM 7 5 6 1
TON ATM 7 1




TON BACH2 1 1
SAM BANK1 1 4 11 13
TON BANK1 2 9 10
NZM BANK1 2 4
CIM BLK 1 5 5 6
NZM BLK 7 2 6 5
SAM BLK 7 1 5 5 5
TON BLK 7 2 6 5 6
SAM BRD2 2 1
NZM BRD2 1
SAM BRE 1
CIM BSN 1 3 5 3
NZM BSN 1 1 2 6 6
TON BSN 5 1 5 5 3




SAM C1QBP 5 2





SAM C6orf10 1 4 2
CIM C6orf10 1
TON C6orf10 2 1
SAM C6orf15 2
NZM C6orf48 1
NZM C7orf72 1 1 1 1
CIM CAMK2A 1 1
TON CAMK2G 1 1
SAM CAMK2G 1 1 3
SAM CAMTA1 1 2 2
CIM CAMTA1 2 1
NZM CAMTA1 3 1
NZM CARD11 1 1 3
SAM CARD11 2
TON CARD11 1 2 3
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TON CCDC36 2 2 5
TON CCNY 1 1
CIM CCR2 3 2 1 3
NZM CCR2 4 2 3 5
SAM CCR2 1
TON CCR2 1 2
CIM CCR3 1 2 1 6 5 2
NZM CCR3 2 4 1 6 5 1 4
SAM CCR3 3 3 1 6 5 4
TON CCR3 3 3 1 6 5 7 5
SAM CCR9 1 2
TON CCR9 1 1
NZM CCRL2 2 2 1
TON CD80 1
SAM CD86 2 2
TON CD86 2
NZM CDH1 1 1
SAM CDH13 2 3 1 5 2
TON CDH13 1 2 1
CIM CDH13 9
NZM CDH13 6
SAM CDH23 2 3 12 16
TON CDH23 1 11 12






CIM CEP250 6 2 5 5
NZM CEP250 4 2 2
SAM CEP250 2 2
TON CEP250 4 3
CIM CEP57 1 2
NZM CEP57 1 5
NZM CFB 1




CIM CNTNAP2 5 2 1 1 4 3
NZM CNTNAP2 2 1 2 2 12 3
SAM CNTNAP2 3 3 4 1 2 3 3 4 3 3
TON CNTNAP2 2 1 5 4 2 2
CIM COBL 1
NZM COBL 2
CIM COG6 2 1 4
NZM COG6 4 5
CIM CPAMD8 3 1 3
NZM CPAMD8 1
SAM CPAMD8 3
TON CPAMD8 3 5 1
TON CTDSP1 1
CIM DAG1 2
NZM DAG1 2 1
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NZM DLEU1 4 4 2




CIM ERAP1 2 4 6 5 6 4
NZM ERAP1 5 4 6 5
SAM ERAP1 4 4 4 1 1




TON ETS1 1 1




CIM FCHSD2 7 3 5 6 2 5 1 1
NZM FCHSD2 3 2 5 6 5 1
TON FCHSD2 1 1
NZM FGFR1OP 1
NZM FIGNL1 6 4 5 5 5 1 1
SAM FIGNL1 1




TON FLI1 1 1
SAM FNIP1 1
CIM FOXP1 7 4 1 1 6
NZM FOXP1 6 4 1
SAM FOXP1 7 3 6 1 5 9 1 6




SAM GART 1 2
TON GART 1 3 4
CIM GIN1 6 3
NZM GIN1 2 1
SAM GIN1 2 1
TON GIN1 6 3
NZM GLIS3 1
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SAM HLA-DOB 2 5 3 3 1 1
TON HLA-DOB 2 1
CIM HLA-DOB 2
SAM HLA-DQA1 1 1
SAM HLA-DQA2 1 4 1 1 3 1 1
CIM HLA-DQA2 1
NZM HLA-DQB1 1 1
SAM HLA-DQB1 4 2 2 4 3
TON HLA-DQB1 1
SAM HLA-DQB2 3 1 3
CIM HLA-DQB2 4
NZM HSPA1L 1 1
SAM IFNGR2 1 2
TON IFNGR2 3 4
CIM IFNGR2 1
CIM IKZF1 2 1
NZM IKZF1 4 4 5 6 1 5 1 1







TON IL1RL2 3 1
NZM IL22RA2 1








CIM IP6K1 2 1 2
TON IP6K1 3







CIM ITGAV 1 1
SAM ITPR3 1 4




SAM JAZF1 4 3 2 1 4
TON JAZF1 5 4 5 6 1 5 1
NZM KCNB2 6 4 3 6 1 5 6 6
SAM KCNB2 1 2 2
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TON LACC1 1 1
CIM LEMD2 1 1 4 2
NZM LEMD2 1 1 2
TON LEMD2 5 1 6 1 1
NZM LMO7 1
SAM LMO7 2 1
TON LMO7 2 2
CIM LPP 7 2 6 5 3 1
NZM LPP 7 4 6 1 5 6 1
SAM LPP 7 2 5 4 1
TON LPP 7 3 5 4 1
NZM LRRC18 1 2 4
CIM LRRK2 1 3 4 5 1
NZM LRRK2 5 3 5 6 5
SAM LRRK2 6 3 5 6 1 1 2 3
TON LRRK2 1 3 4 5 3 3
CIM LSP1 1
CIM LTF 4
NZM LTF 4 5 1 3 1 1
TON LY75 3 3
TON LYST 2 5 3
NZM LYST 1 1 2 5 5
CIM MAML2 1
CIM MANBA 7 4 5 5 2
NZM MANBA 7 2 3 1
SAM MANBA 7 3 5 2
TON MANBA 7 2 3 1
TON MARCH7 1 1
SAM MC1R 5
NZM MEG3 1
SAM METTL10 6 1 3 1
TON METTL10 1
CIM MIR146A 1 1
NZM MIR146A 1 1
SAM MIR210HG 1
TON MLH3 3
CIM MLN 1 2
NZM MLN 1
TON MLN 5 1 6
CIM MST1 2
NZM MST1 1 2 2
TON MST1 3
SAM MSTO1 5
CIM MTMR3 2 2 6





CIM NFKB1 6 5 1
NZM NFKB1 1




SAM NOS2 1 1
TON NOS2 1
SAM NOTCH4 1 2
TON NUSAP1 1
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CIM PAM 6 5 2 1 2 2
NZM PAM 5 5 2
SAM PAM 4 5
TON PAM 7 5
SAM PAPOLG 2 5
TON PAPOLG 4
TON PARK7 1 1
SAM PBX2 1
NZM PBX2 1
CIM PDE2A 1 1 2 1
NZM PDE2A 2
CIM PDGFB 1




TON PFKFB4 1 3
NZM PHACTR2 1 2
NZM PHLDB1 3 1
SAM PHLDB1 3 1
NZM PHRF1 1 3
SAM PHRF1 1
CIM PHTF1 1 1 4






CIM PPIP5K2 6 3 6
NZM PPIP5K2 2 1
SAM PPIP5K2 2 1













SAM PSMB9 3 4 1 2 3
TON PSMB9 1 4 1 1
NZM PSMB9 4
SAM PSMG1 2 1 1
TON PSMG1 2 1 1
TON PTPRC 1
CIM PUS10 1 4
NZM PUS10 1
SAM PUS10 2 6 3 1
TON PUS10 2 6 2 1
SAM PVT1 5 3 1
TON PVT1 2 2 1
CIM PXK 7 1 3
NZM PXK 6
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SAM RAD51B 1 10 31 31








NZM RDH10 7 4 5 6 1 5
SAM RDH10 1 3 2 1
TON RDH10 1 3 2 1
SAM REL 2 6 2 4
TON REL 2 5 4 3
SAM RERE 7 1 1 4
TON RERE 7 1 2 2 4 1
NZM REV3L 1 1
SAM REV3L 1 1 2 3
CIM RHOA 1 1
NZM RHOA 2 1 3
TON RHOA 7 1 3 1
TON RIPK2 1
NZM RMI2 1
SAM RNASEH2C 1 1
TON RNASEH2C 1
CIM RNF123 2 1 1




NZM RPL7 7 4 5 6 1 5
SAM RPL7 2 5 2 2
TON RPL7 1 5 2 2
CIM RPS14 1 1
NZM RPS6KA2 2
TON RPS6KA2 1
NZM RTKN2 6 1 4 1





SAM SEC24C 1 2 4
TON SEC24C 1
CIM SELE 5 4
NZM SELE 6 2 5
CIM SELL 4
NZM SELL 4 1 5
TON SELP 2
NZM SEMA6D 1 1 3
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CIM SLC2A13 3 4 5 2 7 4 3
NZM SLC2A13 6 3 5 6 5 2
SAM SLC2A13 3 4 5 3 3 3
TON SLC2A13 2 4 3 2
CIM SLC36A2 1
CIM SLC36A3 2 2
TON SLC39A11 1 1 1 1
CIM SLC39A11 1
SAM SLC39A11 1 1
CIM SLC39A8 5 1
NZM SLC39A8 4




CIM SLCO6A1 7 3 3 6 5 4 4 6
NZM SLCO6A1 7 3 3 6 5 3 4 6
SAM SLCO6A1 7 2 2 2 3
TON SLCO6A1 7 3 3 6 5
CIM SMAD7 2
NZM SMAD7 2 2 6 2 5 1
TON SNAPC4 1 1
SAM SP140 3
NZM SPATA8 1
CIM STARD10 1 5 2 1 1
NZM STARD10 3
CIM STK11 1 2
NZM STK11 1
SAM STK19 2 2





NZM TERF1 7 2 6 1 5 1 2
SAM TERF1 1 1 2 2
TON TERF1 6 1 1 1 3 3
NZM TET3 1
CIM THADA 6 2 6 5 8 2 1
NZM THADA 7 2 6 5 3 1
SAM THADA 7 2 6 5 3
TON THADA 7 2 6 5 7 12 8 2
TON TMEM39A 3 1
SAM TMEM50B 1 2




NZM TNFAIP3 1 1
TON TNFRSF9 1 1
CIM TNFSF15 2
SAM TNFSF15 1
NZM TNFSF18 1 1
CIM TNIP1 3 2
SAM TNIP1 1
SAM TNXB 1 10
CIM TNXB 2 5
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TON TXNDC11 2 1
SAM UBD 1
CIM UBLCP1 1





CIM USP4 2 6 6
NZM USP4 1 5 7
TON USP4 5 1 4 2 4
CIM WDFY4 1
NZM WDFY4 4 1 1 2 4
CIM WDR78 1 3
CIM ZMIZ1 5 5
NZM ZMIZ1 5 5
SAM ZMIZ1 5 4
TON ZMIZ1 5 1
NZM ZNF365 2 1 5
SAM ZNF365 3 1 1 4 1 1 2
TON ZNF438 1
CIM ZNF831 1
NZM ZPBP 1 1 2
SAM ZPBP 1
XP-EHH is the number of populations from the super population that had at least one
marker sigificant in the gene. Integrated haplotype homozygosity score and nSL are the
number of significant markers. Fay and Wu’s H, Fu and Li’s F, Tajima’s D, and Zeng’s E
are the number of windows intersecting the gene that met the lower threshold.
A2 Chapter 4 Tables
A2.1 Admixture cross-validation error
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A2.2 GWAS catalog studies and references table




Celiac disease Dubois et al. (2010)
Celiac disease Garner et al. (2014)
Celiac disease Hunt et al. (2008)
Celiac disease Östensson et al. (2013)
Celiac disease van Heel et al. (2007)
Crohn’s disease Wellcome Trust Case Control Consortium (2007)
Crohn’s disease Barrett et al. (2008)
Crohn’s disease de Lange et al. (2017)
Crohn’s disease Franke et al. (2007)
Crohn’s disease Franke et al. (2010b)
Crohn’s disease Huang et al. (2012)
Crohn’s disease Jostins et al. (2012)
Crohn’s disease Julià et al. (2013)
Crohn’s disease Jung et al. (2016)
Crohn’s disease Kenny et al. (2012)
Crohn’s disease Libioulle et al. (2007)
Crohn’s disease Liu et al. (2015)
Crohn’s disease McGovern et al. (2010b)
Crohn’s disease Ostrowski et al. (2016)
Crohn’s disease Parkes et al. (2007)
Crohn’s disease Raelson et al. (2007)
Crohn’s disease Rioux et al. (2007)
Crohn’s disease Yamazaki et al. (2013)
Crohn’s disease Yang et al. (2014)
Inflammatory bowel disease de Lange et al. (2017)
Inflammatory bowel disease Duerr et al. (2006)
Inflammatory bowel disease Jostins et al. (2012)
Inflammatory bowel disease Kugathasan et al. (2008)
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Table S7: GWAS catalog studies used. Disease trait as specified in GWAS
catalog (continued)
Disease Trait Reference
Inflammatory bowel disease Liu et al. (2015)
Inflammatory bowel disease Ostrowski et al. (2016)
Inflammatory bowel disease Yang et al. (2016)
Multiple sclerosis Australia and New Zealand Multiple Sclerosis Genetics
Consortium (ANZgene) (2009)
Multiple sclerosis Andlauer et al. (2016)
Multiple sclerosis Aulchenko et al. (2008)
Multiple sclerosis Comabella et al. (2008)
Multiple sclerosis De Jager et al. (2009)
Multiple sclerosis Gourraud et al. (2013)
Multiple sclerosis Hafler et al. (2007)
Multiple sclerosis Jakkula et al. (2010)
Multiple sclerosis Martinelli-Boneschi et al. (2012)
Multiple sclerosis Matesanz et al. (2012)
Multiple sclerosis Nischwitz et al. (2010)
Multiple sclerosis Patsopoulos et al. (2011)
Multiple sclerosis Sanna et al. (2010)
Multiple sclerosis Sawcer et al. (2011)
Multiple sclerosis Wang et al. (2011a)
Primary biliary cirrhosis Cordell et al. (2015)
Primary biliary cirrhosis Hirschfield et al. (2009)
Primary biliary cirrhosis Kawashima et al. (2017)
Primary biliary cirrhosis Liu et al. (2010)
Primary biliary cirrhosis Mells et al. (2011)
Primary biliary cirrhosis Nakamura et al. (2012)
Psoriasis Baurecht et al. (2015)
Psoriasis Capon et al. (2008)
Psoriasis Ellinghaus et al. (2010)
Psoriasis Liu et al. (2008)
Psoriasis Nair et al. (2009)
Psoriasis Strange et al. (2010)
Psoriasis Stuart et al. (2010)
Psoriasis Tsoi et al. (2015)
Psoriasis Yin et al. (2015)
Psoriasis Zhang et al. (2009)
Rheumatoid arthritis Wellcome Trust Case Control Consortium (2007)
Rheumatoid arthritis Freudenberg et al. (2011)
Rheumatoid arthritis Gregersen et al. (2009)
Rheumatoid arthritis Hu et al. (2011)
Rheumatoid arthritis Jiang et al. (2014)
Rheumatoid arthritis Julià et al. (2008)
Rheumatoid arthritis Kochi et al. (2010)
Rheumatoid arthritis Myouzen et al. (2012)
Rheumatoid arthritis Negi et al. (2013)
Rheumatoid arthritis Okada et al. (2012c)
Rheumatoid arthritis Okada et al. (2014)
Rheumatoid arthritis Orozco et al. (2014)
Rheumatoid arthritis Padyukov et al. (2011)
Rheumatoid arthritis Plenge et al. (2007a)
Rheumatoid arthritis Plenge et al. (2007b)
Rheumatoid arthritis Raychaudhuri et al. (2008)
Rheumatoid arthritis Saxena et al. (2017)
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Table S7: GWAS catalog studies used. Disease trait as specified in GWAS
catalog (continued)
Disease Trait Reference
Rheumatoid arthritis Stahl et al. (2010)
Rheumatoid arthritis Terao et al. (2011)
Systemic lupus erythematosus Alarcón-Riquelme et al. (2016)
Systemic lupus erythematosus Armstrong et al. (2014)
Systemic lupus erythematosus Bentham et al. (2015)
Systemic lupus erythematosus Chung et al. (2011)
Systemic lupus erythematosus Demirci et al. (2016)
Systemic lupus erythematosus Graham et al. (2008)
Systemic lupus erythematosus Han et al. (2009)
Systemic lupus erythematosus Harley et al. (2008)
Systemic lupus erythematosus Hom et al. (2008)
Systemic lupus erythematosus Kozyrev et al. (2008)
Systemic lupus erythematosus Lee et al. (2012)
Systemic lupus erythematosus Lessard et al. (2016)
Systemic lupus erythematosus Morris et al. (2016)
Systemic lupus erythematosus Okada et al. (2012a)
Systemic lupus erythematosus Yang et al. (2010c)
Systemic lupus erythematosus Yang et al. (2011c)
Systemic lupus erythematosus Yang et al. (2013b)
Type 1 diabetes Wellcome Trust Case Control Consortium (2007)
Type 1 diabetes Barrett et al. (2009a)
Type 1 diabetes Bradfield et al. (2011)
Type 1 diabetes Cooper et al. (2008)
Type 1 diabetes Grant et al. (2009)
Type 1 diabetes Hakonarson et al. (2007)
Type 1 diabetes Hakonarson et al. (2008)
Type 1 diabetes Huang et al. (2012)
Type 1 diabetes Todd et al. (2007)
Type 1 diabetes Wallace et al. (2010)
Ulcerative colitis Anderson et al. (2011)
Ulcerative colitis Asano et al. (2009)
Ulcerative colitis Barrett et al. (2009b)
Ulcerative colitis de Lange et al. (2017)
Ulcerative colitis Franke et al. (2008)
Ulcerative colitis Franke et al. (2010a)
Ulcerative colitis Haritunians et al. (2010)
Ulcerative colitis Jostins et al. (2012)
Ulcerative colitis Julià et al. (2014)
Ulcerative colitis Juyal et al. (2015)
Ulcerative colitis Liu et al. (2015)
Ulcerative colitis McGovern et al. (2010a)
Ulcerative colitis Ostrowski et al. (2016)
Ulcerative colitis Silverberg et al. (2009)
Ulcerative colitis Yang et al. (2013a)
Vitiligo Jin et al. (2010)
Vitiligo Jin et al. (2011)
Vitiligo Jin et al. (2012)
Vitiligo Quan et al. (2010)
Vitiligo Tang et al. (2013)
Gout and Urate
Gout Köttgen et al. (2013)
Gout Li et al. (2015)
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Table S7: GWAS catalog studies used. Disease trait as specified in GWAS
catalog (continued)
Disease Trait Reference
Gout Matsuo et al. (2016)
Gout Nakayama et al. (2017)
Gout Sulem et al. (2011)
Renal overload gout Nakayama et al. (2017)
Renal underexcretion gout Nakayama et al. (2017)
Urate levels Dehghan et al. (2008)
Urate levels Döring et al. (2008)
Urate levels Kamatani et al. (2010)
Urate levels Köttgen et al. (2013)
Urate levels Li et al. (2007)
Urate levels Tin et al. (2011)
Urate levels Vitart et al. (2008)
Urate levels Wallace et al. (2008)
Urate levels Yang et al. (2010b)
Urate levels in obese individuals Huffman et al. (2015)
Urate levels in overweight individuals Huffman et al. (2015)
Kidney Disease
Chronic kidney disease Köttgen et al. (2010)
Chronic kidney disease Nanayakkara et al. (2014)
Chronic kidney disease Pattaro et al. (2012)
Chronic kidney disease Pattaro et al. (2016)
Chronic kidney disease and serum creatinine levels Gudbjartsson et al. (2010)
End-stage renal disease (non-diabetic) Bostrom et al. (2010)
Kidney function decline traits Gorski et al. (2015)
Renal function and chronic kidney disease Köttgen et al. (2009)
Malaria
Malaria Band et al. (2013)
Malaria Jallow et al. (2009)
Malaria Timmann et al. (2012)
Metabolic Syndrome
Metabolic syndrome Kraja et al. (2011)
Metabolic syndrome Kristiansson et al. (2012)
Metabolic syndrome Zabaneh and Balding (2010)
Metabolic syndrome (bivariate traits) Kraja et al. (2011)
Neurological
Alzheimer’s disease Abraham et al. (2008)
Alzheimer’s disease Antúnez et al. (2011)
Alzheimer’s disease Feulner et al. (2010)
Alzheimer’s disease Harold et al. (2009)
Alzheimer’s disease Heinzen et al. (2010)
Alzheimer’s disease Hollingworth et al. (2011)
Alzheimer’s disease Jonsson et al. (2013)
Alzheimer’s disease Kamboh et al. (2012)
Alzheimer’s disease Lambert et al. (2009)
Alzheimer’s disease Lambert et al. (2013)
Alzheimer’s disease Li et al. (2008b)
Alzheimer’s disease Meda et al. (2012)
Alzheimer’s disease Nelson et al. (2014)
Alzheimer’s disease Pérez-Palma et al. (2014)
Alzheimer’s disease Seshadri et al. (2010)
Alzheimer’s disease Webster et al. (2008)
Parkinson’s disease Do et al. (2011)
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Table S7: GWAS catalog studies used. Disease trait as specified in GWAS
catalog (continued)
Disease Trait Reference
Parkinson’s disease Foo et al. (2017)
Parkinson’s disease Hamza et al. (2010)
Parkinson’s disease Hill-Burns et al. (2014)
Parkinson’s disease Lill et al. (2012)
Parkinson’s disease Nalls et al. (2011)
Parkinson’s disease Nalls et al. (2014)
Parkinson’s disease Pankratz et al. (2012)
Parkinson’s disease Pickrell et al. (2016)
Parkinson’s disease Saad et al. (2011)
Parkinson’s disease Satake et al. (2009)
Parkinson’s disease Simón-Sánchez et al. (2009)
Parkinson’s disease Spencer et al. (2011)
Parkinson’s disease Vacic et al. (2014)
Obesity
Body mass index Berndt et al. (2013)
Body mass index Frayling et al. (2007)
Body mass index Graff et al. (2013)
Body mass index Locke et al. (2015b)
Body mass index Loos et al. (2008)
Body mass index Monda et al. (2013)
Body mass index Namjou et al. (2013)
Body mass index Pei et al. (2014)
Body mass index Speliotes et al. (2010)
Body mass index Thorleifsson et al. (2009)
Body mass index Warrington et al. (2015)
Body mass index Wen et al. (2012)
Body mass index Wen et al. (2014)
Body mass index Willer et al. (2009)
Body mass index Yang et al. (2012)
Body mass index variance Ahmad et al. (2016)
Fat body mass Pei et al. (2014)
Obesity Berndt et al. (2013)
Obesity Bradfield et al. (2012)
Obesity Jiao et al. (2011)
Obesity Meyre et al. (2009)
Obesity Wang et al. (2011b)
Obesity (early onset extreme) Scherag et al. (2010)
Obesity (early onset extreme) Wheeler et al. (2013)
Obesity (extreme) Cotsapas et al. (2009)
Obesity (extreme) Paternoster et al. (2011)
Obesity-related traits Comuzzie et al. (2012)
Obesity-related traits Melka et al. (2012)
Obesity-related traits Scuteri et al. (2007)
Waist circumference adjusted for body mass index Shungin et al. (2015)
Waist circumference adjusted for body mass index Wen et al. (2016)
Waist-to-hip ratio adjusted for body mass index Shungin et al. (2015)
Waist-to-hip ratio adjusted for body mass index Wen et al. (2016)
T2D
Type 2 diabetes Wellcome Trust Case Control Consortium (2007)
Type 2 diabetes Cho et al. (2011)
Type 2 diabetes Cook and Morris (2016)
Type 2 diabetes Cui et al. (2011)
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Table S7: GWAS catalog studies used. Disease trait as specified in GWAS
catalog (continued)
Disease Trait Reference
Type 2 diabetes Ghassibe-Sabbagh et al. (2014)
Type 2 diabetes Hanson et al. (2014)
Type 2 diabetes Hara et al. (2014)
Type 2 diabetes Huang et al. (2012)
Type 2 diabetes Imamura et al. (2012)
Type 2 diabetes Imamura et al. (2016)
Type 2 diabetes Kooner et al. (2011)
Type 2 diabetes Li et al. (2013)
Type 2 diabetes Ma et al. (2013)
Type 2 diabetes Mahajan et al. (2014)
Type 2 diabetes Ng et al. (2014)
Type 2 diabetes Palmer et al. (2012)
Type 2 diabetes Parra et al. (2011)
Type 2 diabetes Perry et al. (2012)
Type 2 diabetes Qi et al. (2010)
Type 2 diabetes Saxena et al. (2007)
Type 2 diabetes Saxena et al. (2013)
Type 2 diabetes Scott et al. (2007)
Type 2 diabetes Shu et al. (2010)
Type 2 diabetes Sim et al. (2011)
Type 2 diabetes Sladek et al. (2007)
Type 2 diabetes Steinthorsdottir et al. (2007)
Type 2 diabetes Tabassum et al. (2013)
Type 2 diabetes Takeuchi et al. (2009)
Type 2 diabetes Timpson et al. (2009)
Type 2 diabetes Tsai et al. (2010)
Type 2 diabetes Unoki et al. (2008)
Type 2 diabetes Voight et al. (2010)
Type 2 diabetes Williams et al. (2014)
Type 2 diabetes Yamauchi et al. (2010)
Type 2 diabetes Yasuda et al. (2008)
Type 2 diabetes Zeggini et al. (2007)
Type 2 diabetes Zeggini et al. (2008)
Type 2 diabetes and other traits Rung et al. (2009)
A2.3 GWAS catalog disease gene lists
Table S8: Disease associated genes by category from the GWAS catalog. For
references see Table S7.
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references see Table S7. (continued)























































Table S8: Disease associated genes by category from the GWAS catalog. For
references see Table S7. (continued)























































Table S8: Disease associated genes by category from the GWAS catalog. For
references see Table S7. (continued)























































Table S8: Disease associated genes by category from the GWAS catalog. For
references see Table S7. (continued)





















































KCNQ1 Yes Yes Yes
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Table S8: Disease associated genes by category from the GWAS catalog. For
references see Table S7. (continued)





















































MTNR1B Yes Yes Yes
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Table S8: Disease associated genes by category from the GWAS catalog. For
references see Table S7. (continued)
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A2.4 Site-frequency spectrum based selection and neutrality statistics
summary tables
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Table S9: Tajima’s D summary statistics by population
Population Mean Std. Dev Min Lower 1% Median Upper 99% Max
AFR
ACB 2.410 0.735 -1.785 0.293 2.499 3.752 4.416
ASW 2.295 0.694 -1.703 0.252 2.385 3.548 4.186
ESN 2.390 0.708 -1.723 0.427 2.462 3.734 4.476
GWD 2.416 0.734 -1.543 0.370 2.492 3.804 4.610
LWK 2.403 0.715 -1.717 0.380 2.479 3.749 4.438
MSL 2.293 0.699 -1.644 0.369 2.359 3.628 4.297
YRI 2.440 0.714 -1.573 0.450 2.515 3.791 4.598
AMR
CLM 2.388 0.904 -1.935 -0.290 2.539 3.899 4.659
MXL 2.113 0.894 -2.252 -0.527 2.260 3.635 4.319
PEL 1.925 0.999 -2.182 -0.853 2.070 3.688 4.505
PUR 2.484 0.885 -1.813 -0.141 2.634 3.970 4.827
EAS
CDX 2.304 0.978 -2.257 -0.652 2.473 3.912 4.726
CHB 2.342 0.998 -1.977 -0.693 2.519 3.975 4.863
CHS 2.378 0.987 -2.171 -0.596 2.551 3.997 4.863
JPT 2.405 0.974 -2.078 -0.559 2.578 3.997 4.821
KHV 2.311 0.984 -2.642 -0.632 2.483 3.935 4.822
EUR
CEU 2.317 0.978 -2.115 -0.613 2.490 3.916 4.859
FIN 2.354 0.954 -2.066 -0.520 2.521 3.927 4.747
GBR 2.288 0.966 -2.084 -0.618 2.462 3.880 4.719
IBS 2.332 0.978 -2.069 -0.581 2.497 3.953 4.780
NZC 2.271 1.006 -2.174 -0.731 2.449 3.919 4.779
TSI 2.361 0.974 -2.200 -0.558 2.530 3.965 4.884
POL
CIM 1.875 1.073 -2.399 -1.093 2.024 3.771 4.673
NZM 1.929 1.042 -2.559 -0.945 2.074 3.780 4.742
SAM 2.061 1.041 -2.088 -0.979 2.226 3.836 4.657
TON 2.151 1.016 -2.129 -0.838 2.314 3.884 4.837
SAS
BEB 2.393 0.879 -1.996 -0.279 2.542 3.872 4.535
GIH 2.454 0.903 -2.274 -0.281 2.607 3.978 4.700
ITU 2.460 0.890 -1.693 -0.232 2.603 3.972 4.772
PJL 2.442 0.892 -2.084 -0.268 2.592 3.930 4.717
STU 2.461 0.890 -1.881 -0.234 2.607 3.970 4.678
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Table S10: Fay and Wu’s H summary statistics by population
Population Mean Std. Dev Min Lower 1% Median Upper 99% Max
AFR
ACB 0.079 0.878 -6.602 -2.598 0.226 1.415 1.763
ASW 0.090 0.832 -6.403 -2.470 0.230 1.350 1.707
ESN -0.016 0.947 -7.802 -2.924 0.141 1.398 1.728
GWD -0.015 0.956 -8.113 -2.958 0.147 1.413 1.809
LWK 0.040 0.908 -7.157 -2.733 0.190 1.414 1.780
MSL 0.023 0.910 -6.862 -2.766 0.178 1.380 1.812
YRI -0.004 0.949 -7.285 -2.922 0.156 1.418 1.794
AMR
CLM -0.614 1.277 -10.627 -4.682 -0.382 1.273 1.817
MXL -0.758 1.317 -10.693 -4.926 -0.517 1.183 1.604
PEL -1.171 1.537 -11.167 -5.894 -0.909 1.134 1.650
PUR -0.503 1.219 -9.980 -4.355 -0.285 1.311 1.753
EAS
CDX -1.046 1.545 -11.374 -5.945 -0.749 1.220 1.708
CHB -1.043 1.557 -10.958 -6.009 -0.745 1.233 1.796
CHS -1.042 1.560 -10.566 -6.014 -0.741 1.241 1.860
JPT -1.036 1.553 -10.782 -5.976 -0.740 1.239 1.745
KHV -1.034 1.542 -10.703 -5.933 -0.739 1.228 1.755
EUR
CEU -0.816 1.417 -11.159 -5.314 -0.549 1.258 1.758
FIN -0.826 1.424 -11.183 -5.354 -0.559 1.257 1.752
GBR -0.808 1.407 -11.106 -5.286 -0.539 1.245 1.742
IBS -0.810 1.416 -13.060 -5.312 -0.545 1.265 1.729
NZC -0.814 1.411 -11.343 -5.303 -0.546 1.254 1.727
TSI -0.801 1.413 -11.402 -5.274 -0.538 1.272 1.789
POL
CIM -1.379 1.685 -10.868 -6.540 -1.076 1.137 1.695
NZM -1.281 1.627 -11.692 -6.294 -0.993 1.146 1.670
SAM -1.261 1.648 -11.413 -6.408 -0.953 1.174 1.732
TON -1.211 1.627 -11.282 -6.335 -0.904 1.185 1.702
SAS
BEB -0.683 1.321 -10.122 -4.924 -0.437 1.253 1.764
GIH -0.723 1.367 -11.022 -5.124 -0.467 1.276 1.827
ITU -0.715 1.359 -10.352 -5.060 -0.461 1.274 1.825
PJL -0.681 1.333 -10.737 -4.953 -0.432 1.277 1.820
STU -0.717 1.360 -10.861 -5.079 -0.466 1.273 1.807
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Table S11: Fu and Li’s F summary statistics by population
Population Mean Std. Dev Min Lower 1% Median Upper 99% Max
AFR
ACB 1.994 0.589 -4.068 0.024 2.072 3.004 3.995
ASW 1.958 0.560 -3.083 0.044 2.037 2.894 3.732
ESN 2.003 0.518 -3.209 0.431 2.050 2.985 4.004
GWD 2.004 0.547 -3.040 0.275 2.058 3.020 3.915
LWK 2.006 0.537 -2.779 0.286 2.060 2.998 3.997
MSL 1.956 0.518 -2.709 0.319 2.005 2.923 3.882
YRI 2.023 0.525 -2.574 0.411 2.070 3.020 4.072
AMR
CLM 1.980 0.667 -3.024 -0.192 2.081 3.101 3.953
MXL 1.827 0.686 -4.809 -0.390 1.945 2.924 3.530
PEL 1.724 0.720 -4.263 -0.575 1.841 2.915 3.642
PUR 2.033 0.656 -4.016 -0.079 2.128 3.147 3.871
EAS
CDX 1.945 0.648 -4.296 -0.068 2.030 3.073 3.859
CHB 1.931 0.693 -4.043 -0.288 2.030 3.113 3.863
CHS 1.969 0.658 -4.099 -0.036 2.055 3.128 3.934
JPT 2.000 0.633 -2.898 0.139 2.080 3.131 3.867
KHV 1.928 0.679 -5.262 -0.218 2.026 3.093 3.723
EUR
CEU 1.900 0.737 -4.328 -0.513 2.025 3.095 3.919
FIN 1.953 0.685 -3.468 -0.253 2.055 3.103 3.964
GBR 1.894 0.726 -3.960 -0.465 2.018 3.070 3.852
IBS 1.903 0.741 -4.195 -0.486 2.026 3.117 3.885
NZC 1.821 0.824 -4.082 -0.890 1.982 3.090 4.013
TSI 1.922 0.735 -5.048 -0.459 2.043 3.121 3.903
POL
CIM 1.642 0.778 -4.082 -0.818 1.775 2.929 3.700
NZM 1.699 0.753 -4.082 -0.699 1.827 2.950 3.650
SAM 1.728 0.761 -4.498 -0.715 1.857 2.981 3.951
TON 1.809 0.710 -4.427 -0.464 1.918 3.011 4.040
SAS
BEB 1.988 0.642 -4.029 -0.089 2.085 3.069 3.660
GIH 2.015 0.651 -3.599 -0.077 2.110 3.118 3.797
ITU 2.022 0.638 -3.047 0.002 2.110 3.119 3.765
PJL 2.007 0.650 -4.068 -0.097 2.102 3.103 3.736
STU 2.026 0.634 -3.057 0.005 2.113 3.121 3.921
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Table S12: Zeng’s E summary statistics by population
Population Mean Std. Dev Min Lower 1% Median Upper 99% Max
AFR
ACB 1.838 0.857 -1.581 -0.132 1.835 3.862 6.147
ASW 1.731 0.822 -1.398 -0.172 1.729 3.682 5.790
ESN 1.893 0.866 -1.472 -0.051 1.877 3.973 6.511
GWD 1.916 0.879 -1.307 -0.062 1.905 4.025 6.077
LWK 1.862 0.856 -1.365 -0.085 1.850 3.902 6.283
MSL 1.785 0.853 -1.404 -0.118 1.770 3.836 5.996
YRI 1.925 0.868 -1.404 -0.026 1.912 4.010 6.411
AMR
CLM 2.356 0.978 -1.684 0.037 2.356 4.683 7.109
MXL 2.259 0.972 -1.676 -0.017 2.248 4.623 6.992
PEL 2.423 1.052 -1.654 -0.004 2.407 4.998 7.652
PUR 2.345 0.966 -1.481 0.033 2.351 4.633 6.988
EAS
CDX 2.614 0.996 -1.577 0.338 2.590 5.088 7.602
CHB 2.640 1.005 -1.464 0.319 2.619 5.145 7.427
CHS 2.665 1.002 -1.403 0.386 2.639 5.173 7.578
JPT 2.681 0.995 -1.291 0.409 2.661 5.167 7.412
KHV 2.610 1.002 -1.513 0.317 2.589 5.084 7.441
EUR
CEU 2.452 1.026 -1.583 0.015 2.453 4.916 7.427
FIN 2.489 1.010 -1.828 0.118 2.485 4.928 7.413
GBR 2.425 1.015 -1.627 0.028 2.425 4.859 7.520
IBS 2.459 1.026 -1.619 0.024 2.456 4.917 8.544
NZC 2.415 1.044 -1.866 -0.097 2.423 4.897 7.444
TSI 2.474 1.021 -1.805 0.062 2.472 4.907 7.222
POL
CIM 2.534 1.085 -1.561 0.051 2.510 5.208 7.827
NZM 2.501 1.078 -1.613 0.020 2.486 5.146 7.716
SAM 2.586 1.052 -1.505 0.201 2.557 5.210 7.566
TON 2.617 1.038 -1.444 0.271 2.587 5.203 7.240
SAS
BEB 2.412 0.959 -1.633 0.163 2.408 4.726 7.032
GIH 2.486 0.975 -1.362 0.201 2.480 4.858 7.354
ITU 2.485 0.968 -1.450 0.219 2.480 4.831 7.125
PJL 2.446 0.969 -1.763 0.162 2.441 4.795 7.126
STU 2.487 0.969 -1.382 0.222 2.481 4.843 7.199
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A2.5 Polynesian windows for clustering of the extremes
Table S13: Genes intersecting the windows of the 1st percentile Tajima’s D in
Polynesian populations. Table can be found in the electronic supplement as file
Appendices/04-td-pol-firstper-genes.csv
Table S14: Genes intersecting the windows of the 99th percentile Tajima’s D in
Polynesian populations. Table can be found in the electronic supplement as file
Appendices/04-td-pol-ninetyninthper-genes.csv
Table S15: Genes intersecting the windows of the 1st percentile Fay and Wu’s H
in Polynesian populations. Table can be found in the electronic supplement as file
Appendices/04-fwh-pol-firstper-genes.csv
Table S16: Genes intersecting the windows of the 99th percentile Fay and Wu’s H
in Polynesian populations. Table can be found in the electronic supplement as file
Appendices/04-fwh-pol-ninetyninethper-genes.csv
Table S17: Genes intersecting the windows of the 1st percentile Fu and Li’s F in
Polynesian populations. Table can be found in the electronic supplement as file
Appendices/04-flf-pol-firstper-genes.csv
Table S18: Genes intersecting the windows of the 99th percentile Fu and Li’s F in
Polynesian populations. Table can be found in the electronic supplement as file
Appendices/04-flf-pol-ninetyninethper-genes.csv
Table S19: Genes intersecting the windows of the 1st percentile Zeng’s E in
Polynesian populations. Table can be found in the electronic supplement as file
Appendices/04-ze-pol-firstper-genes.csv
Table S20: Genes intersecting the windows of the 99th percentile Zeng’s E in
Polynesian populations. Table can be found in the electronic supplement as file
Appendices/04-ze-pol-ninetyninethper-genes.csv
A2.6 Clustered regions from significant markers for iHS and nSL
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Table S21: Positions of regions created by clustering significant markers for iHS
or nSL by population. Table can be found in the electronic supplement as file
Appendices/04-ihs-nsl-significant-marker-clusters.csv
A2.7 Clustered median centered metabolic disease genes
A2.7.1 Urate and Gout
Table S22: Tajima’s D for windows at gout-associated loci. Table can be found in
the electronic supplement as file Appendices/04-gout-td-gene-clus.csv
Table S23: Fay and Wu’s H for windows at urate and gout-associated loci. Table
can be found in the electronic supplement as file Appendices/04-gout-fwh-gene-
clus.csv
Table S24: Fu and Li’s F for windows at urate and gout-associated loci. Table can
be found in the electronic supplement as file Appendices/04-gout-flf-gene-clus.csv
Table S25: Zeng’s E for windows at urate and gout-associated loci. Table can be
found in the electronic supplement as file Appendices/04-gout-ze-gene-clus.csv
A2.7.2 Obesity
Table S26: Tajima’s D for windows at obesity-associated loci. Table can be found
in the electronic supplement as file Appendices/04-obesity-td-gene-clus.csv
Table S27: Fay and Wu’s H for windows at obesity-associated loci. Table can be
found in the electronic supplement as file Appendices/04-obesity-fwh-gene-clus.csv
Table S28: Fu and Li’s F for windows at obesity-associated loci. Table can be
found in the electronic supplement as file Appendices/04-obesity-flf-gene-clus.csv
Table S29: Zeng’s E for windows at obesity-associated loci. Table can be found in
the electronic supplement as file Appendices/04-obesity-ze-gene-clus.csv
273
A2.7.3 Type 2 diabetes
Table S30: Tajima’s D for windows at type 2 diabetes-associated loci. Table can
be found in the electronic supplement as file Appendices/04-t2d-td-gene-clus.csv
Table S31: Fay and Wu’s H for windows at type 2 diabetes-associated loci. Table
can be found in the electronic supplement as file Appendices/04-t2d-fwh-gene-
clus.csv
Table S32: Fu and Li’s F for windows at type 2 diabetes-associated loci. Table can
be found in the electronic supplement as file Appendices/04-t2d-flf-gene-clus.csv
Table S33: Zeng’s E for windows at type 2 diabetes-associated loci. Table can be
found in the electronic supplement as file Appendices/04-t2d-ze-gene-clus.csv
A2.7.4 Kidney disease
Table S34: Tajima’s D for windows at kidney disease-associated loci. Table can
be found in the electronic supplement as file Appendices/04-kd-td-gene-clus.csv
Table S35: Fay and Wu’s H for windows at kidney disease-associated loci. Table
can be found in the electronic supplement as file Appendices/04-kd-fwh-gene-
clus.csv
Table S36: Fu and Li’s F for windows at kidney disease-associated loci. Table can
be found in the electronic supplement as file Appendices/04-kd-flf-gene-clus.csv
Table S37: Zeng’s E for windows at kidney disease-associated loci. Table can be
found in the electronic supplement as file Appendices/04-kd-ze-gene-clus.csv
A2.7.5 Metabolic syndrome
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Table S38: Tajima’s D for windows at metabolic syndrome-associated loci. Table
can be found in the electronic supplement as file Appendices/04-metsyn-td-gene-
clus.csv
Table S39: Fay and Wu’s H for windows at metabolic syndrome-associated loci.
Table can be found in the electronic supplement as file Appendices/04-metsyn-
fwh-gene-clus.csv
Table S40: Fu and Li’s F for windows at metabolic syndrome-associated loci.
Table can be found in the electronic supplement as file Appendices/04-metsyn-flf-
gene-clus.csv
Table S41: Zeng’s E for windows at metabolic syndrome-associated loci. Table






This appendix contains the main scripts that were used to generate results.
B1 GWAS catalog gene list creation
This was the R code used to generate the gene lists for the traits of interest in the thesis.




# read in the gwas catalog entries
gwas_cat <- read.delim(
'gwas_catalog_v1.0.1-associations_e89_r2017-06-19.tsv',
header=TRUE, stringsAsFactors = FALSE, sep='\t')
#filter gwas catalogue for results of genome wide significance
gwas_cat <- gwas_cat[ gwas_cat$P.VALUE < 5e-8,]
gwas_interested <- gwas_cat[grep(
'metabolic syndrome|obesity|diabetes|urate|gout|body mass|lipid traits',
gwas_cat$DISEASE.TRAIT, ignore.case = TRUE) ,]
# create kidney disease associated gene list
kd <- gwas_cat %>%
filter(grepl(
DISEASE.TRAIT, pattern = 'kidney|renal', ignore.case=TRUE) &
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!grepl(DISEASE.TRAIT,
pattern = 'transplant|carcinoma|Type|stones|gout|related')) %>%
filter(DISEASE.TRAIT != "Diabetic kidney disease")








invert = TRUE, ignore.case = TRUE),],
kd)
# pull out the genomic regions for all the transcripts for all the genes
# that we are interested in
gwas_genes <-sort(unique(unlist(
strsplit(gwas_interested$REPORTED.GENE.S., split = ', '))))
gwas_genes_entrez <- na.omit(select(
org.Hs.eg.db, keys = gwas_genes,




keys = gwas_genes_entrez$ENTREZID, keytype="GENEID"), gwas_genes_entrez,












ignore.case = TRUE),]$REPORTED.GENE.S., ', '))),]





ignore.case = TRUE),]$REPORTED.GENE.S., ', '))),]





ignore.case = TRUE),]$REPORTED.GENE.S., ', '))),]





ignore.case = TRUE),]$REPORTED.GENE.S., ', '))),]
# the entries that match the diseases reported in Zhang et al 2013 Table 2
zhang_immune <- gwas_cat %>%
filter(DISEASE.TRAIT %in% c("Crohn's disease", 'Celiac disease',
"Ulcerative colitis", "Inflammatory bowel disease",
"Type 1 diabetes", "Rheumatoid arthritis",
"Multiple sclerosis", "Psoriasis",
"Systemic lupus erythematosus",
"Primary biliary cirrhosis", "Vitiligo")) %>%
dplyr::select(DISEASE.TRAIT, contains('gene'))
# entries that have Parkinson's or Alzheimers disease
neurological <- gwas_cat %>%
filter(DISEASE.TRAIT %in% c("Parkinson's disease", "Alzheimer's disease")) %>%
dplyr::select(DISEASE.TRAIT, contains('gene'))
#entries that have an association with malaria
malaria <- gwas_cat %>% filter(DISEASE.TRAIT %in% c( "Malaria")) %>%
plyr::select(DISEASE.TRAIT, contains('gene'))
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# find the coordinatesfor the transcripts for the genes
gwas_genes <-sort(unique(unlist(strsplit(c(zhang_immune$REPORTED.GENE.S.,
neurological$REPORTED.GENE.S.,











gwas_genes_entrez, by.x ='GENEID', by.y = "ENTREZID")
gwas_genes_ucscGR <- GRanges(gwas_genes_ucsc[!is.na(gwas_genes_ucsc$TXID) ,])
gwas_genes_ucscGR <- gwas_genes_ucscGR[which(gwas_genes_ucscGR@seqnames %in%
paste0('chr',1:22))]













B2 SelectionTools Pipeline NeSI Scripts
The following are a series of script that were run in order to generate the results from the selectionTools
1.1 pipeline. They consist of
B2.1 unimputed_selection_pipeline.sl
This is the slurm workload manager script that was used on the NeSI PAN cluster to generate the
selection results from selectionTools 1.1. It specifies the window and slide sizes for differenct statistics,




#SBATCH -A uoo00008 # Project Account
#SBATCH --time=00:30:00 # Walltime
#SBATCH --mem-per-cpu=2048 # memory/cpu (in MB)










#srun tar -C $TMP_DIR/${POP}/ \
-xzf $DIR/${POP}.tar.gz ${POP}.chr${i}_biallelic_coreExome_markers.vcf
srun gzip -dc $DIR/${POP}.chr${i}.phased.vcf.gz >\
$TMP_DIR/${POP}/${POP}.chr${i}.phased.vcf
cd $TMP_DIR/${POP}/
#srun cat ${POP}.chr${i}_biallelic_coreExome_markers.vcf |\
grep -v '^##contig' > ${POP}_chr${i}_coreExome.vcf




































srun tar -czf ${POP}.chr${i}.tar.gz *
mkdir -p /home/murray.cadzow/uoo00008/NZ_1KGP_unimputed/Indiv_pops_results/$POP
srun cp $TMP_DIR/*.tar.gz NZ_1KGP_unimputed/Indiv_pops_results/${POP}/
B2.2 unimputed_defaults_nesi-18-3-16.cfg




# Defaults config file for VCF process
#
# If the executables are on your path
# just the executable name is required.
#
# ? is the willcard flag for the prefix options
[system]
cores_avaliable = 1
# Library settings do not change, the library folder are









































# not used unless split_by_chromosome is set to False
ancestral_fasta_header_regex =




















This script was used on the results generated by NZ_1KGP_unimputed/unimputed_selection_pipeline.sl.





#SBATCH -A uoo00008 # Project Account
#SBATCH --time=05:59:00 # Walltime
#SBATCH --mem=4096 # memory/node (in MB)




echo $POP chr $i
DIR=$SLURM_SUBMIT_DIR
srun tar -C $TMP_DIR -xzf ${POP}.chr${i}.tar.gz ${POP}/${POP}_${i}_selscan*

















srun tar -czf ${POP}.chr${i}.ihs.tar.gz *log *.out gap1mb
srun cp ${POP}.chr${i}.ihs.tar.gz $DIR/
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B2.4 run_nsl_selscan.sl
This script was used on the results generated by NZ_1KGP_unimputed/unimputed_selection_pipeline.sl.




#SBATCH -A uoo00008 # Project Account
#SBATCH --time=05:59:00 # Walltime
#SBATCH --mem=2048 # memory/node (in MB)




echo $POP chr $i
DIR=$SLURM_SUBMIT_DIR
srun tar -C $TMP_DIR -xzf ${POP}.chr${i}.tar.gz ${POP}/${POP}_${i}_selscan*















srun tar -czf ${POP}.chr${i}.nsl.tar.gz *log *.out gap1mb
srun cp ${POP}.chr${i}.nsl.tar.gz $DIR
286
B2.5 run_xpehh.sl
This script was used on the results generated by NZ_1KGP_unimputed/unimputed_selection_pipeline.sl.





#SBATCH -A uoo00008 # Project Account
#SBATCH --time=12:00:00 # Walltime
#SBATCH --mem=2048 # memory/node (in MB)














#need selscan file for POP






cd $TMP_DIR/${POP1}_${POP2} && \









#srun tar -C $TMP_DIR -xzf ${POP1}_${POP2}.tar.gz \
${POP1}_${POP2}/*${i}.xpehh* ${POP1}_${POP2}/*${i}.*.xp*

















srun tar -czf ${POP1}_${POP2}_chr${i}_xpehh.tar.gz ${POP1}_${POP2}* gap1mb
mkdir -p $DIR/xpehh/${POP1}_${POP2}
srun cp ${POP1}_${POP2}_chr${i}_xpehh.tar.gz $DIR/xpehh/${POP1}_${POP2}/
B2.6 Extract results
extract_results.sh
This bash script was used to extract the results from selectionTools 1.1 into a tidy directory structure,





# extract all the results files generated from the selection pipeline





parallel 'tar -C {3}/ihs/chr{1} -xzf {2} *out *log --wildcards' ::: ${i} ::: \
$(ls $input_dir/*/*chr${i}.ihs.tar.gz) ::: $results_dir
echo nsl
parallel 'tar -C {3}/nsl/chr{1} -xzf {2} *out *log --wildcards' ::: ${i} ::: \
$(ls $input_dir/*/*chr${i}.nsl.tar.gz) ::: $results_dir
echo tajd
parallel 'tar -C {3}/tajd/chr{1} -xzf {2} *taj_d --wildcards' ::: ${i} ::: \




parallel 'tar -C {3}/fawh/chr{1} -xzf {2} *faw --wildcards' ::: ${i} ::: \




parallel 'tar -C {3}/daf/chr{1} -xzf {2} *aachanged.af --wildcards' ::: ${i} \
::: $(ls $input_dir/*/*chr${i}.tar.gz) ::: $results_dir
mv $results_dir/daf/chr${i}/*/*.af $results_dir/daf/chr${i}/
rename _aachanged.af ${i}_aachanged.af $results_dir/daf/chr${i}/*
echo fixed_vcf
parallel 'tar -C {3}/fixed_vcf/chr{1} -xzf {2} *fixed.vcf --wildcards' ::: ${i} \
::: $(ls $input_dir/*/*chr${i}.tar.gz) ::: $results_dir
mv $results_dir/fixed_vcf/chr${i}/*/*vcf $results_dir/fixed_vcf/chr${i}/
echo xpehh
parallel 'tar -C {3}/xpehh/chr{1} -xzf {2} *out *log --wildcards' ::: ${i} \
::: $(ls $input_dir/xpehh/*/*chr${i}_xpehh.tar.gz) ::: $results_dir
done
289
# calc the number of files for each population
for pop in $(basename -a $(find $input_dir -type d |\
grep -v "xpehh" |grep [a-zA-Z] ) |grep -v "results")
do
echo ------ $pop -------
echo ihs $(ls $results_dir/ihs/chr*/${pop}*out | wc -l)
echo nsl $(ls $results_dir/nsl/chr*/${pop}*out | wc -l)
echo fawh $(ls $results_dir/fawh/chr*/${pop}*faw | wc -l)
echo tajd $(ls $results_dir/tajd/chr*/${pop}*taj_d | wc -l)
echo daf $(ls $results_dir/daf/chr*/${pop}*af | wc -l)
echo fixed_vcf $(ls $results_dir/fixed_vcf/chr*/${pop}*vcf | wc -l)





# clean up some of the extraction
cd $results_dir/fixed_vcf/
for pop in $(basename -a $(find $input_dir -type d | \




# combine vcfs, run snpEff and create panel files
parallel 'bgzip {} && tabix -f -p vcf {}.gz ' ::: $(ls */*vcf)
mkdir combined
parallel -j 6 'bcftools merge $(ls chr{}/*gz| \
grep "AMR\|AFR\|EUR\|EAS\|SAS\|POL") |\
bgzip -c > combined/combined_super_chr{}.vcf.gz' ::: $(seq 1 22)
parallel -j 6 'bcftools merge $(ls chr{}/*gz | \
grep -v "AMR\|AFR\|EUR\|EAS\|SAS\|POL") |\
bgzip -c > combined/combined_chr{}.vcf.gz' ::: $(seq 1 22)





-stats chr{2}/{1}{2}.html chr{2}/{1}{2}_fixed.vcf.gz |\
bgzip -c > chr{2}/{1}{2}_fixed_ann.vcf.gz ' ::: $(ls chr22/*gz |\
sed 's/chr22\///g' |cut -d'2' -f1) ::: $(seq 1 22)
for pop in $(basename -a -s 1_fixed.vcf.gz chr1/*fixed.vcf.gz)
do
zcat chr1/${pop}1_fixed.vcf.gz |\
head -100 | grep '^#CHR' |\
cut -f10- | tr '\t' '\n' |\
awk '{print $1"\t"$1}' > ${pop}.panel
done
# calculate Fst
parallel -j 10 '
for p1 in POL
do
for p2 in AFR AMR EUR EAS SAS
do
vcftools --gzvcf combined/combined_super_chr{}.vcf.gz \
--weir-fst-pop ${p1}.panel --weir-fst-pop ${p2}.panel \




' ::: $(seq 1 22)
parallel -j 10 '
for p1 in CIM NZC NZM TON SAM
do
for p2 in $(basename -a -s .panel *.panel | \
grep -v "AMR\|AFR\|EUR\|EAS\|SAS\|POL")
do
if [[ $p1 != $p2 ]]
then
vcftools --gzvcf combined/combined_chr{}.vcf.gz \
--weir-fst-pop ${p1}.panel --weir-fst-pop ${p2}.panel \






' ::: $(seq 1 22)
# normalise the ihs files
cd $results_dir/ihs
for pop in $(ls chr1/*out | cut -d'/' -f2 | cut -d'_' -f1 | sort -u)
do
selscan/bin/linux/norm --ihs \
--files chr*/${pop}_*.out --crit-percent 0.99 --log ${pop}.log
selscan/bin/linux/norm \
--ihs --files chr*/gap1mb/${pop}_*.out --crit-percent 0.99 \
--log ${pop}_gap1mb.log
done
# rename the ihs files to remove the underscore
for i in $(seq 1 22)
do
rename _${i} ${i} chr${i}/*





# normalise the nsl files
cd $results_dir/nsl
for pop in $(ls chr1/*out | cut -d'/' -f2 | cut -d'_' -f1 | sort -u)
do
~/Murray/src/selscan/bin/linux/norm --ihs \
--files chr*/${pop}_*.out --crit-percent 0.99 \
--log ${pop}.log
~/Murray/src/selscan/bin/linux/norm --ihs \
--files chr*/gap1mb/${pop}_*.out --crit-percent 0.99 \
--log ${pop}_gap1mb.log
done
# rename and move the nsl files
for i in $(seq 1 22)
do
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# normalise xpehh files
cd $results_dir/xpehh
for p1 in POL CIM NZC NZM NAD TON SAM EPN WPN;
do
for p2 in $(ls chr1/${p1}*.out | cut -d'_' -f2)
do
if [[ $p1 != $p2 ]]
then
selscan/bin/linux/norm --xpehh \
--files chr*/${p1}_${p2}*.out --crit-percent 0.99 \
--log ${p1}_${p2}.log
selscan/bin/linux/norm --xpehh \





# move normalised xpehh files
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